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Abstract
Event history studies based on disease clinic data often face several complications.
Specifically, patients visit the clinic irregularly, and the intermittent inspection times de-
pend on the history of disease-related variables; this can cause event or failure times to be
dependently interval-censored. Furthermore, failure times could be truncated, treatment
assignment is non-randomized and can be confounded, and there are competing risks of the
failure time outcomes under study. I propose a class of inverse probability weights applied
to estimating functions so that the informative inspection scheme and confounded treat-
ment are appropriately dealt with. As a result, the distribution of failure time outcomes
can be consistently estimated. I consider parametric, non- and semi-parametric estima-
tion. Monotone smoothing techniques are employed in a two-stage estimation procedure
for the non- or semi-parametric estimation. Simulations for a variety of failure time models
are conducted for examining the finite sample performances of proposed estimators. This
research is initially motivated by the Psoriatic Arthritis (PsA) Toronto Cohort Study at
the Toronto Western Hospital and the proposed methodologies are applied to this cohort
study as an illustration.
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Chapter 1
INTRODUCTION
Studies based on disease clinic data often face several complications. Patients may visit
the clinic irregularly, and the intermittent inspection times may depend on disease-related
variables. Intermittent observation can cause failure time outcomes to be dependently
interval-censored, and failure times may also be left-truncated by clinic enrolment time.
Additionally, treatment assignments are frequently not randomized and even can be af-
fected by disease-related variables. In this thesis, a class of inverse probability weighted
estimating function approaches will be proposed to consistently estimate failure time dis-
tributions by adjusting for the informative observation and measured confounders. Sim-
ulation studies are conducted to empirically examine the finite sample performances of
proposed methods. Data from the Psoriatic Arthritis (PsA) Toronto Cohort Study is used
for illustration.
In this chapter, first we provide some background of the PsA cohort study, which main-
ly motivates this thesis research. Secondly, some basic concepts of survival analysis and
causal inference will be briefly introduced. Last but not least, problems and challenges
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arising from intermittent outcome-dependent observation, model marginalization, and col-
lapsibility of association measures will be addressed.
1.1 Motivating Example
In clinical, epidemiological and sociological research, longitudinal studies, which involve
repeated observations on subjects over long periods of time, constitute a primary source of
information on outcomes of interest. For example, researchers may be interested in quanti-
fying the association between air pollution and lung function, where air pollution might be
measured weekly and lung function of individuals is evaluated at periodic clinic visits. In
clinical experiments, variables of interest are usually measured at regular and prespecified
time points, e.g. in months, for lung function assessments. However, in practice, many
longitudinal studies are observational studies in which subjects may miss scheduled visits,
or may visit a clinic at arbitrary time points. In “regular” longitudinal studies, visit times
are prespecified and often common to every subject, so they do not carry any information
related to the outcome of interest. However, in “irregular” longitudinal studies, visit times
are often associated with the outcome or outcome-related variables. If we do not take
this into account in the analysis, estimates can be severely biased. We will discuss this
in detail in a subsequent section. At present, irregular longitudinal data based on inter-
mittent observation or dependent follow-up times are insufficiently studied, but they are
very common in practice, especially in health-related research. In the following, we will
see a real example in which participants are interviewed or evaluated in continuous time,
but the frequency and timing of visits vary greatly and may be highly associated with the
values of previous outcomes or outcome-related variables.
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1.1.1 Data on Psoriatic Arthritis
Psoriasis is a chronic immune-mediated inflammatory skin disease affecting approximately
2% of the general population (Langley et al., 2005). Additionally, about 10−30% of patients
with psoriasis have psoriatic arthritis (PsA), which is defined as seronegative inflammatory
musculoskeletal disease associated with psoriasis. Recent studies indicate that PsA is a
progressive disease, leading to considerable joint pain, inflammation and destruction which
can ultimately cause serious disability and poor quality of life (Chandran et al., 2010;
O’Keeffe et al., 2011). The etiology of PsA is multifactorial, with genetic, environmental,
and immunologic factors involved in its development (Gladman, 1998; Mease and Goffe,
2005).
The Toronto Psoriatic Arthritis Clinic was established by Professor Dafna Gladman
at the University of Toronto in 1978. Since October 1995, it has been at The Centre for
Prognosis Studies in the Rheumatic Diseases (CPSRD) at the Toronto Western Hospital.
During the past 35 years, the clinic has collected comprehensive longitudinal information
on the course and prognosis of PsA. So far, it has enrolled over 1000 patients with PsA
who have been followed over many years. It constitutes one of the largest cohorts of
PsA in the world. The study is approved by the Research Ethics Board of the University
Health Network, Toronto, Ontario, Canada. Patients are assessed about every 6-12 months
according to a defined protocol and data is collected on clinical history, pharmacotherapy,
physician examination, laboratory evaluations such as routine blood and urine tests, and
biennially performed X-ray tests. Physician examination includes the rheumatological
assessment, which assesses the activity and clinical damage of peripheral joints and spine.
Demographic information and family disease history are also registered at recruitment.
Clinical damage of a joint is defined by the presence of a limitation in the range of
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movement of more than 20% of the range when there is no active inflammation, or if
the joint is deformed, flail, ankylosed or has undergone surgery (Siannis et al., 2006).
Clinical joint damage is determined on physical examination of the patient, which is done
at each visit. In general, damage is an irreversible process, while disease activity, which
is reflected by tenderness and/or effusion, is reversible. Therefore, most recent therapies
aim at reducing signs and symptoms of active arthritis so as to inhibit the progression of
structural damage. So far, a variety of therapies have been adopted to control the disease
activity of PsA. There are three main types of treatment. Non-steroidal anti-inflammatory
drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs) are typically used
as the first- and the second-line treatments. More recently, due to the immunologic basis of
PsA, biologics have attracted increasing interest for treating disease activity. In addition,
if these front-line therapies are not effective at reducing inflammation, other treatments
such as intra-articular steroids injected directly into the specific active joint(s) may also
be considered (O’Keeffe et al., 2011).
At present, a major research objective is to identify genetic and genomic variants asso-
ciated with PsA disease progression. In addition, since joint damage mainly characterizes
the disease severity of PsA, much attention has been paid to investigating the link between
joint damage and the dynamic courses of pharmacotherapy and disease activity. Many
interesting questions can be addressed from the PsA cohort, for example, evaluating the
effects of recent therapies on certain joint damage events. Studying an event time outcome
defined with respect to joint damage and biologics will be the focus of Chapter 5.
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1.2 Introduction to Survival Analysis
This section aims to provide an overview of terminology, concepts and techniques for
survival analysis. Survival time (also referred to as lifetime or failure time) is defined as a
positive-valued random variable which typically represents the time to some specific event.
This event can be death, the development of some disease, recurrence of a disease or the
failure of a physical (or mechanical, electrical) component. It could also be a good event,
such as disease remission, cessation of smoking, and so forth. In the PsA example, one
event of interest is time to the appearance of the first joint damage since onset. Section
1.2.1 aims to introduce some basic measures commonly used in survival analysis. Section
1.2.2 focuses on various types of censoring which frequently occur in practice. Following
that, Section 1.2.3 discusses the likelihood function construction based on failure time data.
Finally, some widely used survival models are introduced in Section 1.2.4.
1.2.1 Basic Quantities
Let Ti be a nonnegative random variable that represents the failure time, i.e. time to the
event under study, for subject i, where i = 1, ..., n. Characterization of the distribution
of Ti and discussion of the association between failure time and potential risk factors are
often of interest. In addition to the cumulative distribution function (CDF) and probabil-
ity density (or probability mass) function, other functions including the survival function
and hazard function can be used to characterize the distribution of a failure time random
variable. It can be shown that if any one of these four quantities is known, then the oth-
ers are uniquely determined. In the following, we will introduce these basic quantities by
considering two cases: when Ti is a univariate continuous random variable and when Ti is
a univariate discrete random variable, by referring to Lawless (2003). All functions in the
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following, unless stated otherwise, are defined over (0,∞).
Continuous Quantities
Assume Ti’s are i.i.d. nonnegative random variables from some continuous distribution.
The CDF, denoted by F (t), of Ti, a continuous survival time variable, is defined by
F (t) = Pr(T ≤ t) =
∫ t
0
f(s)ds,
where f(s) = dF (s)/ds is the probability density function of Ti at time s.
The survival function, denoted by S(t), is the probability of an individual surviving
beyond time t, i.e. experiencing the event after time t. It is defined as
S(t) = Pr(T > t) = 1− F (t) =
∫ ∞
t
f(s)ds,
and hence,
f(t) = −dS(t)
dt
.
Another basic quantity, the most commonly used in survival analysis, is the hazard
function denoted by λ(t), which is the probability an individual experiences the event in
the next instant of time given the individual has not experienced an event by time t. The
hazard function is defined by
λ(t) = lim
∆→0+
Pr(t ≤ T < t+ ∆t|T ≥ t)
∆t
=
f(t)
S(t)
= −dln[S(t)]
dt
.
Roughly speaking, λ(t)∆t provides the approximate probability of failure during the time
period [t, t+ ∆t), given survival up to t.
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The cumulative hazard function, Λ(t), is defined by
Λ(t) =
∫ t
0
λ(s)ds,
which is related to the survival function by S(t) = exp{−Λ(t)}. It is clear that any of f(t),
F (t), S(t), λ(t) and Λ(t) uniquely determines the distribution of Ti.
Discrete Quantities
Sometimes, discrete random variables arise due to rounding off measurements or when
survival times refer to an integral number of units (Klein and Moeschberger, 2003). Suppose
T (subscript i suppressed) can take on values t1, t2,..., where 0 = t0 < t1 < t2 < ..., with
probability mass function p(tj) = Pr(T = tj), j = 1, 2, .... Then, the CDF of T is defined
as F (t) = Pr(T ≤ t) = ∑tj≤t p(tj), and the corresponding survival function is given by
S(t) = Pr(T > t) =
∑
tj>t
p(tj).
Note, when T is continuous, S(t) is a monotone decreasing continuous function with S(0) =
1, while when T is discrete, under the above definition, S(t) is a right-continuous, non-
increasing step function, with S(0) = 1 and S(∞) = 0.
The discrete time hazard function is given by
λ(tj) = Pr(T = tj|T ≥ tj)
=
p(tj)
S(tj−1)
= 1− S(tj)
S(tj−1)
, j = 1, 2, ....
Since S(tj) = [1− λ(tj)]S(tj−1) and S(t0) = S(0) = 1, we have
S(t) =
∏
tj≤t
[1− λ(tj)].
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Moreover, as an analog of the continuous case, a discrete cumulative hazard function Λ(t)
equals
∑
j:tj≤t λ(tj) and −lnS(t). A general formulation of Λ(t) can be given by a Riemann-
Stieltjes integral to unify continuous, discrete, and mixed survival time distribution in one
framework of the form (Lawless, 2003):
Λ(t) =
∫ t
0
dΛ(s) =
∫ t
0
λ(s)ds+
∑
j:tj≤t
λj,
where λ(s) = f(s)/S(s) represents the hazard function for T at points where F (s) (or
S(s)) is continuous, and λj = Pr(T = tj|T ≥ tj) is the discrete hazard value at time tj for
which a jump in F occurs.
1.2.2 Varieties of Censoring and Truncation
In practice, survival data are often subject to censoring, which, broadly speaking, occurs
when some event is only known to have occurred within a certain interval but the exact
time is unknown. There are three primary types of censoring: right censoring, left censor-
ing and interval censoring. Each type leads to a certain likelihood structure which forms
the basis for likelihood-based inference.
Right Censoring
First, we introduce right censoring which occurs most often in practice, since the sur-
vival data are always under observation for a finite period of time. Right censoring happens
when a failure has not been observed during follow-up and it may occur later. Let Ci be
the right censoring time of subject i imposed by the follow-up period. Then, (0, Ci] is
the interval over which the failure time of subject i, i.e. Ti, can be observed. Obviously,
only the minimum of failure time Ti and right censoring time Ci can be observed, so define
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Xi = min(Ti, Ci) and δi = I(Ti ≤ Ci). Then, the observed data are pairs of the realizations
of random variables (Xi, δi), i = 1, 2, ..., n, where Xi is referred to as an observed time and
δi is referred to as an event indicator.
Left Censoring
If it is known that the event of interest has already occurred by some time Li, but the
exact failure time is unknown, this is called left censoring. The observations still can be
characterized by (Xi, δi). But, in contrast to right censoring, here the observed time is
defined as Xi = max(Ti, Li) and the event indicator is defined as δi = I(Ti ≥ Li), where
Li denotes the left censoring time of subject i.
Interval Censoring
Interval censoring means that the failure time of interest is only known to lie within a
finite interval instead of being observed exactly. Such censoring usually happens in clinical
trials, industrial experiments or longitudinal studies where periodic follow-ups are assigned
and a patient’s failure time is only known to fall in a certain interval (til, tir] between two
visits, i.e. til < Ti ≤ tir. Note that if the event of interest occurs exactly at the moment of
one visit, then we have til = Ti = tir, which rarely happens in practice.
Left Truncation
In contrast to censoring where at least partial information is known about failure time,
another feature of failure time data, truncation, restricts the inference to conditional es-
timation. Truncation of failure times occurs when only subjects whose failure times lie
within certain observational window (Wil,Wir)’s are included in the analysis (Klein and
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Moeschberger, 2003). When Wir =∞, it is called left truncation which often occurs when
a subject’s study entry time is later than the origin of failure time. A left truncation time
Wil is also called a delayed entry time.
1.2.3 Likelihood Construction for Censored and Truncated Data
Although data may be subject to a variety of types of censoring, the methods for con-
structing likelihood functions are similar. Generally, suppose that data are subject to all
kinds of censoring such as right censoring, left censoring and interval censoring. Then,
under the assumption that censoring is independent and non-informative, the likelihood
function can be constructed as
L ∝
∏
i∈E
f(Ti)
∏
i∈R
S(Ci)
∏
i∈L
[1− S(Li)]
∏
i∈I
[S(til)− S(tir)], (1.1)
where E is the set of exactly observed failure times, R is the set of right-censored ob-
servations, L is the set of left-censored observations, and I is the set of interval-censored
observations. Here, f(·) and S(·) denote the density function and survival function of
failure time Ti, respectively, and Ci, Li, til, tir are defined as before.
Specifically, for right-censored data, the likelihood is of the form
L ∝
n∏
i=1
[f(Ti)]
δi [S(Ci)]
1−δi , (1.2)
where δi = I(Ti ≤ Ci) is the event indicator. For interval-censored data, the likelihood is
given by
L ∝
n∏
i=1
[S(til)− S(tir)]δ
I
i [S(Ci)]
δRi , (1.3)
where δRi is the indicator for right censoring and δ
I
i is the indicator for interval censoring.
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When data is left truncated, all the quantities included in likelihood function (1.1)
would be conditional on Ti being greater than the left truncation time, say ti0 > 0. Then,
the general likelihood function of left-truncated data can be constructed as
L ∝
∏
i∈E
f(Ti)
S(ti0)
∏
i∈R
S(Ci)
S(ti0)
∏
i∈L
[
1− S(Li)
S(ti0)
]∏
i∈I
[S(til)− S(tir)]
S(ti0)
, (1.4)
where Ti, Ci, Li, til and tir are all greater than ti0. Specifically, if data is subject to
interval-censoring as well as left-truncation, the corresponding likelihood function can be
given by
L ∝
n∏
i=1
[
S(til)
S(ti0)
− S(tir)
S(ti0)
]δIi [S(Ci)
S(ti0)
]δRi
. (1.5)
1.2.4 Models in Survival Analysis
In this section, some foundational and widely used models in survival analysis will be briefly
introduced. First, accelerated failure time (AFT) model is usually applied parametrically,
while the other three, proportional hazards (PH) model, additive hazards (AH) model and
proportional odds (PO) model, are often known as being semiparametric. Semiparametric
model assumptions are usually more flexible and more robust than fully parametric models
but bring difficulties in inference due to an unspecified component in the model.
Accelerated Failure Time Regression Model
Suppose the logarithm of Ti follows a location-scale distribution with mean β0+β
′Zi and
standard deviation σ, where Zi = (Zi1, ..., Zip)
′ is a p-dimensional vector of covariates for
subject i, β0 is the intercept and β = (β1, ..., βp)
′ is the p-dimensional vector of coefficients
of covariates Zi. That is,
ln(Ti) = β0 + β
′Zi + σWi,
11
where Wi is assumed to follow a standard location-scale distribution. If, for example, Wi
has a standard extreme value distribution, then the corresponding Ti has a Weibull distri-
bution with shape parameter 1/σ.
Cox Proportional Hazards Regression Model
Suppose that the hazard function is given by
λ(t;Zi) = λ0(t) exp(β
′Zi),
where β = (β1, ..., βp)
′ and Zi = (Zi1, ..., Zip)′. Here, λ0(t), known as the baseline hazard
function, is unspecified. The regression parameter, βj, can be interpreted as the log hazard
ratio when Zij is increased by one unit and other variables are kept unchanged. If the
baseline hazard is specified, a parametric PH model can be obtained. For example, when
λ0(t) = κρ(ρt)
κ−1, we have a Weibull proportional hazards model, where κ is the shape
parameter and 1/ρ is the scale parameter of a Weibull distribution.
Additive Hazards Regression Model
The hazard is given by
λ(t;Zi) = λ0(t) + β
′Zi,
where β = (β1, ..., βp)
′, Zi = (Zi1, ..., Zip)′, and λ0(t) also denotes the baseline hazard and
can be unspecified. Here, βj represents the hazard difference when Zij is increased by one
unit and other variables remain unchanged. In addition, similar to the PH model, the
baseline hazard function can be specified to obtain a parametric AH model.
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Proportional Odds Regression Model
This model takes the form
O(t) = O0(t) exp(β
′Zi),
where β = (β1, ..., βp)
′ and Zi = (Zi1, ..., Zip)′. Here, O(t) = F (t)/{1 − F (t)} is the odds
for distribution function F (t), and O0(t) is the odds for the baseline distribution F0(t).
Similar to the PH model, βj is interpreted as the log odds ratio when Zij is increased
by one unit, with other variables fixed. Also, O0(t) can be unspecified. If F0(t) is speci-
fied by a parametric distribution, e.g. log-logistic, a parametric PO model can be obtained.
1.3 Introduction to Observational Studies and Causal
Inference
In practice, observational studies are often used to study human health, especially in epi-
demiological research. The PsA cohort we introduced in Section 1.1 is an observational
study. Patients may be prescribed treatments with NSAIDs, DMARDs and/or biologics
based on their clinical assessments. It is of interest to estimate the effect of specific treat-
ment such as biologics, but in an observational study, this is challenging because treatment
is prescribed according to a person’s condition. This is the focus of Chapter 3, but here
we review some causality concepts.
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1.3.1 Observational Studies and Causality
The key feature of randomized experiments is that treatments or interventions are randomly
allocated across individuals or experimental units. The simplest situation is that subjects
are assigned to be treated or untreated by the flip of a fair coin, i.e. patients are allocated
to be in the treatment arm or control arm with the same probability of 1/2. On the con-
trary, non-randomized treatments are commonly seen in observational studies. A random
assignment of treatment ensures balance across study groups in terms of measured and un-
measured risk factors and allows the greatest reliability and validity of statistical estimates
of causal effects. In fact, in a randomized experiment, association between treatment and
outcome implies a causal effect of the treatment on outcome.
In an observational study, we can attempt to estimate the effect of a treatment or an
exposure by comparing outcomes when “it is not feasible to use controlled experimenta-
tion, in the sense of being able to impose the procedures or treatments whose effects are
desired to be discovered, or to assign subjects at random to different procedures” (Cochran,
1965). In an observational study, there is no control over the treatment assignment, so
treated and untreated subjects may be quite different with respect to disease-related or
outcome-dependent characteristics: some subjects could be more likely than others to re-
ceive the treatment due to these characteristics. These characteristics which determine
if an individual will receive the treatment are referred to as confounders (or confounding
variables) if they are also risk factors of outcomes. For instance, if doctors are more likely
to assign a surgical treatment to sicker patients, while relatively healthier patients are more
likely to be assigned standard care. Then, while studying the effect of surgery on survival,
health status before treatment is a confounder. In an observational study, associations
cannot be generally interpreted as causal effects. Removing the selection biases caused
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by confounders is a central objective in the analyses of treatment effects in observational
studies.
1.3.2 Causal Diagrams
This section aims to introduce some graphical devices, which are often referred to as causal
diagrams. The graphical approach is helpful to summarize what we know about the study
and what we assume about the relationships between variables relevant to our particular
causal inference problem of interest. In practice, it is common to combine two approaches:
using causal diagrams to conceptualize problems and using the counterfactual approach,
e.g. the marginal structural model (MSM) and inverse probability weighting (IPW) that
we will introduce later, to analyze data and do inference.
A diagram like the ones in Figure 1.1 is known as a directed acyclic graph (DAG)(Pearl,
1995), which is a visual summary of the likely (known, suspected or hypothesized) causal
links between variables. They are called “directed” because one edge implies a direction,
i.e. X may cause A, but not the other way around. The term “acyclic” implies that there
are no cycles, i.e. a variable cannot cause itself, either directly or through another variable
(Herna´n and Robins, 2016).
In a DAG, each variable is represented by a node (vertex), e.g. X, X∗, A and Y in
Figure 1.1. Relationships between variables are represented through edges (the arrows).
Directed edges represent causal associations. We adopt the convention that time flows
from left to right. Thus, Figure 1.1(a) represents a randomized experiment where there
is not an arrow from X to A. Figure 1.1(b) represents an observational study where X
is a common cause of outcome Y and treatment A. In this case, we say X is a known
confounder of the effect of A on Y . Figure 1.1(c) displays that there is an observed variable
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denoted by X∗ that is affected by treatment A and also predicts the outcome. Here, X∗
is called an intermediate variable which is on the causal pathway between A and Y . The
path A → Y represents the direct effect of treatment on outcome, while A → X∗ → Y
represents an indirect effect of treatment on outcome. To unbiasedly estimate the overall
effect of A on Y , one should consider both direct and indirect effects. More details about
DAGs can be found in a comprehensive book on this subject written by Pearl (2003).
X A Y
(a)
X A Y
(b)
A X∗ Y
(c)
Figure 1.1: Examples of randomized treatment (a), confounded treatment (b) and inter-
mediate variable (c) by DAGs, where Y is the outcome variable, A is the treatment whose
effect on Y is of interest, X is a confounder, and X∗ is an intermediate variable.
1.3.3 Causal Inference and Some Important Assumptions
Nowadays, two main competing perspectives on causal inference have risen: the coun-
terfactual perspective and the non-counterfactual perspective. Rubin (1974) proposed a
counterfactual approach for causal inference which is the focus of most recent statistical
research. For simplicity, assume only two interventions are compared: treated and untreat-
ed. Define Y 0i as the outcome that would have resulted if subject i was untreated and Y
1
i
as the outcome that would have resulted had subject i been treated. The causal effect of
this treatment (denoted by A = 0 or 1) on outcome is based on the comparison of these
two counterfactual or potential outcomes, Y 0i and Y
1
i . However, a subject usually can only
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receive one treatment status, i.e. either be treated or be untreated, so only one of these
two potential outcomes is observable. Therefore, one of the potential outcomes is counter-
to-the-fact, i.e. counterfactual. The causal effect, Y 1i − Y 0i , on one single subject can not
be observed, but the average causal effect (ACE), E[Y 1i ]−E[Y 0i ], can be estimated and is
often evaluated, under certain assumptions in causal inference. If outcome Yi is a binary
variable, the effect defined by E[Y 1i ] − E[Y 0i ] is called the causal risk difference. In addi-
tion, a causal risk ratio and causal odds ratio are defined by
Pr(Y 1i =1)
Pr(Y 0i =1)
and
Pr(Y 1i =1)/Pr(Y
1
i =0)
Pr(Y 0i =1)/Pr(Y
0
i =0)
,
respectively. Furthermore, there can be other effect measures which depend on the context
of a study.
The key difference between randomized experiments and observational studies is that
randomized experiments can balance observed risk factors as well as unobserved factors.
However, in observational studies, even applying appropriate analytical adjustments, we
can only balance the known risk factors and have to rely on some assumptions about
the unknown risk factors. Let L be a vector of measured covariates which describe the
characteristics of a subject prior to treatment assignment. We adopt the convention that
upper cases represent random variables, lower cases represent the realized values of random
variables, and upper cases in bold fonts denote a vector of random variables. Let Y a be
the counterfactual outcome of treatment status a and let A be a random variable which
denotes the actual treatment the subject received. As presented in Robins and Herna´n
(2009), the important assumptions needed in causal inference are listed below.
(A0) Consistency: If A = a for a given subject, then Y a = Y for that subject.
(A1) Strongly Ignorable Treatment Assignment/No Unmeasured Confounders:
The exposure or treatment assignment must be independent of the counterfactual
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outcomes given the observed risk factors, i.e. for all a, we have
Y a q A|L, (conditional exchangeability),
and
0 < Pr(A = a|L) < 1, ∀ L (positivity).
(A2) Stable Unit-Treatment Value Assumption (SUTVA): Each subject’s poten-
tial outcomes are not influenced by the actual exposure of another subject.
Consistency, conditional exchangeability and positivity, described in Rosenbaum and
Rubin (1983), were referred to as three identifiability conditions by Robins and Herna´n
(2009). The stable unit-treatment value assumption was labeled as “no interaction be-
tween units” by Cox in 1958 and was referred to as “no interference between subjects” by
Herna´n and Robins (2016). Assumptions (A0)-(A2) are essential in casual inference, under
which consistently estimating causal effects from observational data is possible. Addition-
ally, correct model specification, accurate data measurement and data missing at random
(MAR) are generally required in statistical analyses. Note that all assumptions above are
generally untestable. However, investigators’ expert knowledge is helpful to enhance the
plausibility of these assumptions. In addition, sensitivity analysis could be a useful tool to
study the magnitude of hidden bias, if the proposed assumptions were violated.
1.3.4 Structural Models
Models for counterfactual outcomes are referred to as structural models (Herna´n and Robin-
s, 2016). For example, Robins et al. (2000) proposed a class of marginal structural gener-
alized linear models, i.e.
E[Ya] = g
−1(a;β), (1.6)
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where Ya denotes the counterfactual outcome under the treatment a and g is the link
function. Herna´n et al. (2000) developed a class of marginal structural Cox proportional
hazards models for failure time outcomes, e.g.
λTa(t|V ) = λ0(t) exp(β1a+ β2V ), (1.7)
where λTa(t|V ) is the hazard of failure at t among subjects with baseline covariate V in
the population had, contrary to fact, all subjects received treatment a at t = 0; λ0(t) is
an unspecified baseline hazard. Model (1.6) and model (1.7) are called marginal structural
models (MSMs) (Robins, 1999; Robins et al., 2000; Herna´n et al., 2000; Herna´n and Robins,
2016). Model (1.6) and model (1.7) with a time-varying treatment variable can be found
in Robins et al. (2000) and Herna´n et al. (2000), respectively.
In addition, Herna´n et al. (2005) introduced a class of structural accelerated failure
time models, e.g. for a time-fixed treatment a, which have the form
ln(Ta) = β0 + β1a+ σW, (1.8)
or
Ta = T0 exp(β1a), (1.9)
where Ta is the counterfactual outcome under treatment a and W is a random variable that
follows a standard location-scale distribution. Model (1.9) can be developed for a time-
varying treatment and then the model is referred to as a structural nested AFT model
(SNAFTM) (Herna´n et al., 2005; Young et al., 2008, 2010).
1.3.5 Inverse-Probability-of-Treatment (IPT) Weighting
Inverse probability weighting (IPW) was first proposed by Horvitz and Thompson (1952)
for surveys in which subjects are sampled with unequal probabilities; Zhao and Lipsitz
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(1992) applied that to designs and analysis of two-stage studies; later, Xie and Liu (2005)
applied the IPT weighting method to the Kaplan-Meier estimator (Kaplan and Meier, 1958)
and log-rank test for survival data; Robins et al. (2000) and Herna´n et al. (2000) further
applied the IPT weighting to marginal structural models with time-varying treatment. In
sampling theory, a hypothetical population (often referred to as a pseudo-population) in
which characteristics are balanced across groups can created by weighting. For example,
in an observational study where a treatment effect is of interest, a randomized experiment
is imitated in the pseudo-population, and therefore associations can be used to estimate
causal effects. In practice, the pseudo-population is created by weighting each subject in
the original population by the inverse probability of the treatment this subject actually
received conditional on measured confounders denoted by Xi, i.e. w
∗
i =
1
Pr(Ai=a|Xi=x) .
The denominator is referred to as a propensity score and also known as a balancing score
(Rosenbaum and Rubin, 1983). That is, the pseudo-population consists of w∗i copies of
subject i from the original population. In this sense, estimators constructed by the inverse
probability weighting method are called inverse-probability-of-treatment weighted (IPTW)
estimators.
1.4 Introduction to Intermittent Observation Schemes
and Outcome-Dependent Follow-up
In this section, we discuss problems and challenges in longitudinal cohort studies with
intermittent observation schemes and introduce the situation of outcome-dependent follow-
up. A preliminary analysis of gap times between consecutive clinic visits in the PsA case
will be provided as an illustration. In later chapters, methodology will be proposed to deal
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with the outcome-dependent follow-up problem in survival analysis.
1.4.1 Intermittent Observation
In clinical experiments or planned longitudinal cohort studies, individuals are usually sched-
uled to be evaluated at regular and pre-specified time points during their follow-up. How-
ever, in practice, it is frequently found that individuals may miss some scheduled visits.
They could return later at a scheduled or a non-scheduled time point, or they could even
come to visit at arbitrary time points. That is, observation is intermittent, and the fre-
quency and timing of visits may vary greatly across individuals. This could happen when
a planned visit schedule is not adhered to by everyone, or when additional information is
available from unplanned observation visits, or when studies are designed with no regular
observation schedule (Bu˚zˇkova´ and Lumley, 2007). Therefore, broadly speaking, irregular
longitudinal studies could comprise discrete or continuous visit times or even a mixture
of them. For example, in the PsA example, X-ray tests are scheduled every two years for
assessing radiographical joint damage, but patients miss scheduled tests for various reason-
s. This is an example of discrete time observation scheme with missingness. In addition,
patients come to visit the clinic for lab tests and clinical assessments at non-homogeneous
times, though visits are planned every 6–12 months by the protocol. This is an example
of intermittent visits in continuous time. In addition, Lin et al. (2004) studied a random-
ized trial comparing several housing interventions for homeless people with mental illness.
Although investigators attempted to conduct follow-up interviews every 3 months, partic-
ipants often missed and showed up between scheduled interviews. In their case, the actual
visit times are a mixture of continuous random times and discrete prespecified times.
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1.4.2 Outcome-Dependent Follow-up
When the observation times are uniformly prespecified, e.g. participants were planned to
be assessed every month and actually adhered to the schedule, observation times would
be marginally independent of outcomes and other variables. Then, observation times are
automatically balanced among subjects, so they do not need to be adjusted for. On the
other hand, in longitudinal studies with intermittent inspection times, the frequency and
timing of visits are subject-specific. They could be highly associated with outcomes or
outcome-related variables including the past outcome history and past observation history.
As a result, follow-up times are unbalanced and could be dependent on the outcome pro-
cess. Terms used for this problem in literature are informative follow-up, biased follow-up,
personalized follow-up or observation, and outcome-dependent follow-up or observation.
Here, we adopt the term “outcome-dependent” follow-up. Pullenayegum and Lim (2014)
provided a detailed review of methods in longitudinal studies with irregular observation
times with a focus on visit processes, assumptions, and study design.
One illustration of outcome-dependent follow-up is the hypothetical example described
in Bu˚zˇkova´ and Lumley (2007), where interest lies in quantifying the effect of air pol-
lution A(t) on lung function P (t), e.g. to estimate β in the (marginal) outcome model,
E[P (t)|A(t); β], where β is the regression coefficient of A(t). Define N(t) as the counting
process of the cumulative number of observations or visits by time t. Then, dN(t) = 1
means there is an observation at time t, dN(t) = 0 otherwise. We know air pollution
can trigger an asthma attack, and someone with asthma attacks usually has lower lung
function. Let L(t) indicate an asthma attack at time t, where L(t) = 0 or 1. It is shown in
Figure 1.2 that asthma attack behaves as an intermediate variable between air pollution
A(t) and lung function P (t). Therefore, if we want to estimate the overall effect of air
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pollution on lung function, L(t) should not be directly controlled in the outcome model.
On the other hand, a patient with an asthma attack is more likely to visit the doctor so
that her/his lung function can be measured, which means that asthma attack L(t) is a
common risk factor between observation dN(t) and outcome P (t). The DAG for this hy-
pothetical example is exhibited in Figure 1.2. Investigators study the distribution of lung
function P (t) based on the observed value P obs(t). In this example, if they ignored the
informative observation scheme, i.e. analyze the observed data only, they would very likely
to overestimate the influence of air pollution on lung function, since a high proportion of
observable data is contributed by persons who had asthma attacks. In other words, the
dependent observation scheme acts as a biased selection of the outcomes to be observed
and the resulting bias is similar to the bias induced by informative missing data. In this
case, an inverse probability weighting method can assist to eliminate the selection bias via
appropriately adjusting for the common risk factors between the outcome process and the
observation process.
dN(t)
A(t) L(t) P obs(t)
Figure 1.2: DAG for the air pollution and lung function example. A(t): air pollution
measured at t; L(t): asthma attack indicator at t; P obs(t): lung function measured at t;
dN(t): indicator of a clinic visit at t.
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1.4.3 Preliminary Analysis of Visit Times in the PsA Example
To date, over one thousand patients have been followed up over years in the PsA Toron-
to Cohort Study. Of the 1020 subjects who have at least two recorded clinic visits, we
first consider a subcohort of 880 patients with complete information on key disease and
treatment variables for a preliminary study of intermittent clinic visits. Among the 880
subjects, calendar dates of visits range from 1973-12-12 to 2013-03-25, because the admin-
istrative end of follow-up is Nov. 2013. Demographic information and disease onset times
are collected at enrolment. Time-varying variables such as joint activity, joint damage and
biomarkers are measured only at clinic visits, except treatments (i.e. NSAIDs, DMARDs
and biologics). Therapy history is recalled retrospectively at visits, so the full history of
taking a drug is ascertained. Figure 1.3 describes the visit process in this example. People
who have PsA are recruited in this cohort study, so clinic enrolment time ti0, which is the
first visit, is some time point past the PsA onset time. Clinical evaluation and lab tests are
conducted at visits, i.e. ti0, ..., ti,mi for subject i. Meanwhile, therapy history, e.g. names
of specific drugs, the start date and stop date of usage, and the reasons for termination or
switch, is recalled at visits.
PsA onset ti0 ti1 ti2 ti3 ti4 ti,mi τi time
Figure 1.3: Scenario of the visit process in the PsA example, where ti0 is the clinic enrolment
time and ti1, ..., ti,mi are the mi intermittent clinic visits, and τi is the administrative end
of follow-up for subject i.
To analyse the visit process, we consider the following stratified semi-Markov propor-
24
tional hazards model for visit gap times:
λN(t|Zi(t−);α) = λsN0(B(t)) exp(α′Zi(t−)), s = 1, ..., S, (1.10)
where t is the chronological time since the time origin, i.e. ti0, of the visit process; B(t) is
the gap time between the most recent past visit and time t; λsN0 is the stratified baseline
hazard function which is unspecified, where s denotes the strata defined by the decades of
the most recent visit prior to t, i.e. 1970, 1980,..., 2010; Zi(t
−) represents some features
of the observed history of risk factors prior to t where t− denotes the instant prior to t.
Later we will see from the analysis results that Zi(t
−) could include the history of outcome
or outcome-related variables. On average, patients have about 11 visits from enrolment
to τi. The length of follow-up ranges from 35 days to about 36 years, with a median of
approximately 7 years, and a standard deviation (SD) of about 8 years. The number of
visits ranges from 1 to 56, with a median of 7 and a SD of approximately 12. A “visit
gap” is defined by the time gap between two successive visits and has a median of 196
days (SD = 439 days), with a range from 5 days to about 25 years. Although 53% of visit
gaps are between 6 months and 12 months, as expected, there are some extreme cases such
as visit gaps longer than 20 years. In total, 34% of visit gaps are shorter than 6 months,
13% are longer than 12 months, and about 1.6% are longer than 5 years. Table 1.1 shows
the summary of fitting model (1.10) to the data. The attributes of variables that are
considered in the analysis are given in Table A.1 in Appendix A.1 at the end of the thesis.
From Table 1.1, we see that visit intensities are strongly associated with age, erythrocyte
sedimentation rate (ESR), treatment status of NSAIDs, DMARDs and biologics and the
median length of past visit gaps. Also, there is some evidence that family history of PsA
is also related to visit times. This preliminary analysis indicates that in the PsA example,
visit times are strongly dependent on disease-related variables, especially disease status
represented by biomarkers (e.g. ESR) and treatments, and the history of past visits. That
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is, the visit process will be informative to studies of disease progression.
1.5 Marginal or Partially Conditional Regression Mod-
els
Although multivariate regression models are widely used in observational data analyses,
scientific interests may also include the association between a particular risk factor and
outcome. As for the example described in Figure 1.2, controlling for an asthma attack
by including it as a regressor in the outcome model for lung function could avoid biased
analysis results due to a dependent observation scheme, but researchers’ interest might
lie in studying the marginal effect of air pollution on lung function. Then, the pathway
A(t) −→ L(t) −→ P (t) should not be blocked. Otherwise, not a marginal effect but a
direct effect of A(t) on P (t) will be given, since an asthma attack, L(t), plays the role
of an intermediate variable between air pollution and lung function. In this section, we
discuss marginal (or partially conditional, i.e. only conditional on a primary covariate, e.g.
treatment, of interest) models and the collapsibility of association measures in regression
models.
Suppose A(t) (time-fixed or time-varying) is a covariate of prime research interest. The
marginal effect of A(t) on outcome is a population-averaged association measure, but when
another risk factor, say L(t), is controlled, the effect of A(t) on outcome is interpreted
as the conditional effect of A(t) for a particular subset of individuals given L(t). The
adjusted exposure effect conditional on L(t) and the unadjusted effect can differ, when the
expected value of outcome is modeled as a nonlinear function of the exposure (Greenland
et al., 1999). The difference between the adjusted and unadjusted association measures is
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Table 1.1: Summary of fitting the stratified semi-Markov PH model (1.10) for visit gap
times in the analysis set composed of 880 PsA patients. Variable med.gap denotes the
median length of past visit gap times; coef denotes the coefficient estimate of a regressor,
and exp(coef) is interpreted as a relative risk or hazard ratio of one unit change of the
regressor, and se(coef) is the standard error of the coefficient estimate.
coef exp(coef) se(coef) z Pr(> |z|)
ESR -2.05E-03 9.98E-01 6.30E-04 -3.251 0.00115 **
sex 1.98E-02 1.02E+00 2.15E-02 0.924 0.35572
age 4.20E-03 1.00E+00 9.42E-04 4.461 8.17E-06 ***
PS duration 1.01E-03 1.00E+00 1.02E-03 0.997 0.31869
PsA duration -1.25E-03 9.99E-01 1.42E-03 -0.876 0.38086
family history of PS -1.26E-02 9.88E-01 2.21E-02 -0.567 0.57053
family history of PsA -6.28E-02 9.39E-01 3.34E-02 -1.879 0.06025 .
number of active joints -1.94E-03 9.98E-01 1.28E-03 -1.516 0.12951
number of damaged joints 2.88E-04 1.00E+00 8.76E-04 0.328 0.74267
NSAIDs 1.21E-01 1.13E+00 2.16E-02 5.581 2.40E-08 ***
DMARDs 2.16E-01 1.24E+00 2.14E-02 10.105 < 2e-16 ***
biologics:I(B(t) ≤ 180) -3.13E-02 9.69E-01 6.39E-02 -0.49 0.62418
biologics:I(B(t) > 180) 1.74E-01 1.19E+00 3.32E-02 5.244 1.57E-07 ***
biologics:I(B(t) > 365) 2.34E-01 1.26E+00 1.02E-01 2.304 0.02121 *
med.gap:I(B(t) ≤ 180) -8.07E-04 9.99E-01 1.53E-04 -5.281 1.28E-07 ***
med.gap:I(B(t) > 180) -8.64E-04 9.99E-01 8.17E-05 -10.573 < 2e-16 ***
med.gap:I(B(t) > 365) -8.66E-05 1.00E+00 5.50E-05 -1.574 0.11542
—
Signif. codes: *** 0.001 ** 0.01 * 0.05 . 0.1
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referred to as non-linearity by Janes et al. (2010) and as non-collapsibility by Greenland
et al. (1999). Many widely used regression models are not collapsible due to non-linearity
of association measures. Specifically, Janes et al. (2010) discussed non-collapsibility for
logistic regression models, and Martinussen and Vansteelandt (2013) focused on the Cox
models and additive hazards models. In addition, Aalen et al. (2015) indicated that even
in a randomized survival study, a hazard model, λ(t), is not generally collapsible.
For example, suppose that a conditional Aalen’s additive model (Aalen, 1980, 1989) is
defined by
λ(t|A,L) = β0(t) + βA(t)A+ βL(t)L, (1.11)
then it was shown in Martinussen and Vansteelandt (2013) that the hazard model given A
alone is given by
λ(t|A) = β0(t) + βA(t)A+ βL(t)E(e
−BL(t)LL|A)
E(e−BL(t)L|A) , (1.12)
where BL(t) =
∫ t
0
βL(s)ds. If L and A are independent and we define a new intercept as
β˜0(t) = β0(t) + βL(t)
E(e−BL(t)LL)
E(e−BL(t)L)
,
the collapsibility of βA(t) in model (1.11) is shown by
λ(t|A) = β˜0(t) + βA(t)A.
Martinussen and Vansteelandt (2013) also showed that for a Cox conditional effect model,
in general the marginal effect of A and the conditional effect of A with L controlled are
not equal, and the proportional hazards assumption does not hold for marginal hazards
λ(t|A), even if L and A are independent. Therefore, another issue is that some model
assumptions can be violated in the marginal effect models even though they hold in the
conditional effect models.
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The goal of this thesis is to study a marginal treatment effect when the observation
scheme is intermittent and informative and the treatment or exposure in an observational s-
tudy is likely confounded. A class of inverse probability weighting methods will be proposed
to eliminate the selection bias which arises from irregular inspection times and confounded
treatment for estimation of marginal effect models. Simulation studies will be employed to
investigate the performances of the resulting weighted estimates. However, there is very
limited literature on data generation mechanisms for inverse probability weighted estima-
tion because of the difficulty of model marginalization and non-collapsibility. For example,
suppose that the objective is to estimate the marginal distribution of T given A(t), which
is defined by a hazard model λ(t|A(t)). In addition, there are some other known risk fac-
tor(s) of T , denoted by L(t). A conditional model of T given both A(t) and L(t) is defined
by λ(t|A(t),L(t)). The marginal model given A(t) alone can be obtained theoretically
by marginalizing the conditional model λ(t|A(t),L(t)) over L(t). If L(t) is a time-fixed
discrete variable, the marginalization is relatively feasible, but for a time-varying L(t),
the integration over L(t) is not easy and rarely results in a neat form of model. Most
recent papers on this problem either make certain assumptions about T and the covariate
process L(t) which might not be plausible in practice or give approximate relationships of
simple forms, e.g. Young and Tchetgen Tchetgen (2014), Havercroft and Didelez (2012),
or do not result in a simple form of marginal model. Our simulations in Chapter 2 are
based on a mechanism suggested by Young and Tchetgen Tchetgen (2014), which allows
a time-varying ancillary variable L(t). Another simulation design of log-normal failure
time distribution and time-fixed covariates will be introduced in Chapter 3. Additionally,
Aalen’s additive hazards models will be a focus of Chapter 4, on semiparametric estimation
with intermittent observation.
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1.6 Outline of the Following Chapters
In Chapter 2 and Chapter 4, we will propose an inverse-intensity-of-visit (IIV) weighted
estimating function approach to adjust for intermittent and outcome-dependent inspection
times so that a marginal outcome model for failure time data can be consistently estimat-
ed. In Chapter 3, the estimation of causal effects of exposures or treatments on failure
time outcomes will be considered. In Chapter 5, the association between treatment with
biologics and a joint damage event in the PsA Toronto Cohort Study will be analysed as an
illustration of the methodologies proposed in the preceding chapters. Finally, concluding
remarks and future work will be discussed in Chapter 6.
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Chapter 2
PARAMETRIC ANALYSIS OF
INTERVAL-CENSORED FAILURE
TIME DATA WITH DEPENDENT
INSPECTION TIMES
In Section 1.5, we discussed the marginalization and collapsibility of regression models.
Marginal failure time distributions or the overall associations with some particular factors
are often of substantive interest, and then other covariates that are not the targets of
inference should not be conditioned on, especially when they act as intermediate variables
on the pathway between the primary factor and outcome. For example, in the Toronto PsA
Cohort Study introduced in Section 1.1, one interesting question is how treatment with
biologics is associated with disease-related outcomes such as joint activity or joint damage.
Thus, usage of biologics is the primary factor for scientific interest, and other risk factors
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like gender, age, health status, disease duration, and family history should not be included
in the key outcome model. However, when other factors affect the timing of clinic visits,
marginal analysis of observed data may lead to biased results, which we have discussed in
Section 1.4.2 and will show by simulations in Section 2.3.1. Although some information
obtained at or prior to treatment initiation may affect disease progression as well as the
treatment assignment, we will discuss this later in Chapter 3 which focuses on causal
inference. This chapter aims at the parametric estimation of the marginal distribution of
a failure time outcome variable and its marginal association with a time-fixed exposure or
treatment, like biologics, in the presence of intermittent and outcome-dependent inspection
times.
In the PsA study, patients are planned to be inspected every 6-12 months according
to a protocol. Although the median length of gap times between consecutive clinic visits
is about 6 months, the visit gaps are highly variable and range from 5 days to 25 years.
In Section 1.4.3, we have seen that how often patients come to visit the clinic depends on
demographic information, biomarkers, treatments, family disease history, and the history of
past visits. Therefore, the subject-specific visit times are informative or disease-dependent.
At each visit, disease status such as joint activity or damage is assessed, but the exact onset
time of a joint condition is not observable. That is, a joint event is subject to dependent
interval-censoring due to the irregular clinic visits, so standard estimation methods such
as maximum likelihood estimation (MLE) or generalized estimating equations (GEEs)
could lead to biased estimates. In this chapter, we propose an inverse-intensity-of-visit
(IIV) weighting method applied to estimating equations which can appropriately adjust
for outcome-dependent follow-up times and provide consistent estimation in parametric
survival models. Before Section 2.2.4, we assume that the visit process is not discontinued
by the occurrence of failure or event and that visit times are continuous. For the case
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where failure terminates visits, we convert to a discrete time visit process and pretend to
observe the responses after failure is known to have occurred. This will be discussed in
detail in Section 2.2.4.
2.1 Estimating Equations for Interval-Censored Fail-
ure Time Data
In survival analysis, if a continuous failure time is monitored at periodic visits, it is often
interval-censored. For example, consider a study of the time to onset of bladder cancer,
where participants are scheduled to visit clinic annually. Investigators know that a patient
was first diagnosed with bladder cancer at the jth visit and that bladder cancer was still
absent at the (j−1)th visit, but the exact onset time is unobservable. In the PsA example,
because joint damage is evaluated only at clinic visits, the exact time of appearance of a
damaged joint is not observable. If the inspection times of subject i, denoted by tij where
j = 1, ...,mi, are completely independent of outcomes or are conditionally independent
of outcomes given the covariates which have been included in the outcome model, the
likelihood for interval-censored data given below can produce consistent estimators:
L =
n∏
i=1
mi∏
j=0
[ST (tij)− ST (ti,j+1)]δij , (2.1)
where ti0 = 0 and ti,mi+1 = +∞, δij = I{tij < Ti ≤ ti,j+1}, and ST (t) = Pr(Ti > t)
is the survival function of Ti, i = 1, ..., n. For convenience, we suppress the dependency
of Ti on covariates in the notation. However, when inspection times are informative or
outcome-dependent, the likelihood in (2.1) can lead to biased estimates. One way to
control for the intermittent inspection times is to regress on all the risk factors that are
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related to the outcome process as well as the visit process, but the resulting regression
coefficient indexing the variable of interest will be interpreted as an association with failure
time conditional on the values of all other risk factors. Section 2.2 will introduce an
inverse probability weighting approach which can produce consistent estimates of marginal
regression parameters. This approach is based on estimating functions (White, 1982), so
we will first introduce some estimating functions for failure time data before considering
the adjustment for dependent inspection times.
As an aid to discussion and interpretation, notation will be defined in the context of
the PsA example. Let Ai = (Ai1, ..., Aiq)
′ be a q-dimensional vector of time-fixed exposure
or treatment variables measured at t = 0 for subject i, where i = 1, ..., n. For simplicity,
we assume that the time origin corresponds to a subject’s clinic entry time, unless stated
otherwise. In the PsA example, these variables of particular interest could be gender,
age at PsA’s onset time, family history of disease or treatments received at clinic entry.
Exposure can be considered fixed in three settings: first, if every subject’s exposure occurs
only once at the start of follow-up (e.g. vaccination, radiation from a bomb explosion, a
surgical intervention); second, if the exposure remains constant over time (e.g. genotype);
or third, if the exposure evolves over time in a deterministic way (e.g. age) (Robins and
Herna´n, 2009). Then, define a time-to-event variable denoted by Ti, which can be the time
to the presence of some joint event from clinic entry for subject i, e.g. time to an increase
in the number of damaged joints since enrolment.
Instead of assessing Ti directly, we define a longitudinal binary outcome Pi(t) = I(Ti >
t) whose mean given Ai would be the marginal (or partially conditional) survival function
of Ti given Ai, i.e. E[Pi(t)|Ai] = ST (t|Ai). Then, Pi(t) is a monotone function from 1 to
0. In addition, let Ci be a random drop-out time and τi be the administrative end of follow-
up for subject i, and we define Ci ≤ τi. Additionally, let 0 < ti1 < ti2 < ... < timi ≤ Ci
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be the mi intermittent inspection times of subject i. Moreover, let Li(t) be a vector of
time-varying auxiliary variables which affect the risk of failure as well as the timing of
visits. Some of Li(t) may be defined for all t but measured only at clinic visits, e.g.
inflammation evaluated by lab tests. On the other hand, some factors change at certain
known time points, e.g. the exact start dates and stop dates of treatments such as NSAIDs,
DMARDs and biologics are reported retrospectively at visits, so their whole history is
known. Later, we will introduce an important assumption that the dependent inspection
times are based only on the “observed history” of relevant variables. Finally, we need
to introduce some notation for a counting process: let {Ni(t), t > 0} be the cumulative
number of visits for the ith individual through time t, and write Ni(t) =
∫ t
0
dNi(s), for
t > 0. Let Ci(t) = I(Ci > t) be the at-risk process and define dN
∗
i (t) = dNi(t)Ci(t), so we
have {ti1, ..., timi} = {t > 0 : dN∗i (t) = 1}.
To introduce the estimating function method for failure time data, firstly, we assume
that a subject can be followed up to the last visit, timi , before loss to follow-up, even if
failure occurred before timi . This is realistic in some cases, e.g. in the PsA example where
patients who have already been diagnosed with joint damage can still visit the clinic before
the administrative end of follow-up.
2.1.1 Estimating Function Methods for Interval-Censored Fail-
ure Times
We assume in this section that unless stated otherwise, the visit times, tij where j =
1, ...,mi, are conditionally independent of Ti given Ai. The dependent visit times case
will be considered in Section 2.2, but it is convenient to introduce the type of estimating
functions for failure time outcomes under independent visit scheme first. Suppose that Ti
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follows a parametric model whose survival function given Ai is denoted by ST (t|Ai;θ),
and our objective is to estimate the parameter θ. For example, we could assume that Ti
has a parametric proportional hazards model, i.e. its hazard function is given by
λT (t|Ai;θ) = λT,0(t;γ) exp [β′Ai] , (2.2)
where θ = (γ ′,β′)′, and λT,0(t;γ) is a parametric baseline hazard function, which could
be the hazard of a Weibull, log-normal, log-logistic, Gompertz, etc, and eβl is interpreted
as the marginal hazard ratio contributed by one unit change of Ail, l = 1, ..., q, with
other variables unchanged. The corresponding marginal survival function is ST (t|Ai;θ) =
exp
[
− ∫ t
0
λT (s|Ai;θ)ds
]
, provided that Ti is a continuous variable. Consider Pi(t), t =
ti,1, ..., timi , as the repeated measures of survival status; an estimating function for the
parameter θ can then be defined by
U(θ) =
n∑
i=1
∫ τi
0
c(t|Ai;θ)[Pi(t)− ST (t|Ai;θ)]dN∗i (t) (2.3)
=
n∑
i=1
mi∑
j=1
c(tij|Ai;θ)[Pi(tij)− ST (tij|Ai;θ)],
where dN∗i (t) = dNi(t)Ci(t) and Ci(t) = I(Ci > t) as defined earlier, and c(t|Ai;θ) is a
vector of known functions of t conditional onAi, with the same dimension as θ; components
of c(t|Ai;θ) are linearly independent functions of t for all θ. Note that the unbiasedness
of estimating function (2.3) holds regardless of the specification of c(·). Each Pi(t) has
a Bernoulli (Binomial) distribution with mean ST (ti,j|Ai;θ), so the estimating function
(2.3) is equivalent to the score function of n ×mi independent binary outcome Pi(t)’s, if
the function c(t|Ai;θ) is defined by
c(t|Ai;θ) = ∂ST (t|Ai,θ)/∂θ
ST (t|Ai,θ)[1− ST (t|Ai,θ)] . (2.4)
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Generalized linear models or GEEs (Liang and Zeger, 1986) are widely used for survival
analysis, e.g. for current status data by Jewell and Shiboski (1990); Shiboski and Jewell
(1992), and for general interval-censored data by Sun (1997); Huang and Rossini (1997);
Zhang et al. (2005), and for competing risk models or multi-state models by Andersen
et al. (2003); Klein and Andersen (2005). If dN∗i (t) is independent of the value of outcome
Pi(t) given Ai, i.e. the condition (B0) to be introduced in Section 2.2.1 and independent
random drop-out are satisfied, it is obvious that (2.3) is an unbiased estimation function,
i.e. E{Ui(θ)|Ai} = 0. As a result, by White (1982), we know that the solution to
U(θ) = 0 is a consistent estimator of θ under mild regularity conditions.
In estimating function (2.3), we have assumed that ST (t|Ai;θ) is a parametric model,
e.g. (2.2). Although we consider semi-parametric models or non-parametric models in
Chapter 4, one simple way to gain flexibility for model (2.2) is to apply a piecewise constant
baseline proportional hazards model. That is, for a prespecified set of cut-points 0 = a0 <
a1 < ... < aK =∞, we assume that
λT (t|Ai;θ) =
K∑
k=1
ρkIk(t) exp (β
′Ai) , (2.5)
where Ik(t) = I{t ∈ (ak−1, ak]} and ρk’s are unknown positive constants; θ = (ρ′,β′)′ are
the parameters we want to estimate. It has been discussed in Lawless (2003) that when
K → ∞ and ak − ak−1 ↓ 0, the profile likelihood function for β based on model (2.5) ap-
proaches the partial likelihood of Cox (semi-parametric) proportional hazards model and
the parametric MLE of the baseline hazard estimate of model (2.5) approaches the Bres-
low or generalized Nelson-Aalen estimate for the Cox model. This good approximation to
the Cox model makes model (2.5) more flexible than many ordinary parametric models.
In practice, a moderate value of K is often chosen, because experience indicates that re-
duction of the grid fineness beyond a certain point in model (2.5) yields little change in
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inferences. Actually, for many practical problems, choosing K to be 4 to 6 would be suffi-
cient (Lawless and Zhan, 1998; He and Lawless, 2003). Other choices of flexible parametric
proportional hazards models could be spline specifications (He and Lawless, 2003) or kernel
specifications for baseline hazard functions, especially when smooth estimates of hazard
functions are preferred. Likewise, an approximate non-parametric estimate of the survival
function can by obtained by fitting a piecewise constant baseline hazards models like (2.5)
without covariates. We note that for suitably defined parametric models, ST (t|Ai;θ) is
non-increasing in t. However, for non- or semi-parametric estimation, this is not implicit,
and then constrained estimation may be necessary, which will be discussed in Chapter 4.
Another interesting question in the PsA example is how to assess the time to the
appearance of the first clinical damaged joint from the onset of PsA with respect to some
baseline risk factors such as gender fixed at the onset time. In this case, the time origin
corresponds to the onset time of PsA rather than the clinic entry time, but the visit
process starts after the onset, because only patients who have PsA are enrolled. Then, we
can observe the time to the first damaged joint only if it occurs after clinic entry, so failure
time might be left-truncated at the clinic entry time which is denoted by ti0 for subject i.
An estimating function can still be developed to consistently estimate the parameters in
the outcome model ST (t|Ai;θ), if visit times, drop-out, and the delayed entry time (i.e. ti0)
are all independent of outcomes given Ai. Note that Ai and Ti are defined at t = 0 (≤ ti0),
but the visit process dNi(t) is defined for t > ti0. Here, we define a binary longitudinal
outcome as Pi(t) = I(Ti > t), for all t > ti0, which indicates survival past t. Its mean
conditional on Ai and Ti > ti0 is E[Pi(t)|Ti > ti0,Ai;θ] = ST [t|Ai;θ]/ST [ti0|Ai;θ], for all
t > ti0, if a parametric model for failure time Ti is assumed. Then, the estimating function
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for θ can be defined by
U(θ) =
n∑
i=1
∫ τi
ti0
c(t|Ai;θ, ti0)[Pi(t)− ST (t|Ai;θ)/ST (ti0|Ai;θ)]dN∗i (t), (2.6)
where c(·) is a vector of known functions with the same dimension as θ. Again, ST (·|θ)
could be any (flexible) parametric survival function for a failure time outcome.
2.1.2 Relation between Interval-Censored Maximum Likelihood
and Estimating Function Methods
When failure time is subject to interval censoring, one standard estimation method for
parametric models is to maximize likelihood (2.1), assuming that the inspection times,
tij and ti,j+1, which capture the occurrence of failure, are independent of outcome Ti.
Alternatively, the estimating function given in (2.3) can be used. Given the mi inspection
times and the true covariance matrix of Pi(t), at ti1, ..., timi , correctly specified for subject
i, it can be shown that an estimating function in the form of (2.3) and the score function
based on likelihood (2.1) are identical, as we discuss below.
Recall that 0 < ti1 < ti2 < ... < timi ≤ Ci are the inspection times of subject i. Now, we
define variables δij = I{Ti ∈ (tij, ti,j+1]}, where j = 0, ...,mi with ti0 = 0 and ti,mi+1 = +∞,
to indicate interval censoring or right censoring at the last visit and let piij = E(δij|Ai;θ),
where 0 < piij < 1. Then, we know that
∑mi
j=0 piij = 1 and
∑mi
j=0 δij = 1. The likelihood for
independently interval-censored Ti given in (2.1) can be rewritten as (2.7) below:
L(θ) ∝
n∏
i=1
mi∏
j=0
[ST (tij)− ST (ti,j+1)]δij
∝
n∏
i=1
mi∏
j=0
pi
δij
ij . (2.7)
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Note that all the expectations or variances shown above are based on a parametric model
given Ai, but Ai and parameter θ are suppressed in expressions for simplicity. We no-
tice that equation (2.7) is the likelihood of n independent multinomial random variables
δi = (δi0, ..., δimi)
′ with the number of trials fixed as 1. It is known that the multinomial
distribution with a fixed number of trials is a member of the exponential family whose
probability density or mass function is of the form
f(δi;pi, φ) = exp{[δ′ipi − b(pi)− d(δi, φ)]/a(φ)}. (2.8)
Here, pij = ln(piij/piimi), j = 0, 1, ...,mi, pi = (pi0, ..., pimi)
′, and b(pi) = −ln(piimi),
a(φ) = 1 and d(δi, φ) = 0. Therefore, by Wedderburn (1974) and McCullagh (1983), it is
known that (2.7) is identical to the quasi-likelihood for δi, i = 1, ..., n, whose score function
has the form:
U(θ) =
n∑
i=1
D′i(δ)V
−1
i(δ)[δi − µi(δ)], (2.9)
where µi(δ) = E(δi|Ai,θ), Di(δ) = ∂µi(δ)/∂θ′, and V −1i(δ) is a generalized inverse of Vi(δ) =
V ar(δi|Ai,θ). Explicitly, for δij, µij = piij, V ar(Vij) = piij(1 − piij) and Cov(Vij, Vil) =
−piijpiil, when j 6= l, j, l = 0, 1, ...,mi.
Now, we will show the the quasi-likelihood score function (2.9) is identical to the gen-
eralization of an estimating function given in (2.3) via a variable transformation from δi
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to Pi. By their definitions, we know
δi0
δi1
...
δi,mi−1
δimi

=

1− Pi1
Pi1 − Pi2
...
Pi,mi−1 − Pimi
Pimi

=

1
0
...
0
0

+

−1 0 0 · · · 0
1 −1 0 · · · 0
...
...
...
. . .
...
0 · · · · · · 1 −1
0 · · · · · · 0 1


Pi1
Pi2
...
Pi,mi−1
Pimi

,B0 +BPi, (2.10)
where Pi = (Pi1, ..., Pimi)
′, Pij = I(Ti > tij), j = 1, ...,mi, and the notation , denotes
equal to by definition. By the linear relation (2.10), we have E(δi) = B0 +BE(Pi), i.e.
µi(δ) = B0 + Bµi, where µi denotes E(Pi), and then δi − µi(δ) = B(Pi − µi). Also,
Di(δ) = ∂µi(δ)/∂θ
′ = B∂µi/∂θ′ , BDi, where Di = ∂µi/∂θ′, and Vi(δ) = V ar(δi) =
BV ar(Pi)B
′, and then we have V −1i(δ) = (B
′)−1V −1i B
−1, where Vi = V ar(Pi). Thus, the
quasi-likelihood score function (2.9) can be written alternatively as
U(θ) =
n∑
i=1
D′i(δ)V
−1
i(δ)[δi − µi(δ)]
=
n∑
i=1
D′iB
′(B′)−1V −1i B
−1B(Pi − µi)
=
n∑
i=1
D′iV
−1
i (Pi − µi), (2.11)
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where µi = E(Pi), Di = ∂µi/∂θ
′, and Vi = V ar(Pi), i = 1, ..., n. Note that it is an
extension of (2.3) with c(tij|Ai;θ) replaced by the jth column of D′iV −1i and ST (tij|Ai;θ)
replaced by the jth element of µi. This is also equivalent to a GEE for Pi with the true
covariance matrix of Pi specified for the working covariance matrix.
So far, we have shown that given the visit times, ti1, ..., timi , likelihood (2.1) for interval-
censored Ti and a GEE with the true covariance matrix for Pi correctly specified are
identical and lead to the same estimator for θ. Furthermore, when the random inspection
times tij, j = 1, ...,mi, are independent of Ti given Ai, maximizing the likelihood (2.1) or
solving an estimating equation given in (2.3) gives a consistent estimator for parameter θ.
However, if the random inspection times are outcome-dependent, Ti could be dependently
interval-censored. Then, maximizing the likelihood (2.1) or solving (2.3) may lead to biased
estimates. In the next section, we will introduce an inverse probability weighting method
that can be applied to (2.3) or (2.6) so that the resulting estimates obtained by solving
the weighted estimating functions are consistent, provided that an important assumption
which will be introduced in Section 2.2.1 is satisfied and that both the outcome model and
the weight model are correctly specified.
2.2 Methodology of Inverse-Intensity-of-Visit Weight-
ed Estimation
We have introduced intermittent and outcome-dependent observation in Section 1.4.1 and
Section 1.4.2. In principle, if observation times are discrete and finite and individuals have a
common set of prespecified potential visit times, the outcome-dependent follow-up problem
can be dealt with as a longitudinal missing data problem. Robins et al. (1995) presented the
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assumption of sequentially ignorable nonresponse and proposed using weighted estimating
equations for the adjustment of monotone missing responses, i.e. censoring, with the weight
at time t defined by the inverse probability of the outcome being observed at t. Imputation
and expectation-maximization (EM) algorithms based on a joint model for outcomes and
visits are also commonly employed for longitudinal studies in the presence of missing data.
In particular, Chen et al. (2010) studied the PsA data via a likelihood-based approach
based on multi-state models. They assumed that subjects are scheduled to be examined
at a common set of times, and then applied the EM algorithm to deal with the missing
data at unattended visits.
Most literature dealing with missingness under continuous observation schemes in lon-
gitudinal studies, especially for failure time outcome, considers monotone missingness, i.e.
random drop-out, first presented by Wu and Carroll (1988). A classification of drop-out
processes was defined by Diggle and Kenward (1994): completely random drop-out (CRD),
random drop-out (RD) and informative drop-out (ID), following the terminology in Rubin
(1976), and a class of inverse-probability-of-censoring (IPC) weighted estimating functions
were proposed by Robins (1993), Robins et al. (1995), Scharfstein et al. (1999), Robins
and Finkelstein (2000), and Satten et al. (2001) for various outcome models or censoring
time models. However, there are few papers about the intermittent observation scheme
in continuous time. When observation occurs in continuous time, missing data techniques
do not provide a useful method for the dependent observation problem, unless continuous
observation times are discretized by grouping.
Outcome-dependent observation in continuous time was first addressed by Lipsitz et al.
(2002) where they focused on the repeated measures following a multivariate Gaussian
distribution. They separated the likelihood into two parts: one for the outcome process
and one for the observation process and proposed that the latter can be ignored if it is
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likelihood-based and all the common risk factors between the outcome and observation
processes are conditioned on. Therefore, as we mentioned before, one way to adjust for
dependent intermittent observation is to introduce all common risk factors between the
outcome process and the visit process as covariates or stratifying variables in the analysis
of outcomes. Other methods could be like Sun et al. (2005) where they marginally modelled
the visit process and then modelled the outcome process conditional on visit history, but
this gives conditional regression parameters given the visit history. Alternatively, most
recent literature links the outcome process and the visit process by introducing common
(shared) latent variable(s), e.g. Sun et al. (2007) and Cai et al. (2012), or correlated latent
variable(s), e.g. Liang et al. (2009) and Sun et al. (2012), between these the two processes.
Their methods produce estimates of the regression parameters in the outcome model that
are conditional on unobservable latent variable(s), i.e. random effect(s). Moreover, most
joint modelling approaches for dependent visits via random effect(s) assume time-invariant
random effect(s), which are hardly plausible in many situations. The advantage of such
joint modelling methods is that they can handle the cases where the outcome process and
the visit process are correlated via unknown factors, as long as these effects are of the
assumed form.
However, in many applications, the regression parameters of a model for outcomes
conditional on ancillary variables are not the target of inference. Instead, a model for
the outcome given a smaller set of “primary” covariates is of interest (e.g. Bu˚zˇkova´ and
Lumley (2007)). To estimate the marginal effect of a set of primary factors on outcomes
in the presence of time-varying ancillary variables, a more appropriate and convenient way
to adjust for outcome-dependent inspection times is weighting an estimating equation for
outcomes which is conditional on the primary factors only by an inverse intensity of visit.
Explicitly, Lin et al. (2004) considered the intermittent inspection times as a recurrent event
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process in continuous time; the visit intensity at t may depend on the history of previous
outcomes, previous visits and external covariates prior to t, in addition to the primary
factors included in the marginal outcome model. Bu˚zˇkova´ and Lumley (2007) extended
their method to involve time-varying covariates and discontinuous visit intensities so that
visit schemes with a mixture of scheduled discrete time visits and unplanned continuous
time visits can be dealt with.
Inverse probability weighting (IPW) is a general estimating function methodology for
informative selection, e.g. missingness, censoring, sampling in surveys, treatment assign-
ment in causal inference, etc, when the selection mechanism is ignorable, i.e. at random,
following the notions and terminologies of missing at random (MAR) by Rubin (1976)
and coarsened at random (CAR) by Heitjan and Rubin (1991) and Jacobsen and Keid-
ing (1995). In longitudinal studies, there is a sequential ignorability assumption (Robins
and Rotnitzky, 1992; Hogan et al., 2004; Cook and Lawless, 2014), which states that the
missingness of outcome at time t is independent of the current outcome value given the
past history. This is similar to the important assumption which the inverse-intensity-of-
visit (IIV) weighting relies on. We will discuss this in the next section. Inverse probability
weighting is a very useful approach for outcome-dependent selection problems. It standard-
izes the selected data to the whole underlying population by weighting each observation
with the inverse of the probability that this subject is selected from the population. Horvitz
and Thompson (1952) applied the IPW idea in sampling contexts; later, it was applied
in a variety of studies by Manski and Lerman (1977), Kalbfleisch and Lawless (1988),
and Zhao and Lipsitz (1992); Robins (1993) showed that IPW can also handle dependen-
t censoring; Robins et al. (1994, 1995) developed the IPW estimation for missing data;
Robins et al. (2000) and Herna´n et al. (2000) applied the IPW to adjust for confounders in
observational studies with time-varying treatment. In the studies of dependent follow-up
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times, Lin et al. (2004) and Bu˚zˇkova´ and Lumley (2007, 2009) incorporated the intensity
of observation or visit as a weight into the estimation of marginal association measures for
irregularly observed longitudinal or repeated measures data, to adjust for ancillary vari-
ables associated with the outcome process as well as the observation process in randomized
experiments. Pullenayegum and Feldman (2013) further introduced the IIV weighting to
increment-based methods for irregularly observed longitudinal data and discussed the op-
timal truncation of IIV weights and a doubly robust IIV weighted estimator. In addition,
Pullenayegum and Lim (2014) gave a comprehensive literature review on longitudinal data
analysis with irregular observation.
Lin et al. (2004) and Bu˚zˇkova´ and Lumley (2007)’s IIV weighting method focuses on
repeated responses over time based on parametric or semi-parametric linear or generalized
linear models. We aim to extend this approach to failure time data analysis, where failure
time status is periodically monitored until a known occurrence of failure or loss to follow-up.
In this sense, a known failure discontinues the visit process. For example, this can happen
when an individual who has experienced the failure event is withdrawn from the cohort or
switched to another cohort. Furthermore, if commonly used monotone measures of a failure
time such as the CDF, FT (t) = E{I(T ≤ t)}, and survival function, ST (t) = E{I(T > t)}
are targeted, monotonicity is a challenge for non-/semi-parametric estimation by using
estimating equations.
Outcome-dependent visit times cause failure time to be “dependently interval-censored”,
which makes standard analysis methods for interval-censored data inappropriate. In ad-
dition to likelihood-based methods, other approaches for interval-censored data include
multiple imputation, e.g. Pan (2000); Hsu et al. (2007); Chen and Sun (2010), but irreg-
ular visits which cause large variation of visit times make imputation difficult. Earlier,
van der Laan and Hubbard (1997) and van der Laan and Robins (1998) proposed locally
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efficient estimation for interval-censored data or current status data. If interval censoring is
independent and survival models are parametric, likelihoods involving time-varying covari-
ates can be constructed as in Sparling et al. (2006). Additionally, Finkelstein et al. (2002)
and Zhang et al. (2007) developed an EM algorithm for dependently interval-censored da-
ta. Finally, intermittent visits could also cause failure times to be left-truncated if the time
origin is set before the first visit, and then failures prior to the first visit are not included
in the analysis.
To sum up, the prime advantages of the IIV weighting method is that regression pa-
rameters indexing the marginal associations between the factors of primary interest and
outcomes can be consistently estimated when time-varying ancillary variables are adjusted
for but not directly regressed in the outcome model. Additionally, weighting methods can
be conveniently implemented by existing software such as R functions lm, glm, and geeglm.
The main constraint is that this weighting method relies on an important assumption of
conditional independence between the outcome process and the visit process given the ob-
served history of known variables which we will discuss in the subsequent section. This
condition is one that cannot be avoided without making assumptions that are uncheckable
given the type of data we consider, and other approaches such as imputation and EM
algorithms have the same or equivalent constraints.
2.2.1 Required Assumptions
Dependent observation arises when in addition to the covariates in the regression model
for outcomes, there are still some factors related to the observation process as well as the
outcome process. The values of these variables affect how often and when an individual
comes for a visit. For example, in the PsA example, patients who have more severe joint
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pain could be more likely to visit the clinic. Meanwhile, those patients who suffer more
from joint pain may have a higher risk of joint damage. The common factors between the
outcome process and the visit process could induce a selection bias, if we fail to properly
adjust for them. These common factors may include baseline or time-varying treatments
for PsA, baseline or time-varying biomarkers, and the history of previous outcomes and
previous visits, etc.
Let an overbar denote the history of a variable, i.e. Z¯(t) = {Z(s) : 0 ≤ s ≤ t} is the full
history of a time-varying variable Z(s) up to and including time t, and let Z¯obs(t) be the
corresponding observed history. Then, defineHobsi (t−) = {P¯iobs(t−), N¯i(t−),Ai, L¯iobs(t−)}
be the observed history, which includes not only the outcome model covariates, Ai, but
also the observed history of auxiliary external (time-varying) variables, L¯i
obs
(t−), and,
importantly, the observed history of the outcome process, P¯i
obs
(t−) where Pi(t) = I(Ti > t),
and history of the visit process, N¯i(t
−). We can let L¯i
obs
(t−) be left-continuous, i.e.
L¯i
obs
(t−) = L¯i
obs
(t) for all t. In general, Hobs(t−) can include the observed history of
everything except the current outcome value and current visit status. Then, let Zi(t
−) =
h{Hobsi (t−)} represent some features of the observed history Hobsi (t−), where h(·) is a
vector of certain known functions. The target of inference is to estimate parameter θ in a
parametric model for Ti:
ST (t|Ai;θ) = Pr(Ti > t|Ai;θ) = E{Pi(t)|Ai}. (2.12)
For the adjustment of intermittent visits, we consider the following two conditions for
the visit process:
(B0) Independent Observation Scheme
E{dNi(t)|Ai,Pi(t), Ci(t)} = Ci(t)E{dNi(t)|Ai}, ∀t > ti0, (a)
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E{dNi(t)|Ai} > 0, for all Ai and t > ti0. (b)
(B1) Conditionally Independent Observation Scheme
E{dNi(t)|Hobsi (t−),Pi(t), Ci(t)} = Ci(t)E{dNi(t)|Hobsi (t−)}, ∀t > ti0, (a)
= Ci(t)E{dNi(t)|Zi(t−)},
E{dNi(t)|Zi(t−)} > 0, for all Zi(t−) and t > ti0. (b)
Note Pi(t) = {Pi(s) : s ≥ t} denotes the current and future outcomes, Ci(t) = I(Ci > t)
is the at-risk indicator at t where Ci is a random drop-out time, and ti0 = 0 if not stated
otherwise, for i = 1, ..., n. When ti0 > 0, it indicates that Ti is left-truncated and ti0 is the
delayed entry time. Condition B0 (b) and B1 (b) are referred to as positivity conditions
which are needed to guarantee the existence of n1/2-consistent estimators of θ (Robins et al.,
1995). In principle, we can weaken condition (b) in (B1) to allow E{dNi(t)|Zi(t−)} = 0
at certain t− values, as long as this holds for all possible Zi(t−), but we will ignore this
in our development. In addition, we need to assume that the visit process distribution
and the outcome process distribution have distinct parameters, as for the ignorability of
coarsening mechanism discussed by Heitjan and Rubin (1991). Condition (B1) was referred
to as “sequential ignorability” by Robins and Rotnitzky (1992) and Robins et al. (1995) for
assuming that nonresponse at time t is independent of current and future outcomes given
the history through t− for the case of monotone missing responses in discrete time. This is
satisfied when data is missing at random in the sense of Rubin (1976) for the longitudinal
setting. Pullenayegum and Lim (2014) referred to the condition (B1) as visiting at random
(VAR), and a similar assumption was made for random drop-out by Diggle and Kenward
(1994) which is essential for IPC weighting methods.
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Condition (B0) indicates that given the covariates Ai controlled for in the targeted
outcome model (2.12), visits are outcome-independent, which is an analog to the condition
of “missing completely at random” (MCAR) by Rubin (1976). This was assumed for the
methods discussed in Sections 2.1.1 and 2.1.2. Condition (B1) means that given some
features of the observed past history, intermittent visits are ignorable. This is an analog
to the “missing at random” (MAR) by Rubin (1976). If condition (B0) is not satisfied but
(B1) holds, then consistent estimation of θ still can be achieved via appropriate adjustment
for Zi(t
−).
Condition (B1) requires that visits depend only on the observed history and known
factors. As Pullenayegum and Lim (2014) indicated, history-dependent protocol visits
and physician-driven visits usually satisfy (B1), but patient-driven visits are likely to be
not at random. In that case, (B1) may not hold, because a patient’s decision about
visit attendance may depend on some information which is not provided at past visits,
e.g. the true history H(t−). Condition (B1) is essential for the adjustment of irregular
visits by weighting, though it is usually untestable, like many other MAR conditions.
If (B1) is violated, it means that irregular visits are non-ignorable, and it is similar to
the case of “missing not at random”, which means visit times depend on some unknown
outcome-related factors. Missing not at random may result in weighting methods not being
applicable.
When condition (B1) is satisfied, weighting with an inverse-intensity-of-visit is useful
to adjust for informative past history so that characteristics are balanced between the
observed data and the unobserved data, and the marginal regression parameter θ in the
targeted outcome model (2.12) can be estimated consistently. As Bu˚zˇkova´ and Lumley
(2009) emphasized, the outcome model covariates should be picked on scientific grounds
to answer a question of particular interest, while the weight model must be determined by
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the nature of the observation process. In this section, we will extend a class of inverse-
intensity-of-visit (IIV) weighted estimators proposed by Lin et al. (2004) and Bu˚zˇkova´ and
Lumley (2007, 2009) for irregularly observed longitudinal data to failure time data based
on parametric models.
Lin et al. (2004) considered the visit or observation process {Ni(t), t > 0} as a continu-
ous time recurrent event process. As in Lin et al. (2004) and Bu˚zˇkova´ and Lumley (2007,
2009), we can consider a continuous-time parametric or semi-parametric intensity model
for the visit process conditional on Zi(t
−), with intensity denoted by dΛN(t|Zi(t−);α) =
E{dNi(t)|Zi(t−)}, provided that condition (B1) holds. We will further discuss the mod-
elling of visit times and the estimation of IIV weights in Section 2.2.3.
2.2.2 Weighted Estimating Functions
As mentioned before, if (B0) holds, no weighting is required to adjust for visit times, given
the targeted outcome model ST (t|Ai;θ) = exp
[
− ∫ t
0
λT (s|Ai;θ)ds
]
is correctly specified.
However, if (B0) is not satisfied, (2.3) or (2.6) takes only the observed outcomes, i.e. when
dN∗i (t) = 1, into account and the intermittent inspection times predict which values of
outcomes would be observed. Thus, the resulting estimators obtained by solving (2.3) or
(2.6) could be inconsistent. However, if (B0) is not satisfied, but (B1) holds, then weighting
the observed outcomes by the inverse of the probability or intensity of being observed at
that time can balance the characteristics between observed and unobserved outcomes, and
as a result, selection bias caused by dependent observation is eliminated. First, consider the
case where there is no left truncation of Ti. By solving the following unbiased estimating
function weighted by the inverse-intensity-of-visit, we can obtain a consistent estimator of
θ under certain regularity conditions, provided that the outcome model and weight model
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are both correctly specified. We consider
Uw(θ,α) =
n∑
i=1
Uwi (θ,α) =
n∑
i=1
∫ τi
0
wi(t;α)c(t|Ai;θ)[Pi(t)− ST (t|Ai;θ)]dN∗i (t), (2.13)
where the weight wi(t;α) is defined by
wi(t;α) = a(t|Ai)dt/E[dNi(t)|Zi(t−)], ∀t > 0
= a(t|Ai)/λN(t|Zi(t−);α), (2.14)
where a(t|Ai) is a stabilizing weight; we note that if ci(t) in the proof given below is
multiplied by an additional time-varying function a(t|Ai), (2.13) is still an unbiased esti-
mating function. We let a(t|Ai) = 1 in the following discussion of the thesis, unless stated
otherwise. Notation, e.g. Pi(t), dN
∗
i (t), and c(t|Ai;θ), is defined as in (2.3), and λN(t) is
the intensity of the visit process at time t. To show that (2.13) is an unbiased estimating
function, one needs to show E[Uwi (θ,α)|Ai] = 0. For simplicity, we consider Ai as known
constants and suppress Ai and the parameter notation, θ and α, in the following proof,
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e.g. writing ci(t) for c(t|Ai;θ), ST i(t) = ST (t|Ai;θ), etc. The required expectation is then:
E
{∫ τi
0
1
λN(t|Zi(t−))ci(t)[Pi(t)− ST i(t)]dN
∗
i (t)
}
= E
{∫ τi
0
1
λN(t|Zi(t−))ci(t)[Pi(t)− ST i(t)]Ci(t)dNi(t)
}
=
∫ τi
0
ci(t)EZ,P,C
{
1/λN(t|Zi(t−))[Pi(t)− ST i(t)]Ci(t)E
[
dNi(t)|Hobsi (t−), Pi(t), Ci(t)
]}
=
∫ τi
0
ci(t)EZ,P,C
{
1/λN(t|Zi(t−))[Pi(t)− ST i(t)]Ci(t)E
[
dNi(t)|Hobsi (t−)
]}
by (B1)
=
∫ τi
0
ci(t)EZ,P,C
{
1/λN(t|Zi(t−))[Pi(t)− ST i(t)]Ci(t)λN(t|Zi(t−))dt
}
=
∫ τi
0
ci(t)EP,C {[Pi(t)− ST i(t)]Ci(t)} dt
=
∫ τi
0
ci(t)E[Pi(t)− ST i(t)]E[Ci(t)]dt by independent drop-out
=
∫ τi
0
ci(t)[ST i(t)− ST i(t)]E[Ci(t)]dt
= 0
as desired. Note Ci(t) = I(Ci > t) is the at risk indicator as defined earlier, and E with
subscripts denotes the expectation with respect to relevant variables. The last third line
depends on the assumption that random drop-out is independent of outcome given Ai, i.e.
Pi(t)q Ci(t)|Ai, ∀t > 0. Otherwise, dependent drop-out should be adjusted for as well. A
so-called inverse-probability-of-censoring (IPC) weighted estimator can be applied in that
case.
Secondly, when event time Ti is left-truncated, the estimating function (2.6) can be
weighted by the inverse-intensity-of-visit as well, i.e.
Uw(θ,α) =
n∑
i=1
∫ τi
ti0
wi(t;α)c(t|Ai;θ, ti0)[Pi(t)−ST (t|Ai;θ)/ST (ti0|Ai;θ)]dN∗i (t), (2.15)
where Pi(t), dN
∗
i (t) and c(t|Ai;θ, ti0) are defined as in (2.6) and wi(t;α) = 1/λN(t|Zi(t−);α),
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for all t > ti0. Note that, hereAi is a vector of time-fixed variables defined at t = 0. Assum-
ing that condition (B1) is true, and random drop-out (i.e. Pi(t)q Ci(t)|Ai, for t > ti0) and
left truncation (i.e. ti0 q Ti|Ai) are independent, the unbiasedness of estimating function
(2.15) can be proven in a similar manner as for (2.13).
2.2.3 Models for the Visit Process and Estimation of IIV Weights
The IIV weighted estimation is a two-step procedure. First, we fit a model for the visit
process to estimate weights. Then, by solving the weighted estimating equation (2.13)
or (2.15) with the estimated IIV weights, a consistent estimator of the parameter θ from
the outcome model ST (t|Ai,θ) can be obtained under mild regularity conditions, provided
that the outcome process model and the visit process model are correct.
In the first step, to estimate weights, we need to assume a model for the visit process.
First, we introduce a semi-parametric proportional intensities model employed by Lin et al.
(2004) and Bu˚zˇkova´ and Lumley (2007, 2009). The visit intensity is assumed to be of the
form:
dΛN(t|Zi(t−);α) = E{dNi(t)|Zi(t−)}
= dΛN0(t) exp{Zi(t−)′α}
= λN0(t) exp{Zi(t−)′α}dt (2.16)
where λN0(t) is an unspecified non-negative function of t, which is known as the baseline
visit intensity function. More intensity-based models and theories for recurrent events can
be found in Cook and Lawless (2007).
Then, the weight for subject i at time t can be estimated by
wi(t; α̂, λ̂N0) =
1
λ̂N0(t) exp(Zi(t−)′α̂)
, (2.17)
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or
wi(t; α̂) =
1
exp(Zi(t−)′α̂)
, (2.18)
where α̂ can be obtained by maximizing the partial likelihood for the Cox model or by using
existing software for the Cox model such as R function coxph or SAS procedure PHREG.
Lin et al. (2004) proposed a kernel-smoothed Breslow estimator to estimate the baseline
intensity λN0(t) in formula (2.17). However, Bu˚zˇkova´ and Lumley (2007) suggested that
baseline intensity λN0(t) can be exempted from the weight formula, i.e. they proposed to
use (2.18). This is analogous to introducing a stabilizing weight a(t|Ai) = λ0(t). Further-
more, omitting λ̂N0(t) in weight estimation can avoid the smoothing techniques applied to
λ̂N0(t) and achieve
√
n consistency of the final estimator of θ.
So far, we have been assuming that the visit process (2.16) satisfies a modulated Markov
proportional intensities assumption given covariates Zi(t
−). However, in the PsA example,
the clinic visits were nominally scheduled to be a certain length of time apart (e.g. 6
months), but actual visit gaps often deviated substantially from this. In this case, modeling
the gap times or the inter-arrival times between consecutive clinic visits may be more
plausible. That is, the visit intensity at t could be related to the elapsed time since the
most recent visit prior to t. An alternative assumption would be that, given the most
recent past visit time TN(t−), visit intensity has the form of a modulated renewal process
(or semi-Markov process) (Cook and Lawless, 2007), i.e.
λN(t|Zi(t−);α) = λ†N0(B(t)) exp(α′Zi(t−)), (2.19)
where t is the chronological time, e.g. time from the clinic entry in PsA data (no left
truncation case) or the onset of PsA (left truncation case), and B(t) is the gap time or
elapsed time from the most recent past visit, i.e. B(t) = t − TN(t−). Once again Zi(t−)
may include the features of prior visit history and outcome history. When we estimate
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the IIV weights based on (2.19), one difference from the former visit model (2.16) is that
the renewal baseline intensities λ†N0(B(t)) can not be exempted from the weight formula,
because λ†N0(B(t)) depends on the individual’s previous visit time TN(t−) which is random
and also informative for outcomes due to variables other than Ai. Thus, λ
†
N0(B(t)) also
needs to be estimated while estimating the weights wi(t), i.e.
wi(t; α̂, λ̂
†
N0) =
1
λ̂†N0[B(t)] exp(Zi(t−)′α̂)
. (2.20)
One way is to adopt the Breslow nonparametric estimator, which can be implemented
by most software, and then smooth the resulting baseline estimate to satisfy positivity
condition and achieve a certain convergence rate, like Lin et al. (2004) did. Also, parametric
visit time models can be considered to avoid smoothing of the baseline estimate. For
example, in the simulation studies we will show in Section 2.3.1, a semi-Markov gap times
model (2.19) with a piecewise-constant baseline is considered. Furthermore, in Section
2.2.5, large sample theory of the proposed estimator of θ from a parametric outcome
model with the IIV weights estimated by fitting a parametric semi-Markov visit gap time
model (2.19) will be discussed.
2.2.4 Discrete Observation Process Models
So far, we assume that the occurrence of failure does not terminate the visit process, e.g.
events of interest such as time to joint damage, time to relapse after surgery, or time to
the appearance of a tumor. Individuals are followed up to the end of follow-up, even if it
is known that she/he has already experienced a failure. In this section, we will consider
the case where a known failure occurrence terminates the visit process.
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Pi(t) :
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Figure 2.1: Graphical demonstration of a continuous failure time under a discrete visit
process, with a potential visit time increment of 0.25 units, where {ti1, ..., timi} = {t > ti0 :
dN∗i (t) = 1}; ti1, ..., tim∗i are the actual visits and ti,m∗i+1, ..., timi(= Ci) are the pseudo visits
after failure occurrence; ti0 denotes the start of follow-up for subject i; responses Pi(t) at
{ti0, ti1, ..., timi} are given above the time axis; and the cross denotes a failure occurrence.
We assume that after a known failure, individuals discontinue being inspected. That
is, the “probability” of attending a visit at any t past the known failure occurrence is zero.
In this sense, the positivity assumptions in conditions (B0) and (B1) discussed in Section
2.2.1 are violated. On the other hand, we know a person’s survival status: Pi(t) = 0
for all t > Ti. In this case, it is necessary to artificially continue “observation” of the
individual so as to satisfy the positivity condition. One approach would be to randomly
generate pseudo visit times from the visit process model, and then apply the IIV weighted
estimating function approach as introduced in Section 2.2.2. A simpler alternative, which
we adopt, is to discretize the visit process and assume an individual “visits” at each possible
time following their observed failure, i.e. let dNi(t) = 1 when P¯
obs
i (t
−) = 0, with probability
1 up to the end of follow-up to create pseudo visits. Suppose there are Mi prespecified
potential visit times, ti0 = ai0 < ai1 < ... < aiMi = Ci, for subject i, where ti0 ≥ 0 is
the start of follow-up and ti0 > 0 indicates that Ti is left-truncated. In Figure 2.1, we set
the time increment ∆a = 0.25 for illustration, but Mi should be a fairly large integer to
make the grid fine enough to approximate a continuous visit process in cases where ties
of visit times rarely exist or we want to use existing software for continuous failure time
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or recurrent event time data to fit a model to estimate the weights. An actual continuous
visit time tij which falls in (aik, ai,k+1] will be carried forward to the upper bound ai,k+1,
k = 0, ...,Mi − 1. Since P (t) = I(T > t) is a monotone response from 1 to 0, it is obvious
that after the visit subsequent to the occurrence of failure, e.g. the visit ti,m∗i in Figure
2.1, P (t) = 0 is known. Therefore, dNi(t) can be considered equal to 1 with probability 1
between the first visit after failure occurrence (i.e. ti,m∗i ) and the drop-out time (i.e. Ci).
That is, we consider the visits ti,1, ..., ti,m∗i as actual visits and ti,m∗i+1, ..., timi as pseudo
visits. Because the distribution of the visit process changes after failure occurrence, i.e.
visits are associated with the observed outcome history, condition (B0) which states that
visits and outcomes are correlated only through Ai does not hold in this case. However,
condition (B1) can be modified as follows:
(B1*) Let P¯ obsi (ai,k−1) be the most recently observed status of response Pi through ai,k−1,
and then when P¯ obsi (ai,k−1) = 1 for any k = 1, ...,Mi, we assume
E{dNi(aik)|Hobsi (ai,k−1),Pi(aik), Ci(aik)} = Ci(aik)E{dNi(aik)|Hobsi (ai,k−1)} (a1)
= Ci(aik)E{dNi(aik)|Zi(ai,k−1)},
E{dNi(aik)|Zi(ai,k−1)} > 0, for all Zi(ai,k−1), (b)
and when P¯ obsi (ai,k−1) = 0, we have
E{dNi(aik)|Hobsi (ai,k−1),Pi(aik), Ci(aik)} = Ci(aik), (a2)
to create pseudo visits, where Pi(aik), Ci(aik), dNi(aik), and Zi(ai,k−1) = h{Hobsi (ai,k−1)}
are defined similarly as in (B1), and we note that Hobsi (a−ik) =Hobsi (ai,k−1) in the discrete
time setting. If (B1*) is satisfied, we still say the observation scheme is conditionally inde-
pendent, and we see the independence is conditional on the observed history of outcome,
i.e. P¯ obsi (ai,k−1).
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We can still consider the following two visit process models, a modulated Markov
proportional intensities model (2.21) or a modulated renewal (semi-Markov) process model
(2.22) given below, to estimate the IIV weights, when P¯ obsi (ai,k−1) = 1, for k = 1, ...,Mi:
λN(aik;α) = λN0(aik) exp{Zi(ai,k−1)′α}, (2.21)
or
λN(aik;α) = λ
†
N0(B(aik)) exp(Zi(ai,k−1)
′α), (2.22)
where λN(aik;α) denotes a discrete visit intensity at aik. The IIV weights are defined by
ŵi(aik) = 1/λN(aik; α̂), when P¯
obs
i (ai,k−1) = 1, and by 1, when P¯
obs
i (ai,k−1) = 0, if the
weight estimate is given by (2.17) based on model (2.21) or by (2.20) based on model
(2.22). Note that if model (2.21) is assumed for the visit process and ŵi(aik) is formulated
as (2.18) when P¯ obsi (ai,k−1) = 1, then ŵi(aik) = λ̂N0(aik) when P¯
obs
i (ai,k−1) = 0.
The IIV weighted estimating functions (2.13) and (2.15) can be defined for a discrete
visit process by
U(θ;α) =
n∑
i=1
Mi∑
k=1
wi(aik;α)c(aik|Ai;θ, ti0)[Pi(aik)− µT (aik|Ai;θ, ti0)]dN∗i (aik), (2.23)
=
n∑
i=1
mi∑
j=1
wi(tij;α)c(tij|Ai;θ, ti0)[Pi(tij)− µT (tij|Ai;θ, ti0)],
where dN∗i (aik) = dNi(aik)I(Ci ≥ aik) and ti1 < ti2 < ... < timi are the mi visits, including
the m∗i actual visit times before failure occurrence and the mi − m∗i pseudo visit times
after failure occurrence, among the Mi potential visit times, ai1, ..., aiMi , for subject i. The
mean function µT (aik|Ai;θ, ti0) is defined by ST (aik|Ai;θ)/ST (ti0|Ai;θ), where ti0 ≥ 0 is
the start of follow-up of subject i, and when ti0 > 0 indicates that Ti is left-truncated and
ti0 = 0 otherwise.
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2.2.5 Large Sample Theory
In this section, we will discuss the asymptotic distribution of the proposed IIV weighted
estimator θ̂ for a parametric failure time model where Ti may be subject to dependent
interval censoring. In the following, the case where failure occurrence does not stop visits
and the visit process is continuous will be considered. The case where failure terminates
visits and the visit process is discretized will be discussed at the end.
Let Ui1(θ,α) and Ui2(α) be the estimating functions contributed by the outcome pro-
cess and the visit process of subject i, respectively, and let Ui(θ,α) = (U
′
i1(θ,α),U
′
i2(α))
′
be the combined estimating functions for all the parameters, (α′,θ′)′.
First, Ui1(θ,α) for the outcome process can be written as
Ui1(θ,α) =
mi∑
j=1
wi(tij;α)c(tij|Ai;θ, ti0)[Pi(tij)− µT (tij|Ai;θ, ti0)], (2.24)
where ti0 ≥ 0 is the start of follow-up for subject i, and the IIV weight wi(tij;α) =
[λN(tij|Zi(t−ij);α)]−1 is defined in (2.14). The above estimating function can be applied
for the left truncation case where some ti0’s are greater than zero, and the mean func-
tion µT (t|Ai;θ, ti0) = E[Pi(t)|Ti > ti0,Ai;θ] = ST (t|Ai;θ)/ST (ti0|Ai;θ) reduces to
ST (t|Ai;θ) when ti0 = 0 for the no left truncation case.
Secondly, for the visit process, assume that ti1 < ... < timi are the mi intermittent
visit times for subject i. Here, we consider a parametric semi-Markov model (2.19) for
illustration, but any parametric recurrent event or gap time model can be employed, e.g.
the proportional intensities model (2.16) if λN0(t) is parametric. Let Ui2(α) be the log
likelihood contribution of the mi+1 visit gap times based on model (2.19) with a parametric
baseline λ†N0(B(t);α0), i.e.
λN(t|Zi(t−);α) = λ†N0[B(t);α0] exp(α′1Zi(t−)), (2.25)
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where α = (α′0,α
′
1)
′, and B(t) denotes the gap time at t from the previous visit, e.g.
B(ti,j+1) = ti,j+1 − tij. We notice that visit gap times are exactly observed except for
the last one, which is right-censored at the end of follow-up, i.e. Ci. Therefore, the score
function based on the above semi-Markov model (2.25) is given by the log likelihood (4.47)
in Cook and Lawless (2007) for general parametric multiplicative intensity models for gap
times:
Ui2(α) =
mi∑
j=1
∂ln{λ[B(tij)]}
∂α
−
mi+1∑
j=1
∫ B(tij)
0
∂λ(s)
∂α
ds, (2.26)
where λ(B(t)) = λ(B(t);α) = λ†N0[B(t);α0] exp(α
′
1Zi(t
−)) and ti,mi+1 = Ci.
Since Ui1(θ,α) and Ui2(α) are both unbiased estimating functions, given the condition
(B1) is true and both the outcome process and the visit process are correctly modelled, by
Theorem 2.2 and Theorem 3.2 in White (1982), we have the following theorem:
Theorem 1. Given the regularity conditions in White (1982), (θ̂′, α̂′)′ by solving the IIV
weighted estimating equations
∑n
i=1Ui(θ,α) = (
∑n
i=1U
′
i1(θ,α),
∑n
i=1U
′
i2(α))
′ = 0, where
Ui1(θ,α) and Ui2(α) are defined by (2.24) and (2.26) respectively, is a consistent estimator
of (θ′,α′)′ and is asymptotically normal distributed with covariance matrix Γ−1Σ (Γ−1)′,
where Γ and Σ are defined by
Γ =
 −E(∂Ui1/∂θ′) −E(∂Ui1/∂α′)
0 −E(∂Ui2/∂α′)
 ,
 Γ11 Γ12
0 Γ22
 ,
and
Σ =
 E(Ui1 U ′i1) E(Ui1 U ′i2)
E(Ui2 U
′
i1) E(Ui2 U
′
i2)
 ,
 Σ11 Σ12
Σ′12 Σ22
 .
Then, the IIV estimator θ̂ has the following asymptotic distribution
√
n(θ̂ − θ) D−→ N(0, Vθ),
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where
Vθ = Γ
−1
11 (Σ11 − Γ12Γ−122 Σ′12 − Σ12Γ−122 Γ′12 + Γ12Γ−122 Γ′12) Γ−111 . (2.27)
If estimating function (2.24) is a GEE with an independent working covariance matrix
and is written in a matrix form by
Ui1 = D
′
iV
−1
i Wi[Pi − µi],
where Pi = (Pi(ti1), ..., Pi(timi))
′, µi = (µi1, ..., µimi)
′, µij = µT (tij|Ai;θ, ti0), Di =
∂µi/∂θ
′, Vi = diag{µi1(1−µi1), ..., µimi(1−µimi)}, andWi = diag{wi(ti1;α), ..., wi(timi ;α)},
then we have
Γ̂11 =
1
n
n∑
i=1
D′iV
−1
i Wi Di
∣∣
α̂,θ̂
, (2.28)
and
Γ̂12 =
1
n
n∑
i=1
mi∑
j=1
λ−2(B(tij); α̂)
∂λ(B(tij);α)
∂α′
∣∣∣∣
α̂
c(tij|Ai; θ̂, ti0)[Pi(tij)− µT (tij|Ai; θ̂, ti0)].
(2.29)
Additionally, since Ui2 is likelihood-based, Σ22 = Γ22 is the Fisher information matrix of
Ui2. If we employ likelihood-based software to estimate α in Ui2, e.g. R function phreg
with a piecewise constant baseline intensity, then Σ22 and Γ22 can be estimated by the
observed Fisher information matrix reported by the software divided by sample size n.
Finally, we can use Σ̂11 =
1
n
∑n
i=1Ui1 U
′
i1 and Σ̂12 =
1
n
∑n
i=1Ui1 U
′
i2.
Now, consider the case where failure occurrence terminates the visit process as we have
discussed in the preceding section. The IIV weighting approach is still applicable if we
discretize the visit process and set the weights equal to 1 when P¯ obsi (t
−) = 0. Then the
asymptotic theory discussed above still can be applied. For the outcome process, the IIV
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weighted estimating function is (2.23) and the required assumption is (B1*). For the visit
process, only the visits that occurred when P obsi (t
−) = 1 contribute to the estimation of α
using model (2.25), i.e. ti1,...,ti,m∗i in Figure 2.1, and the score function for visit gap times
becomes
U∗i2(α) =
m∗i∑
j=1
{
∂ln{λ[B(tij)]}
∂α
−
∫ B(tij)
0
∂λ(s)
∂α
ds
}
(2.30)
− I(P¯ obsi (tim∗i ) = 1)
∫ Ci−tim∗
i
0
∂λ(s)
∂α
ds.
This follows because if Ti is interval-censored, all visit gap times when P
obs
i (t
−) = 1, which
contribute to the estimation of α, are exactly observed, while if Ti is right-censored at the
last actual visit tim∗i , the last visit gap time is right-censored at Ci. Theorem 1 still holds
with Ui2 replaced by U
∗
i2. Note that since IIV weight wi(t) equals 1 when P
obs
i (t
−) = 0,
(2.29) is modified to
Γ̂12 =
1
n
n∑
i=1
m∗i∑
j=1
λ−2(B(tij); α̂)
∂λ(B(tij);α)
∂α′
∣∣∣∣
α̂
c(tij|Ai; θ̂, ti0)[Pi(tij)− µT (tij|Ai; θ̂), ti0].
(2.31)
2.3 Simulation Studies
This section aims to empirically examine the finite sample performances of the proposed
IIV weighted estimators in the presence of dependent follow-up times and to compare with
standard estimation approaches such as the unweighted GEE and MLE. To simplify, in
this section, we assume that random drop-out is absent. We will discuss three cases: (i)
subjects visit intermittently until the administrative end of follow-up; (ii) subjects visit
intermittently but stop visiting after a known failure; and (iii) failure stops visits and the
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failure time may be left-truncated at the first visit. We will also investigate how the IIV
weighted estimators perform under misspecification of the visit process model.
2.3.1 Performances of the IIV Weighted Estimators and Stan-
dard Estimators
In this simulation study, we examine the IIV weighted estimation of a parametric propor-
tional hazards model like (2.2) with a time-fixed treatment variable Ai of interest, and a
time-varying variable Li(t) which affects the visit process as well as the failure time Ti as
an intermediate variable. Another simulation study based on an AFT marginal outcome
model with a time-fixed intermediate variable Li will be introduced in Chapter 3. As we
discussed in Section 1.5, a specific model form for outcomes will not necessarily keep the
same structure or even have a neat closed form after some regressors have been marginalized
over, e.g. proportional hazards models like (2.2). However, for some particular distribu-
tions of the outcomes and under certain assumptions about the ancillary variable process,
proportional hazards can still hold, though the marginal regression parameters and the
conditional regression parameters differ. The following empirical studies will be based on
a model developed in Young and Tchetgen Tchetgen (2014).
Here, we consider a binary Ai, i.e. Ai = 0 or 1. In Section 2.2.4, we have introduced
the theory and methods under a discrete visit process. To make the simulated data ap-
plicable for all the three cases, (i)-(iii), throughout this section and simulation studies in
Chapter 3 and Chapter 4, the discretization of continuous time is based on a grid of 100
per time unit. We set the administrative censoring time for each subject as τ = 5. Let
a0 = 0, a1 = 0.01, ..., aM = τ be the universal prespecified potential visit times for all
individuals. For example, if we aim to study the effect of biologics on time to a joint dam-
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age event during the first episode of biologics, since the median length of the treatment
durations of the first episode of biologics in the PsA cohort study is about 3 ∼ 3.5 years,
then ∆a approximates 2 days. Additionally, since the median length of visit gap times
is approximately 6 months, we assume there is never more than one visit within 2 days.
Discretization in this way makes using the software for continuous survival data, e.g. R
functions survreg, phreg, coxph and coxreg a reasonable approach for estimating the param-
eter α in the visit process model, though data are simulated and “observed” in discrete
time. In the following, a variable with subscript m denotes the value or level of it at time
am, m = 0, 1, ...,M , where M = 500. We assume the whole history of Li(t) is known,
i.e. L¯i
obs
(t) = L¯i(t), for simplicity, e.g. physical temperature or blood pressure that can
be measured by patients, though it is more plausible in practice that the visit process is
associated with L¯i
obs
(t). Subscript i may be dropped for simplicity as well. In each of the
following simulation studies in this section, sample size is set as n = 1000 and the number
of simulation replicates is N = 500.
CASE I: Event occurrence does not terminate visits
Firstly, we consider a case where event occurrence does not prohibit a patient from
visiting the clinic. In the present simulation, we imitate a randomized trial with Pr[A =
1] = 0.5 and Pr[A = 0] = 0.5, and the ancillary variable Lm at am is assumed to be
independent of its previous history and be normally distributed given A, i.e.
Lm|A, L¯m−1 ∼ N(β1A, σl), (2.32)
where β1 is the effect of treatment A = 1 versus A = 0 on the mean of Lm for any m and
we let σl = 1. Here, we assume that the process Lm retains the same distribution before
and after the occurrence of the outcome event. Now, to generate the outcome process, it
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is assumed that the discrete time hazard of T at time am+1 has the following form:
Pr[Pm+1 = 0|L¯m, A, Pm = 1] = Φ(θ0 + θ1Lm + θ2A), (2.33)
where Φ denotes the CDF of a standard normal distribution N(0, 1) and Pm = I(T > am).
Once a zero has been generated for some Pm, we have Ps = 0 for all s > m, because survival
status P (t) is a decreasing function. Note that P0 = 1 for all individuals. We set θ0 = −2,
θ1 = 1, θ2 = −0.1 and β1 = −1 so that the treatment A has a negative effect on the risk
of failure and Lm behaves as an intermediate variable which is inhibited by treatment and
is positively related to the risk of failure. Model (2.33) can be rewritten proportionally as
Pr[Pm+1 = 0|L¯m, A, Pm = 1] = eη0 exp(η1Lm + η2A+ η3ALm),
where eη0 = Φ(θ0) is the baseline hazard, and
η1 = ln
[
Φ(θ0 + θ1)
Φ(θ0)
]
,
η2 = ln
[
Φ(θ0 + θ2)
Φ(θ0)
]
,
η3 = ln
[
Φ(θ0)Φ(θ0 + θ1 + θ2)
Φ(θ0 + θ1)Φ(θ0 + θ2)
]
.
Then, the marginal hazard function of T given A alone can be obtained by marginalizing
over Lm as
Pr[Pm+1 = 0|A,Pm = 1] = Φ {c · [θ0 + (θ2 + θ1β1)A]} , (2.34)
where c = 1/
√
1 + θ21σ
2
l and equation (2.34) can be rewritten in proportional hazards form
as well, i.e.
Pr[Pm+1 = 0|A,Pm = 1] = eψ0 exp(ψ1A), (2.35)
where ψ0 = ln {Φ(c · θ0)}, ψ1 = ln
{
Φ[c·(θ0+θ2+θ1β1)]
Φ(c·θ0)
}
. Here ψ0 and ψ1 are the parameters
we wish to estimate. Based on the values of θ0, θ1, θ2, β1 and σl given above, the baseline
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hazard rate eψ0
.
= 0.08 and the marginal hazard ratio eψ1
.
= 0.18 for A = 1 versus A = 0,
i.e. treatment results in about an 82% risk reduction.
The discrete visit process, {dNm : m = 1, ...,M}, is generated by a Markov proportional
intensities model with a constant baseline intensity:
Pr[dNm+1 = 1|A,Lm] = exp(γ0 + γ1Lm + γ2A), (2.36)
= eγ0 exp(γ1Lm + γ2A)
where γ0 = −4, γ1 = 0 or 1, and γ2 = −0.2, so that the average visit gap time is
approximately 0.59 in the untreated group and 0.63 in the treated group, when γ1 = 0,
and is about 0.33 in the untreated group and 1 in the treated group, when γ1 = 1. Since we
assume that the outcome event does not stop visits, the visit process generated by model
(2.36) is non-informative unless γ1 6= 0. Thus, the scenario where γ1 = 0 satisfies the
independent observation assumption (B0), while the scenario with γ1 = 1 gives dependent
visit times. In fact, when γ1 = 1 and θ1 = 1, Lm is a strong outcome-dependent risk
factor of the visit process which fails to be adjusted for when standard analysis methods
such as MLE and unweighted GEE are applied, and as a result, estimates could be biased.
On the other hand, model (2.36) ensures that the conditionally independent observation
assumption (B1) holds when both of A and Lm have been adjusted for via weighting, so
that resulting estimators are consistent. The scenario of this simulation study is illustrated
by a DAG shown in Figure 2.2, assuming M = 2 for simplicity.
Three methods, MLE, unweighted GEE and IIV weighted GEE, will be compared for
the estimation of parameters ψ0 and ψ1 from model (2.35). The unweighted GEE estimator
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A L0 L1 L2
P0 P1 P2
dN1 dN2
Figure 2.2: DAG for the simulation setting when individuals can still be followed up even
after event occurrence to the administrative end τ , where Pm = I(T > am), P0 = 1 and
dNm indicates a clinic visit at am, where m = 0, 1, 2.
will be obtained by solving the following estimating function:
U(ψ) =
n∑
i=1
M∑
m=1
c(am|Ai;ψ, ti0)[Pi(am)− µT (am|Ai;ψ, ti0)]dN∗i (am), (2.37)
where µT (am|Ai;ψ, ti0) = ST (am|Ai;ψ)/ST (ti0|Ai;ψ) and ti0 is the start of follow-up and
we assume dNi(am) = 0 for all am ≤ ti0. Here, we have ti0 = 0, since we are not considering
left-truncated failure times in the present case. In addition,
c(am|Ai;ψ, ti0) = ∂µT (am|Ai;ψ, ti0)/∂ψ
µT (am|Ai;ψ, ti0)[1− µT (am|Ai;ψ, ti0)] ,
i.e. the GEE given in (2.11) with an independent working covariance matrix specified. In
addition, based on model (2.35), ST (am|Ai;ψ) is given by
ST (am|Ai;ψ) = [1− eψ0 exp(ψ1Ai)]m.
The IIV weighted GEE estimator will be obtained by similarly solving the estimating
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function (2.38) with the same c(·) function defined above:
U(ψ,α) =
n∑
i=1
M∑
m=1
wi(am;α)c(am|Ai;ψ, ti0)[Pi(am)− µT (am|Ai;ψ, ti0)]dN∗i (am). (2.38)
The IIV weights wi(am;α) can be estimated by fitting the following semi-Markov piecewise-
constant baseline proportional hazards model for visit gap times:
λN(am+1;ρ,α) =
K∑
k=1
ρkIk[B(am+1)] exp(α1Lm + α2A), m = 0, 1, ...,M − 1, (2.39)
where Ik(t) = I{t ∈ (dk−1, dk]}, 0 = d0 < d1 <, ..., < dK = +∞ are the cut-points of
visit gap times and ρ = (ρ1, ..., ρK)
′ are positive unknown constants and α = (α1, α2)′.
We do this in order to reflect the desirability of using flexible models for the visit time
process. The actual visit time process model (2.36) in the simulation is of this form but
with K = 1. Here, we chose K = 4 and d1 = 0.40, d2 = 0.75 and d3 = 1.00, roughly
based on the quartiles of visit gap times. In general, K and cut-points can be chosen
by a graphical comparison of the resulting estimate of ρ based on model (2.39) with a
non-parametric estimate of the baseline intensity function based on the Cox model. Here,
ρ = (ρ1, ..., ρ4)
′ and α = (α1, α2)′ are estimated by the R function phreg. Because the
common risk factors of failure risk and visit intensity at am+1 have been adjusted for by
model (2.39), given the condition (B1) with Zi(am) = (Ai, Lm)
′ is true, the IIV weighted
GEE estimators should be consistent.
The MLE for ψ can be obtained by solving the score function based on the likelihood
given in (2.1). All the estimating equations for ψ, GEEs or score functions, are numerically
solved by using R function nleqslv with the Newton-Raphson method specified, setting ψ =
(−1,−1)′ as the initial value. The resulting estimates by IIV weighted GEE, unweighted
GEE and MLE are summarized in Table 2.1 for the case of independent follow-up times
(γ1 = 0) and the case of dependent follow-up times (γ1 = 1). Bias and mean squared error
69
(MSE) are respectively estimated by
B̂IAS =
1
N
N∑
r=1
(ψ̂lr − ψlr), l = 0, 1,
and
M̂SE =
1
N
N∑
r=1
(ψ̂lr − ψlr)2, l = 0, 1.
where ψ̂lr is the rth estimate of ψl and N = 500 is the number of simulations. The coverage
probability (CP) for nominal 95% confidence intervals of an estimator of ψl, l = 0, 1, is
estimated by:
ĈP =
1
N
N∑
r=1
I{ψ̂lr − 1.96 se(ψ̂lr) < ψl < ψ̂lr + 1.96 se(ψ̂lr)}, l = 0, 1,
where se denotes the asymptotic standard error of an estimate, and ASE in Tables 2.1-2.4
denotes the average of asymptotic standard errors. The asymptotic distribution (2.27) and
asymptotic standard error of the proposed IIV weighted GEE estimator of ψ is given in
Theorem 1 in Section 2.2.5. The asymptotic standard error of an unweighted GEE esti-
mator can be estimated by the ordinary sandwich form variance formula given in White
(1982) and Liang and Zeger (1986), i.e. Vψ = Γ
−1Σ (Γ−1)′, where Γ = −E(∂Ui(ψ)/∂ψ′)
and Σ = E{Ui(ψ)Ui(ψ)′}, where Ui(ψ) is the ith subject’s contribution for the estimating
function given in (2.37). The MLE’s asymptotic variance Vψ is the inverse of its Fisher
information matrix. It can be estimated by the negative Jacobian matrix of the score
function divided by the sample size. When we use nleqslv to solve the score function, the
Jacobian matrices at the resulting MLEs are outputted. In addition, the empirical stan-
dard error (ESE) is the sample standard deviation of estimates across the 500 simulated
data sets.
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Table 2.1: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for (ψ0, ψ1)
′ in model
(2.35) when individuals still can be followed up even after failure occurrence. In (2.36),
γ1 = 0, which means that visit times are independent, i.e. assumption (B0) is satisfied;
γ1 = 1, which means that visit times are dependent, but we assume that (B1) is satisfied.
Sample size: n = 1000, and simulation replicates: N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
γ1 = 0
MLE
ψ0 -2.543 0.006 0.069 0.071 0.005 0.94
ψ1 -1.713 -0.002 0.085 0.085 0.007 0.95
Unweighted
ψ0 -2.543 0.010 0.072 0.075 0.006 0.93
ψ1 -1.713 -0.004 0.090 0.089 0.008 0.95
IIV Weighted
ψ0 -2.543 0.010 0.072 0.076 0.006 0.93
ψ1 -1.713 -0.004 0.090 0.089 0.008 0.95
γ1 = 1
MLE
ψ0 -2.543 0.111 0.060 0.062 0.016 0.53
ψ1 -1.713 -0.072 0.081 0.081 0.012 0.87
Unweighted
ψ0 -2.543 0.119 0.068 0.066 0.019 0.59
ψ1 -1.713 -0.075 0.091 0.088 0.013 0.87
IIV Weighted
ψ0 -2.543 0.004 0.085 0.090 0.008 0.93
ψ1 -1.713 -0.002 0.113 0.115 0.013 0.93
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From Table 2.1, when γ1 = 0, we see that when visit times are outcome-independent,
bias of all the three methods, MLE, unweighted GEE and IIV weighted GEE, is negligible
relative to the sampling standard error. The ASEs agree well with the corresponding ESEs,
which indicates that the asymptotic distribution and sandwich variance estimator given in
Theorem 1 in Section 2.2.5 provides satisfactory estimation of the asymptotic variances of
the proposed IIV weighted estimators for sample size n = 1000. Additionally, it is seen that
weighted GEE and unweighted GEE estimates have approximately the same ASEs, and
MLEs give slightly smaller ASEs, which suggests that the MLEs are a little more efficient.
In addition, all the three methods give coverage probabilities around 93% − 95% which
are close to the nominal level, 95%, so the overall performances of these three methods
with an independent observation scheme are satisfactory. We found that when sample
sizes are increased, the asymptotic variances can be more accurately estimated so that
coverage probabilities can be improved. Some simulation results for a smaller sample size
n, e.g. n = 500, can be found in Table 2.4 and Table 2.5, where we can see that coverage
probabilities become relatively lower.
The lower part of Table 2.1 summarizes the simulation results for the settings with
outcome-dependent visit times (γ1 = 1). We see that the bias of the IIV weighted es-
timator is still negligible and the coverage is close to the nominal level. However, MLE
and unweighted GEE estimator show large bias (over 80% of the ESE) and poor coverage
probabilities. The estimation of the asymptotic variances of IIV weighted estimators by
the sandwich form estimator given in Theorem 1 is satisfactory.
To summarize this simulation study for the case where failure does not prohibit visits,
we see when the intermittent visit times are non-informative for the inference of out-
comes, i.e. condition (B0) is true, standard estimation methods result in sound inference.
However, when the visit times are not independent, but adjustable by known factors, i.e.
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condition (B1) is true, standard methods fail. The proposed IIV weighting method results
in consistent estimates and comparable efficiency to the MLE when visits are independent,
and also leads to consistent estimates even when visits are dependent.
CASE II: Event occurrence terminates visits
Now, suppose subjects who have experienced the event of interest will not come to
visit the clinic any longer, i.e. follow-up discontinues once a failure is known. In this
case, we assume that the visit process follows a proportional intensity model conditional
on Zm = (A,Lm, P¯
obs
m )
′ under assumption (B1*), i.e.
Pr[dNm+1 = 1|A,Lm, P¯ obsm ]
=
 exp(γ0 + γ1Lm + γ2A), if P¯ obsm = 11, if P¯ obsm = 0 , m = 0, 1, ...,M − 1, (2.40)
where subscripts for subjects are suppressed for simplicity, and γ = (γ0, γ1, γ2)
′ is specified
the same as in CASE I. Data generation for A, Lm, Pm and relevant parameter values are
also the same as in CASE I. The DAG of this scenario is displayed in Figure 2.3 where we
see that current visit intensity is associated with the previous outcome and previous visit
status. Therefore, the observed past outcome should be adjusted for to achieve consistent
estimation by using estimating function estimation methods, though Lm might not be a
common risk factor between outcomes and visit times. That is, even if γ1 from the visit
process model (2.40) equals zero the unweighted GEE without considering the difference of
visit intensities before and after failure occurrence leads to biased estimates, which we can
see from Table 2.2. On the other hand, comparing Table 2.1 with Table 2.2 and Table 2.3,
the MLE based on likelihood (2.1) gives the same estimates, because only the two actual
visits tij < Ti ≤ ti,j+1 are needed in the likelihood (2.1). To obtain the IIV weighted GEE
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estimates, the IIV weights needed in (2.23) are estimated by ŵi(am+1) = 1/λN(am+1; ρ̂, α̂)
by fitting the semi-Markov (discrete) visit gap times model given in (2.39) when P¯ obsm = 1,
and ŵi(am+1) = 1 when P¯
obs
m = 0, and function c(·) is the same as for CASE I. The
unweighted GEE estimates are obtained similarly by letting ŵi(am+1) = 1 for all m =
0, ...,M − 1, and MLEs are computed by maximizing likelihood (2.1). The simulation
results for γ1 = 0 and γ1 = 1 are summarized in Table 2.2 and Table 2.3, respectively.
From Table 2.2, when γ1 = 0 in (2.40), we see that the bias of MLEs and IIV weighted
GEE estimator is negligible and their coverage probabilities are overall satisfactory. How-
ever, unweighted GEE estimates are biased, as we expected. For the unweighted GEE
method, we pretend to observe the outcome after failure occurrence, i.e. the visit process
changes distribution after failure occurrence, but the past observed outcome history fails
to be adjusted for, so the resulting estimates are biased. In addition, although both MLE
and the IIV weighted GEE estimator are consistent, MLE shows less variability than the
weighted GEE estimator, i.e. MLE is more efficient.
When γ1 = 1 in (2.40), it is seen from Table 2.3 that the bias of IIV weighted GEE
estimator is still negligible, the corresponding ASEs and ESEs are close to each other,
and coverage probabilities are around the nominal 95% level. On the other hand, likeli-
hood (2.1) leads to biased estimates and unsatisfactory coverage probabilities for MLE,
because the information (i.e. Lm) carried by visit times fails to be taken into account.
The unweighted GEE method results in heavily biased estimates and nearly zero coverage
probabilities, because more information fails to be adjusted for.
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A L0 L1 L2
P0 P1 P2
dN0 dN1 dN2
Figure 2.3: DAG for the simulation setting when individuals are assumed to stop visiting
after a known failure, where Pm = I(T > am) and let P0 = 1 and dNm indicates a clinic
visit at am, where m = 0, 1, 2.
Table 2.2: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for (ψ0, ψ1)
′ in model
(2.35) when individuals stop visiting after a known failure, with γ1 = 0 in (2.40). Sample
size: n = 1000, and replicates: N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
MLE
ψ0 -2.543 0.006 0.069 0.071 0.005 0.94
ψ1 -1.713 -0.002 0.085 0.085 0.007 0.95
Unweighted GEE
ψ0 -2.543 0.748 0.054 0.057 0.562 0.00
ψ1 -1.713 0.434 0.069 0.070 0.193 0.00
IIV Weighted
ψ0 -2.543 0.006 0.072 0.076 0.006 0.92
ψ1 -1.713 -0.001 0.089 0.090 0.008 0.95
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Table 2.3: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for (ψ0, ψ1)
′ in model
(2.35) when individuals stop visiting after a known failure, with γ1 = 1 in (2.40). Sample
size: n = 1000, and replicates: N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
MLE
ψ0 -2.543 0.111 0.060 0.062 0.016 0.53
ψ1 -1.713 -0.072 0.081 0.081 0.012 0.87
Unweighted GEE
ψ0 -2.543 0.844 0.051 0.054 0.715 0.00
ψ1 -1.713 0.425 0.071 0.069 0.185 0.00
IIV Weighted
ψ0 -2.543 0.009 0.081 0.086 0.008 0.95
ψ1 -1.713 0.007 0.109 0.114 0.013 0.95
CASE III: Event occurrence terminates visits and failure times
could be left-truncated
In the PsA example, only patients who have PsA are enrolled in the cohort, so onset
times of PsA occurred before clinic enrolment times. If we are interested in the time to
the appearance of the first joint damage since onset (t = 0), it may be left-truncated at
clinic entry time ti0 (> 0). To model left-truncation in the setting discussed above, we
simulate a delayed entry time ti0 as the maximum of 0 and a random number generated
from N(0.15, 0.1). As a result, 90% − 95% of ti0’s are greater than zero and the delayed
entry times are completely random. About 40% of subjects whose failures occurred before
ti0 are excluded from the analysis. The outcome process, treatment A and intermediate
variable Lm are generated the same as for CASE II. Visits are generated based on model
(2.40) onward from t0.
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The IIV weighted GEE and unweighted GEE estimates are obtained the same as in
CASE II but note that ti0 > 0 for most individuals. MLEs are found by maximizing the
likelihood (1.5). All these estimates are summarized in Table 2.4 for the scenario where
γ1 = 1 in (2.40). Table 2.4 shows that the IIV weighted GEE performs satisfactorily with
negligible bias and good coverage probabilities. Comparing with Table 2.3, ASEs and ESEs
are higher, because sample size is smaller and fewer visits contribute to the analysis when
failure times could be left-truncated. MLEs are still biased, because Lm is not adjusted
for if only A is conditioned on in the likelihood. Finally, the unweighted GEE method still
performs very poorly.
Table 2.4: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for (ψ0, ψ1)
′ in model
(2.35) when individuals stop visiting after a known failure and failure time could be left-
truncated at ti0, with γ1 = 1 in (2.40). Initial sample size: n = 1000, analysis sample size:
n∗ .= 600 (i.e. n∗ =
∑n
i=1 I{Ti > ti0}), and simulation replicates: N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
MLE
ψ0 -2.543 0.124 0.098 0.107 0.027 0.77
ψ1 -1.713 -0.079 0.116 0.124 0.021 0.89
Unweighted GEE
ψ0 -2.543 0.855 0.083 0.085 0.738 0.00
ψ1 -1.713 0.414 0.099 0.101 0.182 0.02
IIV Weighted
ψ0 -2.543 0.020 0.128 0.134 0.018 0.93
ψ1 -1.713 0.001 0.150 0.159 0.025 0.94
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2.3.2 Investigation of the IIV Weighted Estimator under Model
Misspecification for the Visit Process
In Section 2.2.1, we mentioned that in addition to the conditionally independent observa-
tion scheme condition (B1) or (B1*), the outcome model as well as the visit model need
to be correctly specified when the IIV weighting approach is applied. When a marginal
outcome model is the inference target, we should be careful with the model collapsibility
as discussed in Section 1.5. Moreover, if the model for the visit process is misspecified or
certain assumptions which the visit time model relies on are violated, the finally resulting
IIV weighted estimates could be biased. Therefore, this section aims to study the impact
on the IIV weighted estimator when the visit time model fails to be correctly specified.
Except for the model for generating intermittent visits, data are simulated from the same
scenario as CASE II in Section 2.3.1, where a known failure occurrence is assumed to
terminate visits and failure times are not left-truncated.
In CASE II of Section 2.3.1, we generated the visits from a constant baseline propor-
tional intensities model (2.40) when P¯ obsm = 1, so both the weight formulated as (2.17)
which was considered by Lin et al. (2004) and our proposed weight (2.20) can be applied
to estimate the IIV weights when P¯ obsm = 1. However, here we generate the visit process
from a semi-Markov model for (discrete) visit gap times given by
Pr[dNm+1 = 1|A,Lm, P¯ obsm ]
=
 {[λ0B(am+1)]κ − [λ0B(am)]κ} exp{γ1Lm + γ2A}, when P¯ obsm = 1,1, when P¯ obsm = 0, (2.41)
where 1/λ0 is the scale parameter and κ is the shape parameter of a Weibull distribution.
We set λ0 = 1.8 and consider two values of shape parameter κ in model (2.41): κ = 1.0 and
κ = 1.5 and note that when κ = 1.0, model (2.41) reduces to model (2.40), since we know
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am+1 − am = 0.01. Let γ1 = 1 in (2.41), so Lm should be adjusted for, and let γ2 = −0.2
as in CASE II. When κ = 1.0, the overall average length of visit gap times is 0.75: 0.34 for
the untreated (A = 0) group and 1.06 for the treated (A = 1) group, and when κ = 1.5,
the overall average length of visit gaps is 0.62: 0.35 for the untreated group and 0.80 for
the treated group.
Given the assumption (B1*) is true with Z(am) = (A,Lm, P¯
obs
m )
′, we consider the
following two working visit models for estimating the IIV weights when P¯ obsm = 1:
λN(am+1) = λN0(am+1;ρ) exp(α1Lm + α2A), (2.42)
and
λN(am+1) = λ
†
N0(B(am+1);ρ) exp(α1Lm + α2A), (2.43)
where baselines λN0(am+1;ρ) and λ
†
N0(B(am+1);ρ) are both piecewise constant. Although
Lin et al. (2004) proposed to adopt the Breslow estimator to estimate a non-parametric
baseline λN0(t) in (2.42) and then apply kernel smoothing to attain a certain conver-
gence rate, we consider a parametric baseline so that it can be fairly compared with our
weight formula (2.43) based on a piecewise constant baseline for visit gap times. Cut-
points for the piecewise constant baseline hazards are chosen to be equally spaced, e.g.
(0.30, 0.60, 0.90, 1.20, 1.50) for model (2.42) and (0.3, 0.6, 0.9) for model (2.43).
In Table 2.5, we see that when either κ = 1.0 or κ = 1.5, estimate ψ˜ based on weight
model (2.42) and ψ̂ based on weight model (2.43) have comparable mean squared errors.
We assume condition (B1*) is satisfied and both weight model (2.42) and (2.43) have
taken Z(am) into account, so they are supposed to give asymptotically unbiased estimates
of ψ, provided that the weight model is correctly specified. When κ = 1.0 in (2.41), i.e.
visit times are generated from a constant baseline intensity model, (2.42) and (2.43) are
actually equivalent. As a result, from Table 2.5, we can see that these two models result
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Table 2.5: Investigation of the IIV weighted estimator under different model specifications
for the estimation of IIV weights, where ψ˜ denotes the estimator based on weight model
(2.42) and ψ̂ denotes the estimator based on weight model (2.43). Line 5 and line 6
represent the case of weight model misspecification. BSE denotes the mean of bootstrap
estimated standard errors, and ECP denotes 95% empirical coverage probability; ESE
denotes empirical standard error; MSE denotes mean squared error. Sample size: n=500,
the number of replicates: 500, and bootstrap sample size: 100.
TRUE VALUE BIAS BSE ESE MSE ECP
κ = 1.0
ψ˜0 -2.543 0.015 0.112 0.130 0.017 0.90
ψ˜1 -1.713 0.017 0.150 0.163 0.027 0.92
ψ̂0 -2.543 0.014 0.112 0.129 0.017 0.91
ψ̂1 -1.713 0.010 0.151 0.163 0.027 0.92
κ = 1.5
ψ˜0 -2.543 0.034 0.121 0.127 0.017 0.92
ψ˜1 -1.713 0.067 0.149 0.155 0.028 0.91
ψ̂0 -2.543 0.010 0.126 0.134 0.018 0.93
ψ̂1 -1.713 0.009 0.158 0.166 0.028 0.92
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in estimates with similar bias and standard errors. However, when κ = 1.5, ψ̂ obtained
by using the correct visit process model leads to smaller bias than ψ˜ obtained by a wrong
visit process model. For example, the bias for ψ˜1 is about 0.43 times of the ESE, while
the bias for ψ̂1 is about 0.05 times of the ESE. To conclude, given the essential condition
(B1*) is true, from this study, we see that models should be assessed carefully based on
the characteristics of the real problem and data. Otherwise, biased estimates could result.
Later, in Chapter 6, we will introduce a doubly robust estimator for the IIV weighting
approach, which was also considered by Pullenayegum and Feldman (2013). In addition,
overall low coverage probabilities should be caused by the small sample size, but when the
weight model is correctly specified, coverage is a bit closer to the nominal level.
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Chapter 3
CAUSAL INFERENCE FOR
TREATMENT EFFECTS IN
OBSERVATIONAL STUDIES
WITH DEPENDENT INSPECTION
TIMES
In the previous chapter, our objective was to validly assess a marginal association when an
observational longitudinal cohort had features such as interval censoring, left truncation
and outcome-dependent intermittent inspection times. We did not discuss the estimation
of a (marginal) causal effect when these problems are present. In this chapter, we propose
a double weighting method which leads to consistent estimation of the causal effect of a
treatment variable on an interval-censored event time outcome under a outcome-dependent
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observation scheme. This method can be extended to the case with a time-varying treat-
ment which is assigned at a set of regular discrete times, but we will focus on a time-fixed
treatment in the context of the PsA example. The doubly weighted estimator can eliminate
the selection bias due to intermittent outcome-dependent follow-up times as well as poten-
tial confounding of the treatment effect. Similar methodology can be applied to the non-
and semi-parametric estimation which will be introduced in Chapter 4, but parametric
estimation is the focus of this chapter. We continue the discussion based on a parametric
proportional hazards model (2.2) as an example. Then empirical studies will be employed
to examine the finite sample performances of proposed estimators, with simulations of
both a randomized experiment and an observational study. The proposed method will be
applied to the PsA cohort in Chapter 5 where treatments such as biologics are confounded
with disease risk factors and the event time outcome is dependently interval-censored due
to intermittent visits.
3.1 A Doubly Weighted Estimator for Causal Infer-
ence with Intermittent Outcome-Dependent In-
spection Times
From the previous chapter, we know that IIV weights eliminate the selection bias caused
by outcome-dependent intermittent observation. Now, we will discuss how to deal with
the selection bias due to confounders in observational studies. See Section 1.3.1 for the
definition of causal effect and confounding. An example we mentioned earlier is to study
the effect of biologics on the time to some joint damage event, e.g. time to an increase in
the number of damaged joints since treatment started. In the PsA cohort study, the median
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durations of the first episodes of biologics is over 3 years, so treatment with biologics can
be considered as a time-fixed treatment, when the treatment effect of biologics on joint
damage event times is of interest. It is known that the prescription of biologics could
be determined by disease status, biomarkers, demographic information, family history, or
other concurrent treatments such as NSAIDs and DMARDs, which were assessed at or
prior to biologics’ assignment. On the other hand, those variables may be risk factors of
joint damage as well. The common causes between treatment assignment and outcomes are
confounders and result in selection bias in the analysis of outcomes. For example, patients
who have more joint activity are more likely to receive biologics and are also at higher
risk of joint damage. A crude estimate of the association between biologics and the joint
damage event by directly comparing the two treatment groups might be misleading, which
we will discuss in Section 5.1.2 and Section 5.2. In this chapter, we consider a longitudinal
observational study with confounding variables as well as dependent inspection times which
are adjusted for by double weighting so that causal marginal treatment effect(s) can be
validly evaluated and plausibly interpreted.
3.1.1 Structural Models versus Associational Models
Recall that model (2.2) which was introduced in Section 2.1.1 is a parametric proportional
hazards model which allows the estimation of the marginal association of a variable of
primary interest, e.g. A, and a failure time outcome, T , i.e.
λT (t|A = a;θ) = λT,0(t;γ) exp(βa), (3.1)
where we let A be a dichotomous treatment random variable, e.g. 1 if treated, or 0
otherwise; a denotes the realization value of A; λT (t|A = a;θ) is the hazard function of
T conditional on the actual treatment A = a; λT,0(t;γ) is a parametric baseline hazard
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function, and θ = (γ ′, β)′. An estimate of β from the above model represents association
between A and T , but can not be interpreted as a causal effect of A on T unless treatment A
is randomized, so models like (3.1) are referred to as associational models. Alternatively,
Robins et al. (2000) introduced a class of so-called marginal structural models (MSMs)
relating the hypothetical exposure or treatment, a, to the corresponding counterfactual
outcome, T a and allowing the unconditional or marginal effect of a to be estimated. The
MSM corresponding to model (3.1) is defined by
λTa(t;θ
∗) = λT 0(t;γ
∗) exp(β∗a), (3.2)
where λTa is the hazard function of the counterfactual outcome T
a under hypothetical
treatment a. Here, θ∗ = (γ∗′, β∗)′ and λT 0 , the parameter and baseline hazard in the
counterfactual outcome model (3.2), are the targets of inference. Specifically, T 0 and T 1
represent the counterfactual outcomes under being untreated and treated, respectively. As
we introduced in Section 1.3.3, usually only one of the counterfactual outcomes can be
observed for each subject, but the average causal effect (ACE), e.g. the causal hazard
ratio in MSM (3.2), can be evaluated for the population. In this MSM, eβ
∗
is interpreted
as the casual hazard ratio of being treated (a = 1) versus being not untreated (a = 0),
which is usually different from the crude hazard ratio, eβ, of A = 1 versus A = 0 from
model (3.1), when treatment A is non-randomized.
In a randomized experiment, the association parameter β and the causal effect β∗ are
equal, since randomization ensures the absence of measured or unmeasured confounder-
s. But in an observational study, they are usually different, unless it is evident that the
treatment is not confounded. Greenland et al. (1999) defined the difference between the
population-averaged causal effect, β∗, and the raw marginal association between treatment
and outcome, β, as the amount of confounding bias. Standard methods to estimate a causal
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effect, e.g. β∗, and eliminate the confounding bias are standardization, inverse probability
weighting, and propensity score adjustment approaches such as matching, stratification
and covariate adjustment. Among them, inverse probability weighting is commonly used
in practical applications. Explicitly, in an observational study, under the assumption of no
unmeasured confounders, i.e. (A1) in Section 1.3.3, parameters in MSMs can be consistent-
ly estimated by modifying the crude estimates obtained from an associational model, e.g.
(3.1), by weighting each subject with the inverse probability of receiving that treatment.
In this sense, treatment can be considered as unconfounded in the pseudo-population. As
a result, weighted estimates based on the associational model have causal interpretations.
In the following, we will introduce an inverse-probability-of-treatment (IPT) weight first
and then combine that with the IIV weight we proposed in Section 2.2.2 for parametric
survival models.
3.1.2 A Doubly Weighted Estimator
Section 1.3.5 provides a preliminary introduction to the inverse-probability-of-treatment
(IPT) weighting approach, which is also referred to as propensity score weighting method,
because the IPT weights are formulated as the inverse of propensity scores. This section will
further introduce the IPT weighting method and combine that with the IIV weighting to
remove various sources of selection bias. As we discussed earlier in Section 1.3.3, in addition
to the consistency assumption and stable unit-treatment value assumption (SUTVA), an
important assumption we need to assume is the conditional exchangeability of treatment,
i.e. no unmeasured confounders, which can be defined for our context as
(C1) Strongly Ignorable Treatment Assignment/No Unmeasured Confounders
P a(t)q A|V , ∀t > 0 and ∀a,
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where P a(t) = I(T a > t), a = 0 or 1 if treatment is a dichotomous variable, and
its mean is E[P a(t)] = Pr(T a > t) , STa(t). Also, we assume that for any a, the
following positivity assumption is satisfied
0 < Pr(A = a|V ) < 1, for all V .
Assuming that the vector Vi includes all the measured confounders between Ai and Ti
and there are no unmeasured confounders, we can construct the following weight:
w∗i =
1
Pr(Ai = a|Vi; ζ) (3.3)
, 1
f(a|Vi; ζ) ,
where f(a|Vi, ζ) denotes a parametric mass function or a density function of random
treatment variable Ai at value or level a, conditional on confounders Vi. The measured
confounders Vi can be anything which predicts the assignment of treatment, affects the
outcome, and was measured before the assignment of treatment. Some good candidates
for the confounders of treatment with biologics could be age, gender, joint activity, PsA
duration, results of lab tests, family history of disease, and other treatments used concur-
rently. Further detailed theory about the propensity scores and IPT weighting methods
can be found in Rosenbaum and Rubin (1983) and Herna´n and Robins (2006, 2016).
If Ai is binary, the parameter ζ in weight formula (3.3) can be estimated by fitting a
logistic regression:
ln
[
Pr(Ai = 1|Vi; ζ)
1− Pr(Ai = 1|Vi; ζ)
]
= ζ ′Vi, (3.4)
where Vi = (1, Vi1, ..., Viq)
′. Then, ζ can be estimated by solving the quasi-likelihood score
equation
∑n
i=1Ui3(ζ) = 0 based on the logistic regression model (3.4):
Ui3(ζ) =
∂p(Vi; ζ)/∂ζ
p(Vi; ζ)[1− p(Vi; ζ)] [Ai − p(Vi; ζ)], (3.5)
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where p(Vi; ζ) = Pr[Ai = 1|Vi; ζ]. This can also be done by using software for generalized
linear models such as R function glm. Next, the IPT weight w∗i can be estimated by
w∗i (ζ̂) = Pr[Ai|Vi; ζ̂]−1 = {exp(Aiζ̂ ′Vi)/[1 + exp(ζ̂ ′Vi)]}−1. (3.6)
To consistently estimate the causal effect, e.g. β∗ in model (3.2), in an observation-
al study where treatment is confounded and failure times may be dependently interval-
censored, a double weight given below can be applied:
w†i (t) = w
∗
i wi(t), (3.7)
where wi(t) is the IIV weight defined by (2.14) for adjusting for the outcome-dependent
follow-up times, and w∗i is the IPT weight defined by (3.3) for adjusting for confounding.
For example, we can solve the estimating function (2.3) incorporated with the double
weight w†i (t) for the case where failure occurrence does not terminate visits (CASE I) and
visit times are continuous, i.e.
Uww(θ∗,α, ζ) =
n∑
i=1
∑
all a
∫ τi
0
w∗i (ζ)wi(t;α)I(Ai = a)c(t|a,θ∗)[Pi(t)− STa(t;θ∗)]dN∗i (t),
(3.8)
where STa(t;θ
∗) is a parametric survival function of the counterfactual outcome T a, with
assuming that a is a discrete treatment; I(·) is an indicator function; dN∗i (t) = dNi(t)Ci(t)
where Ci(t) is the at risk indicator, i.e. Ci(t) = I(Ci > t), and Ci is the random drop-out
time of subject i; c(t|a,θ∗) is defined similarly as in (2.3).
In the following, we will show the doubly weighted estimating function (3.8) is an
unbiased estimating function to estimate the parameter θ∗, provided that assumption (B1)
and assumption (C1) are satisfied and all the involved models are correctly specified. To
show (3.8) is an unbiased estimating function, we need to prove that E{Uwwi (θ∗,α, ζ)} = 0.
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We assume that there is no random drop-out for simplicity, i.e. Ci(t) = 1 and dN
∗
i (t) =
dNi(t) for all t > 0. Variable Zi(t
−) denotes some features of the observed history so that
the conditionally independent observation scheme assumption (B1) is satisfied. We assume
that {Ai,Vi} ⊂Hobsi (t−) for all t and suppress the parameters θ∗, α and ζ in the notation
for convenience. Then,
E
{∑
all a
∫ τi
0
w∗iwi(t)I(Ai = a)c(t|a)[Pi(t)− STa(t)]dNi(t)
}
=
∑
all a
∫ τi
0
c(t|a)E
{
I(Ai = a)
f(a|Vi)
dt
E[dNi(t)|Zi(t−)] [Pi(t)− ST
a(t)]dNi(t)
}
=
∑
all a
∫ τi
0
c(t|a)EA,V,Z,P
{
I(Ai = a)
f(a|Vi)
dt
E[dNi(t)|Zi(t−)] [Pi(t)− ST
a(t)]EdN |A,V,P,Hobs [dNi(t)]
}
=
∑
all a
∫ τi
0
c(t|a)EA,V,Z,P
{
I(Ai = a)
f(a|Vi)
dt
E[dNi(t)|Zi(t−)]
× [Pi(t)− STa(t)]E
[
dNi(t)|Zi(t−)
]}
, by (B1)
=
∑
all a
∫ τi
0
c(t|a)EA,V,P
{
I(Ai = a)
f(a|Vi) [Pi(t)− ST
a(t)]
}
dt
=
∑
all a
∫ τi
0
c(t|a)EA,V
{
I(Ai = a)
f(a|Vi) [E(Pi(t)|Ai = a,Vi)− ST
a(t)]
}
dt
=
∑
all a
∫ τi
0
c(t|a)EA,V
{
I(Ai = a)
f(a|Vi) [Pr(Ti > t|Ai = a,Vi)− ST
a(t)]
}
dt
=
∑
all a
∫ τi
0
c(t|a)EA,V
{
I(Ai = a)
f(a|Vi) [Pr(T
a
i > t|Vi)− STa(t)]
}
dt, by (C1)
=
∑
all a
∫ τi
0
c(t|a)EV
{
[Pr(T ai > t|Vi)− STa(t)]
1
f(a|Vi)E[I(Ai = a)|Vi]
}
dt
=
∑
all a
∫ τi
0
c(t|a)EV
{
[Pr(T ai > t|Vi)− STa(t)]
1
f(a|Vi)f(a|Vi)
}
dt
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=
∑
all a
∫ τi
0
c(t|a) {EV [Pr(T ai > t|Vi)]− STa(t)} dt
=
∑
all a
∫ τi
0
c(t|a)[Pr(T ai > t)− STa(t)]dt
=
∑
all a
∫ τi
0
c(t|a)[STa(t)− STa(t)]dt
= 0,
where Pi(t) = I(Ti > t) is the observed response, and P
a
i (t) = I(T
a
i > t) denotes the
counterfactual response under hypothetical treatment value or level a.
Let U1i(θ
∗,α, ζ) be Uwwi which is given in (3.8), the doubly weighted estimating func-
tion for the outcome process, Ui2(α) be an unbiased estimating function for the IIV weight
wi(t), and Ui3(ζ) be an unbiased estimating function for the IPT weight w
∗
i . Then, define
Ui = (U
′
1i,U
′
i2,U
′
i3)
′. Since Ui is a vector of unbiased estimating functions, by White
(1982), under mild regularity conditions, solving
∑n
i=1Ui(θ
∗,α, ζ) = 0 leads to consistent
estimators of parameters θ∗, α and ζ, given the outcome model STa(t;θ∗) and the models
for weight w∗i (ζ) and weight wi(t;α) are all correctly specified.
Similar to the Theorem 1 given in Section 2.2.5, the proposed doubly weighted estimator
of θ∗ has an asymptotically Normal distribution with a sandwich form variance, i.e.
√
n(θ̂∗ − θ∗) D−→ N(0, Vθ∗), (3.9)
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where Vθ∗ is the r × r left upper block of A−1B (A−1)′, r is the dimension of θ∗, and
A =

−E(∂Ui1/∂θ∗′) −E(∂Ui1/∂α′) −E(∂Ui1/∂ζ ′)
0 −E(∂Ui2/∂α′) 0
0 0 −E(∂Ui3/∂ζ ′)
 (3.10)
,

A11 A12 A13
0 A22 0
0 0 A33

and
B = E{Ui U ′i}
=

E(Ui1U
′
i1) E(Ui1U
′
i2) E(Ui1U
′
i3)
E(Ui2U
′
i1) E(Ui2U
′
i2) E(Ui2U
′
i3)
E(Ui3U
′
i1) E(Ui3U
′
i2) E(Ui3U
′
i3)
 (3.11)
,

B11 B12 B13
B21 B22 B23
B31 B32 B33
 .
Matrices A and B can be estimated by
Â =

− 1
n
∑n
i=1 ∂Ui1/∂θ
∗′ − 1
n
∑n
i=1 ∂Ui1/∂α
′ − 1
n
∑n
i=1 ∂Ui1/∂ζ
′
0 − 1
n
∑n
i=1 ∂Ui2/∂α
′ 0
0 0 − 1
n
∑n
i=1 ∂Ui3/∂ζ
′

∣∣∣∣∣∣∣∣∣
(θ̂∗,α̂,ζ̂)
,
and B̂ = 1
n
∑n
i=1Ui(θ̂
∗, α̂, ζ̂) Ui(θ̂∗, α̂, ζ̂)
′
, respectively, where n is the sample size. Details
about the estimation of Vθ∗ will be discussed under specific models in simulation studies.
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3.2 Simulation Study
Now, we will empirically study the finite sample performance of the proposed doubly
weighted estimator. In Section 2.3, we investigated the IIV weighted estimator in a para-
metric proportional hazards outcome model. In this section, as an alternative, we consider
a structural accelerated failure time (AFT) model, e.g. model (1.8) which was introduced
in Section 1.3.4. We assume a Log-normal distribution for failure times Ti, i = 1, ..., n.
That is, the logarithm of Ti has a Normal location-scale distribution:
ln(Ti) = θ0 + θ1Ai + θ2Li + θ3Vi + σWi, Wi ∼ N(0, 1), (3.12)
where all the regressors Ai, Li and Vi are time-fixed. We set θ0 = 0.5, θ1 = 1, θ2 = −0.3,
θ3 = −0.3 and σ = 1.5 so that approximately 90% − 95% of the Ti are interval-censored
and the rest are right-censored at the last visit before the administrative end of follow-
up time τi = 5. Factors Vi and Li are assumed to be associated with shorter failure
times, while treatment Ai is supposed to prolong failure times. Here, Vi is a confounder
between treatment Ai and outcome Ti, and it is assumed to follow a Normal distribu-
tion N(µv, σv), where µv = 3 and σv = 1. Treatment Ai is a binary random variable
from BIN
(
1,
exp(ζ0+ζ1Vi)
1+exp(ζ0+ζ1Vi)
)
. Note that when ζ1 = 0, treatment Ai is independent of
Vi. Otherwise, it is confounded by Vi. We consider two scenarios: ζ = (ζ0, ζ1)
′ = (0, 0)′
represents a randomized experiment, and ζ = (−6, 2)′ represents an observational study
where treatment is confounded. In either case, the probability of being treated, i.e. Ai = 1,
is approximately 0.5. Additionally, there is an intermediate variable Li that affects visit
times, with Li|Ai ∼ N(β0 + β1Ai, σl), where β0 = 4, β1 = −2, and σl = 1. Therefore, the
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distribution of (Ai, Li, Vi) in model (3.12) is designed to have:
f(Ai, Li, Vi) =fL(Li|Ai, Vi)fA(Ai|Vi)fV (Vi)
=fL(Li|Ai)fA(Ai|Vi)fV (Vi),
where fL, fA and fV are the probability density or mass functions of the relevant random
variables.
It can be shown that the (marginal) structural AFT model of T ai is given by
ln(T ai ) = θ
∗
0 + θ
∗
1a+ σ
∗W, W ∼ N(0, 1), (3.13)
where θ∗0 = θ0 + θ2β0 + θ3µv, θ
∗
1 = θ1 + θ2β1 and σ
∗ =
√
σ2 + θ22σ
2
l + θ
2
3σ
2
v . This can be
shown as below by marginalizing over Li and Vi, assuming Ai is randomized, i.e. Ai q Vi:
E[ln(T ai )] =E[ln(T
a
i )|Ai = a]
=E{E[ln(Ti)|Ai = a, Li, Vi]|Ai = a}
=θ0 + θ1a+ θ2E[Li|Ai = a] + θ3E[Vi|Ai = a]
=θ0 + θ1a+ θ2E[Li|Ai = a] + θ3E[Vi]
=θ0 + θ2β0 + θ3µv + (θ1 + θ2β1)a.
Parameter θ∗ = (θ∗0, θ
∗
1, σ
∗)′ in (3.13) is the parameter of interest.
To imitate intermittent and dependent visit times, we assume a discrete time visit
process, as discussed in Section 2.2.4. Here, we consider the case: failure occurrence
terminates the visit process (i.e. CASE II). That is, dNi(t) is defined at 0 < a1 < ... <
aM = τ = 5, with a time increment of 0.01 and M = 500, and the visit process is generated
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by
Pr[dNi,m+1 = 1|Ai, Li, Vi, P¯ obsim ]
=
 exp(γ0 + γ1Ai + γ2Li + γ3Vi), if P¯ obsim = 11, if P¯ obsim = 0 m = 0, 1, ...,M − 1, and i = 1, ..., n.
(3.14)
where γ0 = −5, γ1 = −0.2, γ2 = 0.2, and γ3 = 0.1, so that the median length of visit gaps
is about 0.45 ∼ 0.50 for the untreated group, and 0.80 ∼ 0.85 for the treated group. There-
fore, variable Zi(t
−) in the assumption (B1*) is actually defined by {Ai, Li, Vi, P¯ obsi (t−)}.
We assume that there is no random drop-out for simplicity. Similar to the simulation stud-
ies in Section 2.3.1, IIV weights wi(t) are estimated by fitting a semi-Markov proportional
hazards model with a piecewise constant baseline for visit gap times, which is defined by
Pr[dNi,m+1 = 1|Ai, Li, Vi, P¯ obsim ;α]
=

∑K
k=1 αkIk[B(am+1)] exp(αK+1Ai + αK+2Li + αK+3Vi), if P¯
obs
im = 1
1, if P¯ obsim = 0
, (3.15)
where B(t) is the gap time between the most recent past visit prior to t and t; Ik[B(t)] =
I{B(t) ∈ (dk−1, dk]}, 0 = d0 < d1 <, ..., < dK = +∞ are the cut-points for the piecewise
constant baseline and they are set as (0, 0.40, 0.75, 1.0,+∞) when sample size is 500 and as
(0, 0.25, 0.50, 0.75,+∞) when sample size equals 1000 or 2000. Parameter α = (α1, ..., α7)′
can be approximately estimated by the R function phreg or by solving the following esti-
mating function:
Ui2(α) =
m∗i∑
j=1
{
∂ln{λ[B(tij)]}
∂α
−
∫ B(tij)
0
∂λ(s)
∂α
ds
}
(3.16)
− I(P¯ obsi (tim∗i ) = 1)
∫ τ−tim∗
i
0
∂λ(t)
∂α
dt,
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where 0 < ti1 < ... < tij < ... < tim∗i < τ are the actual visits of subject i before a failure
is observed, and λ(s) =
∑K
k=1 αkIk(s) exp(αK+1Ai + αK+2Li + αK+3Vi), K = 4. The IIV
weights are computed by (2.14) when P¯ obsim = 1 and are set to be 1 when P¯
obs
im = 0.
A
L
V
P0 P1 P2
dN0 dN1 dN2
Figure 3.1: DAG for the simulation setting with risk factors A (treatment), L (intermediate
variable), and V (confounder), when individuals are assumed to stop visiting after failure
occurrence, where Pm = I(T > am), with P0 = 1, and dNm indicates a clinic visit at am,
m = 0, 1, 2.
A DAG is displayed in Figure 3.1 to demonstrate the simulation scenario, where we can
see L is an intermediate variable on the pathway from treatment A to outcome P (t), and
V is a confounder between A and P (t). Furthermore, the visit process dN(t) and outcome
process P (t) share common risk factors, A, L and V . The visit process dN(t) is also
associated with dN(t−) and P (t−). Therefore, this example corresponds to a longitudinal
study with dependent follow-up times and a confounded treatment.
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Then, the doubly weighted estimating function of the outcome model for subject i is
defined by
Ui1(θ
∗,α, ζ) =
1∑
a=0
mi∑
j=1
w∗i (ζ)wi(tij;α)I(Ai = a)c(tij|a;θ∗)[Pi(tij)− STa(tij;θ∗)], (3.17)
where tij’s include the m
∗
i actual visits and mi − m∗i pseudo-visits after failure occurred
and the survival function of the counterfactual outcome T ai based on model (3.13) is given
as
STa(tij;θ
∗) = 1− Φ
(
ln(tij)− θ∗0 − θ∗1a
σ∗
)
,
where Φ(t) is the CDF of a standard normal distribution at t. Regarding the IPT weight,
parameter ζ = (ζ0, ζ1)
′ in the logistic regression (3.4) can be estimated by software for
generalized linear models or by solving the estimating equation
∑n
i=1Ui3(ζ) = 0 given in
(3.5).
Three estimators, (i) the MLE based on likelihood (2.1), (ii) the IIV weighted estimator
based on estimating function (2.38), and (iii) the proposed doubly weighted estimator based
on estimating function (3.17), will be examined and compared with each other. Function
c(·) needed in (ii) and (iii) is given in (2.4), so (ii) and (iii) are weighted GEE estimators
with independent working covariance matrices. The MLEs are obtained by R function
survreg which can handle interval-censored survival data for AFT models and yield robust
sandwich variance estimates. The GEE estimates with independent working covariance
matrices are obtained by R function glm with η = Φ−1(1 − µ) for binary responses P ai (t)
and with relevant weights applied, where η = b0 + b1a+ b2ln(t) is the linear predictor and
µ = E[P ai (t)] = STa(t;θ
∗) is the mean function. The reparameterization is θ∗0 = −b0/b2,
θ∗1 = −b1/b2, and σ∗ = 1/b2.
For each estimator, Bias, ASE, ESE, MSE and CP are summarized in Tables 3.1-3.6
for 500 simulation replicates; we considered three sample sizes, n = 500, 1000, and 2000.
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The asymptotic variance Vθ∗ of the proposed doubly weighted GEE estimator is estimated
by the sandwich form variance estimator Â−1B̂ (Â−1)′, where the estimators of Â11 and
Â12 in (3.10) can be derived similarly as for Section 2.3.1 by (2.28) and (2.31), respectively,
and A13 can be estimated by
Â13 =
1
n
n∑
i=1
1∑
a=0
mi∑
j=1
(2a− 1)wi(tij; α̂)w∗2i (ζ̂)
∂p(Vi|ζ)
∂ζ ′
∣∣∣∣
ζ=ζ̂
c(tij|a; θ̂∗)[Pi(tij)−STa(tij; θ̂∗)].
(3.18)
Since Ui2 and Ui3 are score functions, A22 = B22 and A33 = B33 can be estimated by the
observed Fisher information matrices provided by phreg and glm, respectively.
From Tables 3.1-3.6, we see that MLEs are biased both when treatment is randomized
and confounded. Especially, when A is confounded by V , i.e. in Tables 3.2, 3.4 and 3.6
when ζ = (−6, 2)′, the bias produced by MLEs is very large because likelihood (2.1) fails
to take the informative inspection times as well as the confounded treatment into account.
Tables 3.1, 3.3 and 3.5 show that the IIV weighted estimator results in negligible bias and
good coverage probabilities around the 95% nominal level. However, in Tables 3.2, 3.4 and
3.6, the IIV weighted estimates which do not adjust for confounding have some selection
bias caused by the non-randomized treatment. For the doubly weighted estimator, when
treatment is randomized, from Tables 3.1, 3.3 and 3.5, we see that bias is negligible and
coverage is good; when treatment is not randomized, from Tables 3.2, 3.4 and 3.6, bias
is mush less than that for the IIV weighted estimator, and coverage becomes close to
the nominal level when sample size grows. Slightly low coverage of the doubly weighted
estimates in Tables 3.2, 3.4 and 3.6 reflects the fact that ASEs are a bit smaller than the
ESEs, but when sample size increases the difference becomes smaller and coverage is closer
to 95%. Robins et al. (2000) commented that large variability in the weights can result
in weighted estimators with large variances. In our study, there are some extremely large
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weights, especially when wi(t) and w
∗
i are combined for the doubly weighted estimator. How
to deal with large variability in weights and improve the weighted estimators is discussed
in Chapter 6.
In this chapter, we applied the double weighting method to estimating functions for
parametric models. In fact, it can be applied to non- or semi-parametric estimation based
on estimating equations as well. We will illustrate that in the analyses of the PsA data in
Chapter 5.
Table 3.1: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for the case where Ai is
randomized, i.e. ζ = (0, 0)′. Sample size: n = 500. Number of replicates: N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
θ∗0 -1.600 0.109 0.108 0.097 0.021 0.85
MLE θ∗1 1.600 -0.124 0.152 0.141 0.035 0.88
ln(σ∗) 0.444 -0.079 0.040 0.039 0.008 0.48
θ∗0 -1.600 0.005 0.150 0.141 0.020 0.96
IIV Weighted θ∗1 1.600 -0.034 0.189 0.178 0.033 0.95
ln(σ∗) 0.444 -0.014 0.062 0.065 0.004 0.93
θ∗0 -1.600 0.003 0.150 0.140 0.020 0.96
Doubly Weighted θ∗1 1.600 -0.028 0.187 0.178 0.032 0.95
ln(σ∗) 0.444 -0.014 0.062 0.065 0.004 0.94
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Table 3.2: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for the case where Ai is
confounded by Vi, i.e. ζ = (−6, 2)′. Sample size: n = 500. Number of replicates: N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
θ∗0 -1.600 0.261 0.108 0.108 0.080 0.33
MLE θ∗1 1.600 -0.440 0.151 0.155 0.218 0.18
ln(σ∗) 0.444 -0.073 0.039 0.039 0.007 0.52
θ∗0 -1.600 0.176 0.144 0.155 0.055 0.73
IIV Weighted θ∗1 1.600 -0.371 0.184 0.197 0.176 0.46
ln(σ∗) 0.444 -0.017 0.061 0.066 0.005 0.92
θ∗0 -1.600 0.015 0.227 0.270 0.073 0.91
Doubly Weighted θ∗1 1.600 -0.061 0.295 0.360 0.133 0.91
ln(σ∗) 0.444 -0.015 0.090 0.110 0.012 0.90
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Table 3.3: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for the case where Ai is
randomized, i.e. ζ = (0, 0)′. Sample size: n = 1000. Number of replicates: N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
θ∗0 -1.600 0.104 0.077 0.075 0.016 0.73
MLE θ∗1 1.600 -0.117 0.107 0.103 0.024 0.81
ln(σ∗) 0.444 -0.076 0.028 0.028 0.007 0.22
θ∗0 -1.600 -0.005 0.107 0.111 0.012 0.93
IIV Weighted θ∗1 1.600 -0.020 0.134 0.132 0.018 0.94
ln(σ∗) 0.444 -0.009 0.044 0.045 0.002 0.95
θ∗0 -1.600 -0.006 0.106 0.110 0.012 0.94
Doubly Weighted θ∗1 1.600 -0.018 0.133 0.130 0.017 0.95
ln(σ∗) 0.444 -0.009 0.044 0.045 0.002 0.95
100
Table 3.4: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for the case where Ai
is confounded by Vi, i.e. ζ = (−6, 2)′. Sample size: n = 1000. Number of replicates:
N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
θ∗0 -1.600 0.263 0.076 0.071 0.074 0.06
MLE θ∗1 1.600 -0.446 0.107 0.100 0.209 0.01
ln(σ∗) 0.444 -0.073 0.027 0.027 0.006 0.23
θ∗0 -1.600 0.181 0.102 0.099 0.043 0.54
IIV Weighted θ∗1 1.600 -0.380 0.130 0.126 0.161 0.16
ln(σ∗) 0.444 -0.017 0.043 0.043 0.002 0.94
θ∗0 -1.600 0.005 0.171 0.204 0.041 0.93
Doubly Weighted θ∗1 1.600 -0.026 0.225 0.259 0.068 0.93
ln(σ∗) 0.444 -0.012 0.069 0.085 0.007 0.91
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Table 3.5: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for the case where Ai is
randomized, i.e. ζ = (0, 0)′. Sample size: n = 2000. Number of replicates: N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
θ∗0 -1.600 0.111 0.054 0.050 0.015 0.47
MLE θ∗1 1.600 -0.124 0.076 0.071 0.020 0.64
ln(σ∗) 0.444 -0.074 0.020 0.018 0.006 0.02
θ∗0 -1.600 0.010 0.075 0.073 0.005 0.95
IIV Weighted θ∗1 1.600 -0.036 0.095 0.090 0.009 0.94
ln(σ∗) 0.444 -0.006 0.031 0.031 0.001 0.94
θ∗0 -1.600 0.008 0.075 0.073 0.005 0.95
Doubly Weighted θ∗1 1.600 -0.033 0.094 0.090 0.009 0.94
ln(σ∗) 0.444 -0.006 0.031 0.031 0.001 0.94
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Table 3.6: Bias, average of asymptotic standard errors (ASE), empirical standard error
(ESE), mean squared error (MSE) and coverage probability (CP) for the case where Ai
is confounded by Vi, i.e. ζ = (−6, 2)′. Sample size: n = 2000. Number of replicates:
N = 500.
TRUE VALUE BIAS ASE ESE MSE CP
θ∗0 -1.600 0.264 0.054 0.051 0.072 0.00
MLE θ∗1 1.600 -0.448 0.076 0.074 0.206 0.00
ln(σ∗) 0.444 -0.069 0.019 0.019 0.005 0.03
θ∗0 -1.600 0.184 0.072 0.071 0.039 0.30
IIV Weighted θ∗1 1.600 -0.383 0.092 0.092 0.155 0.01
ln(σ∗) 0.444 -0.012 0.031 0.030 0.001 0.94
θ∗0 -1.600 0.013 0.121 0.134 0.018 0.96
Doubly Weighted θ∗1 1.600 -0.044 0.160 0.166 0.029 0.92
ln(σ∗) 0.444 -0.010 0.049 0.053 0.003 0.94
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Chapter 4
NON- AND SEMI-PARAMETRIC
ESTIMATION FOR
INTERVAL-CENSORED FAILURE
TIME DATA WITH DEPENDENT
INSPECTION TIMES
In Chapter 2, we discussed parametric estimation of the distributions of failure times, in
the case where failure times could be dependently interval-censored due to intermittent and
outcome-dependent inspection times. This chapter focuses on non- and semi-parametric
estimation for interval-censored failure times with intermittent observation. The inverse-
intensity-of-visit (IIV) weighted estimating function approach will be extended and applied.
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4.1 IIV Weighted Non-Parametric Estimation of Dis-
tribution Functions
Non-parametric estimation of survival functions or distribution functions is important in
the analysis of lifetime or failure time data. First, a graphical display based on non-
parametric estimation of a distribution function or survival function can help one choose
models for fitting data or check certain model assumptions. For example, the proportional
hazards assumption which is needed for a Cox model can be graphically checked by the
ln(−ln) transformation of survival curves. If the assumption is satisfied, then the plot
of ln{−ln[ST (t)]} versus time t or ln(t) should show roughly vertical parallel curves for
individuals grouped according to covariate values (Lawless, 2003). Non-parametric esti-
mates of survival or distribution functions can also be employed for robustly estimating
distribution quantities, e.g. median or percentiles, and for multi-sample comparison with
respect to a particular risk factor without model fitting.
As discussed in the preceding chapters, the assessment of failure time distributions for
the whole population or subgroups stratified by some fixed variable is often of interest, e.g.
the marginal CDF, FT (t), or FT (t|A) for t > 0, of failure time T . To validly estimate the
CDF, FT (t), or survival function, ST (t), by standard methods such as the Kaplan-Meier
estimator for right-censored data, we need censoring times to be independent of failure
times. For interval-censored data, when inspection times are independent of failure times,
failure times are independently interval-censored. Then, Turnbull (1976)’s non-parametric
estimator of FT (t) is obtained by maximizing likelihood (2.1). The resulting estimate
F̂T (t) has positive support in specified intervals according to the observed interval-censored
observations but may be undefined over some intervals (Lawless, 2003). The validity of this
estimator relies on inspection times being independent of failure times. When inspection
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times til and tir in likelihood (1.3), or tij and ti,j+1 in likelihood (2.1), are not marginally
independent of failure times, estimators could be inconsistent, as we have shown in Section
2.3.1 in the simulations for parametric models.
Non-parametric estimation for dependently right-censored failure time data has been
heavily discussed in the literature via a variety of techniques: e.g. inverse probability
weighting by Robins (1993); Wang and Wells (1998); Robins and Finkelstein (2000); Satten
et al. (2001); Hajducek and Lawless (2013), and EM algorithm by Finkelstein et al. (2002);
Zhang et al. (2007); Chen et al. (2010). However, dependent interval censoring has received
limited attention so far. van der Laan and Robins (1998) considered this for current status
data, which involves a single observation time per individual. van der Laan and Hubbard
(1997) also considered current status data but did not develop estimation methods for more
general interval-censored data. Their methods assume that there exists a covariate Z(t)
such that given its history, the visit or observation time process is ignorable. Alternatively,
introducing latent variable(s) to connect the failure time process and the visit process,
which was reviewed in Chapter 2, is another way to deal with dependent interval censoring.
Additionally, Park et al. (2006) considered dependent censoring as a competing risk of
failure and their method for nonparametric inference can be used for dependently right-
censored as well as dependently interval-censored data. In the following, we will develop an
IIV weighted estimating function approach for the nonparametric estimation of distribution
function FT (t) so that dependent interval censoring caused by intermittent visits can be
handled.
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4.1.1 Monotone-Smoothed IIV Weighted Estimators of Distri-
bution Functions
Suppose that we are interested in the inference about the distribution function FT (t) of a
failure time outcome T . Estimator of the survival function ST (t) can be simply obtained
by 1 − F̂T (t). We define a set of finite discrete assessment times where FT (t) will firstly
be estimated, denoted by 0 < s1, ..., < sm ≤ τ . We assume that the administrative end of
follow-up time, τ , is the same for all individuals for simplicity. Later, we will refine the
crude estimates.
Let θl = FT (s`), where ` = 1, ...,m. First, we assume that the visit process is not ter-
minated by the occurrence of failure and that visit times are continuous. Then, motivated
by (2.13), for estimating θ = (θ1, ..., θm)
′, with c(t; θ`) = {θ`(1 − θ`)}−1, we define IIV
weighted estimating functions for θ by
U`(θ) =
n∑
i=1
∫ τ
0
Kb(s` − t)wi(t)
θ`(1− θ`) [Yi(t)− θ`]dN
∗
i (t), ` = 1, ...,m, (4.1)
where Yi(t) = I(Ti ≤ t), dN∗i (t) = dNi(t)Ci(t), dNi(t) is the indicator of a visit at t,
Ci(t) = I(Ci > t) and Ci denotes a random drop-out time for subject i. The function
Kb(u) = K(u/bm)/bm, where K(·) is a bounded kernel function defined to be zero outside
[−1, 1], e.g. uniform (rectangular), triangular, or Epanechnikov (quadratic), and {bm}
denotes a positive bandwidth sequence converging to 0 when
∑
mi → +∞, where mi
denotes the total number of visits for subject i.
Note that (4.1) is not an unbiased estimating function, even given the conditionally
independent observation assumption (B1) is true. That is, the solution to E(Ui`) = 0
gives θ∗` =
∫ τ
0 Kb(s`−t)FT (t)SC(t)dt∫ τ
0 Kb(s`−t)SC(t)dt
6= θ`, provided that (B1) holds and the random drop-
out is independent (i.e. Yi(t) q Ci(t), ∀t > 0), where SC(t) = Pr(Ci > t) = E[Ci(t)].
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Nevertheless, when the number of visits increases, i.e.
∑
mi → +∞, bm ↓ 0, and the
estimates solved from (4.1) approach θ`, i.e. FT (s`). Small bandwidths result in small bias
at the cost of large variance since fewer visits lie in [s` − bm, s` + bm] and contribute to
the estimation of FT (s`). In practice, people widely use data-driven bandwidth algorithms
to do bandwidth selection, e.g. least-squares cross-validation (Hall et al., 2004). A wise
selection of bandwidth can lead to good precision of estimation. In the simulation studies
in Section 4.1.2 and the real data analysis in Chapter 5, we simply chose bandwidths to
have about 50 − 100 visits fall in the window [s` − bm, s` + bm] so that the variances of
estimates are moderate and normal approximations are accurate.
When failure occurrence terminates the visit process, motivated by (2.23) in Section
2.2.4, the estimating function for θ with a discrete time visit process can be written by
U`(θ) =
n∑
i=1
M∑
k=1
Kb(s` − ak)wi(ak)
θ`(1− θ`) [Yi(ak)− θ`]dN
∗
i (ak), ` = 1, ...,m, (4.2)
where {dNi(ak) : k = 1, ...,M} is a discrete time visit process with 0 < a1 < ... < aM = τ .
Also, we have dNi(ak) = 1 and wi(ak) = 1, when Y¯
obs
i (ak−1) = 1 since responses Yi(ak)’s
are all known as 1 after the visit following failure occurrence. Let m∗i denote the number
of actual visits when Y¯ obsi (ak−1) = 0 and mi−m∗i denote the number of pseudo visits when
Y¯ obsi (ak−1) = 1 for subject i.
The estimating equation U`(θ) = 0 given in (4.1) or (4.2) yields a closed form estimate
for FT (s`), ` = 1, . . . ,m, i.e.
Y¯` =
∑n
i=1
∑mi
j=1K(
s`−tij
bm
)wi(tij)Yi(tij)∑n
i=1
∑mi
j=1K(
s`−tij
bm
)wi(tij)
, ` = 1, . . . ,m, (4.3)
where {ti1, ..., timi} = {t > 0 : dN∗i (t) = 1}, which denote the mi actual visit times for
subject i in (4.1) and include both the m∗i actual visit times and the mi−m∗i pseudo visit
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times which follow failure occurrence in (4.2). From (4.3), we see only visits which lie in
[s` − bm, s` + bm] contribute to the estimation of FT (s`) and only the s` with at least one
visit contained in [s`− bm, s` + bm] can be estimated. In an extreme case where bandwidth
equals zero and tij’s are all distinct, each solution Y¯` to U`(θ) = 0 is either 0 or 1.
Note that the estimates given in (4.3) are non-monotone in general, so we call them
crude or raw estimates, and techniques for monotone smoothing will now be adopted.
Isotonic regression is one of the most commonly used methods for achieving monotonic-
ity; it yields non-decreasing estimates by minimizing a weighted sum of squares under a
non-decreasing constraint. However, the fitted values provided by isotonic regression are
generally step functions, so we consider the combination of an isotonic regression followed
by a kernel non-parametric regression, which was proposed by Mukerjee (1988) and recent-
ly applied by Datta and Sundaram (2006) to multistage models with current status data.
As discussed in He and Shi (1998), theoretically, monotone smoothing can be implement-
ed by combining isotonic regression with any smoothing tools, e.g. kernel or spline, and
smoothing can be done either before or after isotonic regression.
Analogous to Sun (2006) and Zhang and Sun (2010) where isotonic regression is ap-
plied to estimate distribution functions or survival functions with current status data, the
isotonic regression problem in our context is to minimize
Qw(θ) =
m∑
`=1
n∑
i=1
mi∑
j=1
K[(s` − tij)/bm]wi(tij){Yi(tij)− θ`}2
subject to θ1 ≤ ... ≤ θm. This is equivalent to minimizing
Q∗w(θ) =
m∑
`=1
w+(s`){Y¯` − θ`}2, for ` = 1, ...,m, (4.4)
subject to the non-decreasing constraint, where
Y¯` =
n∑
i=1
mi∑
j=1
K[(s` − tij)/bm]wi(tij)Yi(tij)/w+(sl),
109
and
w+(s`) =
n∑
i=1
mi∑
j=1
K[(s` − tij)/bm]wi(tij).
The above equation can be solved by the max-min formula (Barlow et al., 1972; Robert-
son et al., 1988) for isotonic regression:
F˜T (s`) = max
r≤`
min
u≥`

u∑
v=r
w+(sv)Y¯v
u∑
v=r
w+(sv)
 , (4.5)
or by software based on the well known Pool-Adjacent-Violators Algorithm (PAVA) (Miles,
1959). More details about isotonic regression and PAVA can be found in Barlow et al.
(1972), Robertson et al. (1988) and de Leeuw et al. (2009).
The next step is to implement kernel non-parametric regression so that the estimated
survival curve of T is smooth and the estimates of FT (t) can be obtained at any t rather
than only at s`’s. We consider the local-constant estimator also known as the Nadaraya-
Watson estimator (Nadaraya, 1964; Watson, 1964), which is given below, with a log-concave
kernel function K∗(·) to smooth the estimates yielded by isotonic regression, i.e. F˜T (a`),
` = 1, ...,m.
F̂T (t) =
∑m
`=1 F˜T (s`)K
∗( s`−t
hm
)∑m
`=1K
∗( s`−t
hm
)
, ∀t > 0, (4.6)
where kernel K∗(·) is a log-concave density so that the monotonicity of (4.6) is retained
(Mukerjee, 1988) and {hm} is a positive bandwidth sequence converging to 0 when
∑
mi →
+∞. It is found that bias is mainly caused by a poor choice of bm in (4.3), since (4.1) or
(4.2) is not an unbiased estimating function for θ` or FT (t), though they are asymptotically
unbiased when bm ↓ 0. The selection of of hm in (4.6) is not sensitive to the final estimated
survival curves, so one can select {hm} to make the final estimates of survival curves have
reasonable curvature. Asymptotics are much harder here than in standard settings, e.g.
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Mukerjee (1988), involving a single kernel estimator. In the proposed two-stage estimation
procedure, we employ two kernels; especially in the first stage, the crude estimate Y¯` solved
from (4.1) is not a consistent estimator of θ` but its limiting value θ
∗
` approaches θ` when
bandwidth bm goes to 0. Then, in the second stage we apply isotonic regression and kernel
again to achieve a monotone smoothing, which is extended from Mukerjee (1988) and
Datta and Sundaram (2006) to the present setting. Thus, the whole procedure demands
non-standard asymptotics for the final estimate F̂T (t). Instead, we consider the bootstrap
to estimate the standard error of F̂T (t) in simulation and real data analysis.
4.1.2 Simulation Study
To demonstrate the proposed method and examine the finite sample performance of re-
sulting estimates, a simulation study is conducted for the non-parametric estimation of
FT (t|A) for two treatment groups separately, A = 0 and A = 1. The simulation design
is basically the same as in Section 2.3 for parametric estimation, and we will discuss two
cases as usual: failure occurrence does not terminate visits (CASE I) and failure occur-
rence terminates visits (CASE II). Since bootstrap is very computationally intensive, the
sample size is set as 200 in total (about 100 for each treatment group) and the number of
simulation replicates is 500; 100 bootstrap samples are used to estimate a standard error.
At t = 0, treatment variable A is generated from BIN(1, p) with p = 0.5. The admin-
istrative end of follow-up time, τ , is set to be 5. For technical simplicity, time is discretized
in this simulation study for both CASE I and CASE II, with an increment of 0.01, so (4.2)
will be used for crude estimates and M in (4.2) equals 500. Then for any ak, k = 0, ...,M
with a0 = 0 and aM = 5, an ancillary variable Lk is generated by
Lk|A, L¯k−1 ∼ N(β1A, σl), (4.7)
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with β1 = −0.5 and σl = 1 so that treatment A is an inhibitor for Lk. Then, response Yk+1
is generated by
Pr[Yk+1 = 1|L¯k, A, Yk = 0] = Φ(η0 + η1Lk + η2A), (4.8)
where Φ denotes the CDF of a standard normal distribution N(0, 1) and Yk = I(T ≤ ak).
Parameters η0, η1 and η2 are given by −2.8, 0.5 and −0.1, respectively, so that treatment
A has a negative effect on the risk of failure and Lk is an intermediate variable between
A and failure time which has a positive strong effect on the risk of failure but is inhibited
by treatment. As a result, 98% of untreated individuals (A = 0) and 80% of treated
individuals (A = 1) fail before τ . After marginalizing over Lk, the marginal outcome
model can be presented as
Pr[Yk+1 = 0|A, Yk = 1] = eψ0 exp(ψ1A), (4.9)
where c = 1/
√
1 + η21σ
2
l , ψ0 = ln {Φ(c · η0)} = −5.09, ψ1 = ln
{
Φ[c·(η0+η2+η1β1)]
Φ(c·η0)
}
= −0.93,
so there is about a 60% risk deduction for A = 1 versus A = 0.
For the case where visits continue after failure occurs (CASE I), the discrete time visit
process, {dNk : k = 1, ...,M}, is generated by a Markov proportional intensities model
with a constant baseline intensity:
Pr[dNk+1 = 1|A, L¯k] = exp(γ0 + γ1Lk + γ2A) (4.10)
= eγ0 exp(γ1Lk + γ2A), k = 0, 1, ...,M − 1,
where γ0 = −3.5, γ1 = 0.5, and γ2 = −0.2 so that the average visit gap time is approxi-
mately 0.30 for the untreated group (A = 0) and about 0.44 for the treated group (A = 1).
From model (4.10), we see that the visit process is outcome-dependent via A as well as
L¯k. For the case where failure occurrence stops visits (CASE II), {dNk : k = 1, ...,M} are
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generated by
Pr[dNk+1 = 1|A, L¯k, Y¯ obsk ]
=
 exp(γ0 + γ1Lk + γ2A), if Y¯ obsk = 01, if Y¯ obsk = 1 , k = 0, 1, ...,M − 1. (4.11)
To estimate FT (t|A) for a given A, we have proposed a two-stage estimation procedure
in the preceding subsection. First, we estimate the inverse-intensity-of-visit (IIV) weights
wi(t) for the crude estimator given in (4.3), which can be done by fitting a piecewise con-
stant proportional hazards semi-Markov model given in (2.39) for the gap times of “actual”
visits. Here, we use R function phreg with (0.40, 0.75, 1.0) as cut-points to estimate the IIV
weights. In addition, we let the kernel function in (4.3), K(·), be the Epanechnikov (EP)
kernel, i.e. k(x) = 3
4
(1− x2)I(|x| ≤ 1), which is bounded and smooth. The bandwidth bm
in (4.3) is selected to be 0.125, so m = 20. Then, there are about 70 actual visits contained
in interval [s` − bm, s` + bm] for crudely estimating FT (s`) in CASE I. Second, the isotonic
regression of crude estimates (Y¯1, ..., Y¯m) with weights (w+(s1), ..., w+(sm)) is implemented
by the R function monoreg in package fdrtool. Finally, kernel smoothing for the monotone
estimates F˜T (s`)’s is done with a standard normal (Gaussian) kernel given for K
∗(·) and
a bandwidth hm specified as 0.2 for the CASE I and 0.3 for the CASE II, which can be
implemented by the R function npreg in the package np. Simulation results are summarized
and the plots of estimated distribution function curves are shown for A = 1 versus A = 0
in the following.
CASE I: Failure occurrence does not terminate visits
Figure 4.1 shows the mean raw estimate Y¯` at each s`, s` = 1, ...,m, in 500 simulation
replicates, for different m or bm. We can see bias is negligible in each plot, so estimation is
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not very sensitive to bandwidth selection, when the number of visits around s` is sufficient.
Therefore, we let m = 20, i.e. bm = 0.125 in the following. Figure 4.2 and Figure 4.3
demonstrate the crude estimates Y¯`, isotonic estimates F˜T (s`) and kernel-smoothed isotonic
estimates F̂T (t) for A = 0 and 1 in one simulation sample, respectively. We see that isotonic
regression monotonizes the raw estimates and then the kernel smoothing with a bandwidth
of 0.2 produces smooth distribution function curves. It is seen that the raw estimates in
Figure 4.2 have relatively smaller variability than those in Figure 4.3, because untreated
individuals have more visits than the treated ones by design. Also, the raw estimates for
A = 0 in Figure 4.2 are close to monotone, while isotonic regression corrects relatively
more the raw estimates for A = 1 in Figure 4.3. For either group, the kernel-smoothed
isotonic estimate of distribution function, denoted by a solid curve agrees quite well with
the true distribution function curve denoted by a dashed curve. Figure 4.4 displays the
estimated and true distribution functions of the two groups as a comparison, where we
can see that for sample size n = 200 and the visit frequency for the treated (A = 1)
group, estimate of FT (t|A = 1) will not be really smooth. Additionally, note that Figures
4.2-4.4 display the performance of estimates in one simulation sample to demonstrate the
two-stage estimation procedure.
Table 4.1 summarizes the kernel-smoothed isotonic estimates of FT (t|A) by (4.6) at
t = 0.5, 1.0, ..., 4.5, 5.0, for the two groups across the 500 simulation samples and provides
95% pointwise empirical coverage probabilities (ECPs) to draw statistical conclusions. S-
tandard errors are estimated by non-parametric bootstraps, which can be implemented by
resampling with replacement using R function sample. The bootstrap sample size is set to
be 100. All the true values, estimates and standard errors are reported for FT (t|A), while
coverage probabilities and Z tests are presented after a ln(−ln(FT (t|A))) transformation.
If we let ln(−ln(F̂T (t|A))) be ϑ̂(t), then an empirical confidence interval is computed by
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ϑ̂(t)± 1.96 se(ϑ̂(t)) where se(ϑ̂(t)) is the bootstrap estimated standard error of ϑ̂(t). Ap-
proximate normality is checked in Figure 4.5 by histograms and QQ-plots of the pooled Z
tests across time, which are defined by z(t) = ϑ̂(t)−ϑ(t)
se(ϑ̂(t))
for all t = 0.5, 1.0, ..., 4.5, 5.0. We
see that estimates in either group have good coverage, except for the regions close to t = 0
or 5. The mean of bootstrap standard errors (BSEs) underestimate the empirical standard
errors (ESEs) slightly, which may be explainable by the small sample size (i.e. 200) and
should improve when sample size n increases. Poor coverage for t = 0.5 and t = 5.0 is
caused by the greater underestimation of ESE. For example, at t = 5.0, approximately 98%
of individuals fail in the untreated group, i.e. FT (t|A = 0) is close to 1. Also, we know that
kernel smoothing usually does not perform perfectly close to bounds, so underestimation of
standard errors and low coverage could result. Poor normal approximation close to t = 0
and t = 5 can be found in Figure 4.5 as well. Figure 4.6 shows the truncated histograms
and QQ-plots for t = 1.0−4.0, and we see that estimates appear to be normally distributed
over this range.
CASE II: Failure occurrence terminates visits
For the case where failure occurrence discontinues the visit process, Figure 4.7 shows the
mean raw estimate Y¯` for different bandwidth bm selections in the 500 simulations. Each
plot shows that the raw estimates are essentially unbiased at each t. In addition, Figure
4.8 and Figure 4.9 show the raw estimates, isotonic estimates and kernel-smoothed isotonic
estimates (final estimates) for the untreated group (A = 0) and the treated group (A = 1)
in one simulation sample, respectively. Additionally, Figure 4.10 compares the estimated
and true distribution functions of the two groups. Overall, estimates F̂T (t|A = 0) and
F̂T (t|A = 1) shown in Figure 4.10 agree well with the true distribution functions, though
because of sampling variation they naturally fall above or below the true functions.
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Figure 4.1: Plot of the mean of raw estimates Y¯` at s`, ` = 1, ...,m, for m = 10, 20, 50,
in 500 simulations, compared with the true FT (t|A) curves for two treatment groups in
CASE I. (a) is for m = 10, i.e. bm = 0.25, (b) is for m = 20, i.e. bm = 0.125, (c) is for
m = 50, i.e. bm = 0.05. Sample size is 200.
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Figure 4.2: The plot of raw estimates, isotonic estimates, kernel-smoothed isotonic esti-
mates and true FT (t|A = 0) of one simulation sample in CASE I. Sample size is about 100,
m = 20, and bandwidth hm in (4.6) is 0.2.
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Figure 4.3: The plot of raw estimates, isotonic estimates, kernel-smoothed isotonic esti-
mates and true FT (t|A = 1) of one simulation sample in CASE I. Sample size is about 100,
m = 20, and bandwidth hm in (4.6) is 0.2.
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Figure 4.4: The kernel-smoothed isotonic estimate by (4.6) and true FT (t|A), A = 1 versus
A = 0 of one simulation sample in CASE I. Sample size is about 100 for each treatment
group, m = 20, and bandwidth hm in (4.6) is 0.2.
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Table 4.1: Bias, empirical standard error (ESE), mean of bootstrap estimated standard
errors (BSE), and empirical coverage probability (ECP) of the kernel-smoothed isotonic
estimate at time t by (4.6) for CASE I. Sample size is 200 (about 100 for each treatment
group), number of simulation replicates is 500, with m = 20, i.e. bm = 0.125, and hm =
0.2. Note that ECPs are reported based on ln(−ln(F̂T (t|A))), while other quantities are
reported based on F̂T (t|A).
A=0 A=1
t True Value BIAS ESE BSE ECP True Value BIAS ESE BSE ECP
0.5 0.265 -0.007 0.050 0.048 0.93 0.114 -0.002 0.041 0.036 0.90
1.0 0.459 -0.009 0.056 0.057 0.95 0.215 -0.002 0.052 0.049 0.92
1.5 0.603 -0.007 0.059 0.056 0.92 0.305 0.002 0.057 0.055 0.93
2.0 0.708 -0.002 0.053 0.051 0.93 0.384 0.004 0.058 0.059 0.95
2.5 0.785 -0.002 0.049 0.046 0.94 0.454 0.002 0.062 0.059 0.93
3.0 0.842 -0.003 0.042 0.041 0.93 0.517 0.002 0.063 0.059 0.93
3.5 0.884 -0.003 0.038 0.035 0.93 0.572 0.001 0.064 0.058 0.92
4.0 0.915 0.000 0.032 0.030 0.93 0.621 0.002 0.061 0.057 0.92
4.5 0.937 0.003 0.027 0.025 0.93 0.664 0.009 0.060 0.057 0.93
5.0 0.954 0.003 0.025 0.021 0.86 0.702 0.013 0.070 0.063 0.92
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Figure 4.5: Histograms and QQ-plots of z(t)’s based on the transformed estimates,
ln(−ln(F̂T (t|A))), corresponding to Table 4.1 for CASE I.
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Figure 4.6: Histograms and QQ-plots of z(t)’s based on the transformed estimates,
ln(−ln(F̂T (t|A))), where t = 1.0− 4.0, corresponding to Table 4.1 for CASE I.
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The pointwise kernel-smoothed estimates of FT (t|A) at t = 0.5, 1.0, ..., 4.5, 5.0 are sum-
marized in Table 4.2, for the two groups separately. As in Table 4.1, true values, bias,
standard errors are reported in the original form, while coverage probabilities are reported
with a ln(−ln) transformation. Figure 4.11 shows the histograms and QQ-plots of pooled
z(t) values and Figure 4.12 shows the truncated histograms and QQ-plots for t = 1.0−4.0.
Similar to CASE I, it can be concluded that except when t is close to 0 or 5, estimates
have negligible bias and empirical coverage is close to the 95% nominal level.
4.2 IIV Weighted Semi-Parametric Estimation Based
on Additive Hazards Models
In the preceding section, we proposed an IIV weighted non-parametric estimator for FT (t)
of dependently interval-censored failure times due to intermittent and outcome-dependent
inspection times. In the present section, we will introduce the IIV weighted semi-parametric
estimation under additive hazards models (Aalen, 1980, 1989; Lin and Ying, 1994), which
have the form
λT (t|Ai(t−)) = λT,0(t) + β′Ai(t−), i = 1, .., n, (4.12)
where λT,0(t) is an unspecified baseline hazard function, and Ai(t
−) is a vector of time-
varying covariates which are usually assumed to be external covariates (Kalbfleisch and
Prentice, 2002). Semi-parametric analysis of model (4.12) with left-truncated and right-
censored data was studied by Lin and Ying (1994), and Lin et al. (1998) proposed a semi-
parametric estimation method for “case-I” interval-censored data (current status data), i.e.
when there is only one inspection time per subject. The appealing idea of Lin et al. (1998)
is to reduce the problem to ordinary Cox models so that the partial likelihood principle can
123
tY
0.00 0.75 1.50 2.25 3.00 3.75 4.50
0.
00
0.
15
0.
30
0.
45
0.
60
0.
75
0.
90
true FT (t|A=0)
raw estimate Y for A=0
true FT (t|A=1)
raw estimate Y for A=1
(a)
t
Y
0.00 0.75 1.50 2.25 3.00 3.75 4.50
0.
00
0.
15
0.
30
0.
45
0.
60
0.
75
0.
90
true FT (t|A=0)
raw estimate Y for A=0
true FT (t|A=1)
raw estimate Y for A=1
(b)
t
Y
0.00 0.75 1.50 2.25 3.00 3.75 4.50
0.
00
0.
15
0.
30
0.
45
0.
60
0.
75
0.
90
true FT (t|A=0)
raw estimate Y for A=0
true FT (t|A=1)
raw estimate Y for A=1
(c)
Figure 4.7: Plot of the mean of raw estimates Y¯` at s`, ` = 1, ...,m, for m = 10, 20, 50,
in 500 simulations, compared with the true FT (t|A) curves for two treatment groups in
CASE II. (a) is for m = 10, i.e. bm = 0.25, (b) is for m = 20, i.e. bm = 0.125, (c) is for
m = 50, i.e. bm = 0.05. Sample size is 200.
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Figure 4.8: The plot of raw estimates, isotonic estimates, kernel-smoothed isotonic esti-
mates and true FT (t|A = 0) of one simulation sample in CASE II. Sample size is about
100, m = 20, and bandwidth hm in (4.6) is 0.3.
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Figure 4.9: The plot of raw estimates, isotonic estimates, kernel-smoothed isotonic esti-
mates and true FT (t|A = 1) of one simulation sample in CASE II. Sample size is about
100, m = 20, and bandwidth hm in (4.6) is 0.3.
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Figure 4.10: The kernel-smoothed isotonic estimate by (4.6) and true FT (t|A) for A = 0
versus A = 1 of one simulation sample in CASE II. Sample size is about 100 for each
treatment group, m = 20, and bandwidth hm in (4.6) is 0.3.
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Table 4.2: Bias, empirical standard error (ESE), mean of bootstrap estimated standard
errors (BSE), and empirical coverage probability (ECP) of the kernel-smoothed isotonic
estimate at time t by (4.6) for CASE II. Sample size is 200 (about 100 for each group),
number of simulation replicates is 500. Let m = 20, i.e. bm = 0.125, and hm = 0.3. Note
that ECPs are reported based on ln(−ln(F̂T (t|A))), while other quantities are reported
based on F̂T (t|A).
A=0 A=1
time true value BIAS ESE BSE ECP true value BIAS ESE BSE ECP
0.5 0.265 0.004 0.041 0.041 0.94 0.114 0.006 0.034 0.032 0.92
1.0 0.459 -0.010 0.049 0.048 0.94 0.215 0.002 0.043 0.042 0.95
1.5 0.603 -0.009 0.051 0.049 0.93 0.305 0.004 0.047 0.048 0.96
2.0 0.708 -0.005 0.048 0.046 0.93 0.384 0.003 0.051 0.051 0.96
2.5 0.785 -0.003 0.045 0.042 0.94 0.454 0.003 0.055 0.052 0.95
3.0 0.842 -0.003 0.040 0.038 0.93 0.517 0.003 0.055 0.053 0.94
3.5 0.884 -0.003 0.035 0.033 0.93 0.572 0.002 0.055 0.053 0.93
4.0 0.915 0.000 0.030 0.028 0.93 0.621 0.003 0.054 0.052 0.94
4.5 0.937 0.002 0.026 0.024 0.93 0.664 0.007 0.055 0.052 0.93
5.0 0.954 -0.001 0.025 0.021 0.88 0.702 0.003 0.062 0.056 0.91
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Figure 4.11: Histograms and QQ-plots of z(t)’s based on the transformed estimates,
ln(−ln(F̂T (t|A))), corresponding to Table 4.2 for CASE II.
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Figure 4.12: Histograms and QQ-plots of z(t)’s based on the transformed estimates,
ln(−ln(F̂T (t|A))), where t = 1.0− 4.0, corresponding to Table 4.2 for CASE II.
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be applied, with restricting inspection times under proportional hazards models. Later,
Ghosh (2001) and Martinussen and Scheike (2002) followed up their paper by discussing
and improving efficiency. For general interval-censored data, i.e. “case-II”, Zhao and Hsu
(2005) studied the problem via empirical likelihood and Zeng et al. (2006) proposed a
maximum likelihood estimation approach. However, most literature on semi-parametric
analysis for case-II interval-censored data under model (4.12) assumes that inspection
times or monitoring times, e.g. til and tir in (1.3), are independent of failure time Ti given
Ai(t
−). Work on the setting where inspection times are related to failure times is limited.
Recently, Wang et al. (2010) accommodated informative interval censoring by introducing
an unobservable random process to characterize the dependency between inspection times
and failure times, and Zhao et al. (2015) utilized copula models to model the correlation. In
this section, we will generalize the IIV weighted estimating function approach to the case of
semi-parametric estimation based on additive hazards models so that dependently case-II
interval-censored data can be consistently analysed. The procedure that will be introduced
below can be applied to proportional hazards models as well, and we will discuss that at
the end of this section.
4.2.1 An Iterative Two-Stage IIV Weighted Semi-Parametric Es-
timation Procedure
Given model (4.12) and the fact that ST (t) = exp{−ΛT (t)} for continuous failure times Ti
where ΛT (t) =
∫ t
0
λT (s)ds is the cumulative hazard function, the survival function is
ST (t) = ST,0(t) exp
{
−
∫ t
0
β′Ai(s)ds
}
, (4.13)
where ST,0(t) = exp(−ΛT,0(t)) is the baseline survival function. We now proceed in two
stages.
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First, we estimate the baseline survival function ST,0(t) for a given value of the regression
parameter β. Similar to Section 4.1.1, we define a set of finite time points where ST,0(t)
is estimated, i.e. 0 < s1 <, ..., < sm ≤ τ and let θ` = θ`(β) be ST,0(t;β) at s`, ` = 1, ...,m.
Then, given β = β0, an IIV weighted estimating function for θ = (θ1, ..., θm)
′ can be
defined by
U1`(θ(β0)) =
n∑
i=1
mi∑
j=1
Kb(s` − tij)wi(tij) exp
{
−
∫ tij
0
β′0Ai(s)ds
}
×
{
Pi(tij)− θ` exp
[
−
∫ tij
0
β′0Ai(s)ds
]}
, (4.14)
for ` = 1, ...,m, where Kb(u) = K(u/bm)/bm; K(·) is a bounded kernel function; 0 < bm ↓ 0
is a bandwidth sequence; Pi(t) = I(Ti > t) is the response at t; ti1, ..., timi denote the actual
visits in CASE I (failure does not terminate visits) but include the actual visits and pseudo
visits in CASE II (failure terminates visits), and in general we define {ti1, ..., timi} = {t > 0 :
dN∗i (t) = 1}. Following the convention defined before, for CASE I we have {dNi(t) : t > 0}
as a continuous visit process; in CASE II, we consider the visit process as a discrete time
process, i.e. {dNi(ak) : k = 1, ...,M}. After the visit following failure occurrence in CASE
II, i.e. when P¯ obsi (t
−) = 0, we set the IIV weight wi(t) to be 1, provided that assumption
(B1*) is true. Only the actual visits in either CASE I or CASE II are used for estimating
the IIV weights wi(t) = 1/λN(t|Zi(t−)), where λN(t) is the visit intensity at t and Zi(t−)
includes features in the observed history prior to t. We have proposed earlier to estimate
wi(t) by fitting a semi-Markov proportional hazards model for visit gap times, like (2.19).
Solving U1`(θ) = 0 gives a closed form estimate of θ`, i.e. ST,0(s`), as
θ̂` =
∑n
i=1
∑mi
j=1Kb(s` − tij)wi(tij) exp
{
− ∫ tij
0
β′0Ai(s)ds
}
Pi(tij)∑n
i=1
∑mi
j=1Kb(s` − tij)wi(tij) exp
{
−2 ∫ tij
0
β′0Ai(s)ds
} . (4.15)
Note that only visits that happened within window [s` − bm, s` + bm] contribute to the
estimation of θ` and the selection of bandwidth bm depends on the number of visits that
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fall in [s` − bm, s` + bm], as well as concern for the variability and smoothness of final
estimate of ST,0(t).
If we define w+(s`) =
∑n
i=1
∑mi
j=1Kb(s` − tij)wi(tij) exp
{
−2 ∫ tij
0
β′0Ai(s)ds
}
, then
(4.15) can be rewritten as
θ̂` =
∑n
i=1
∑mi
j=1Kb(s` − tij)wi(tij) exp
{
− ∫ tij
0
β′0Ai(s)ds
}
Pi(tij)
w+(s`)
.
To monotonize the raw estimates, θ̂`, based on the constraint θ1 ≥ θ2 ≥ ... ≥ θm, we can
adopt an antitonic (monotonically non-increasing) regression of (θ̂1, ..., θ̂m) with weights
(w+(s1), ..., w+(sm)) to produce non-increasing estimates of ST,0(s`)’s which are denoted
by θ˜`, ` = 1, ...,m. Following that, a kernel-smoothed estimate of baseline survival function
ST,0(t) is defined by
ŜT,0(t;β0) =
∑m
`=1 θ˜`K
∗
(
s`−t
hm
)
∑m
`=1K
∗
(
s`−t
hm
) , for all t > 0, (4.16)
where K∗(·) is a log-concave density and {hm} is a positive bandwidth sequence.
Second, we construct an IIV weighted profile GEE with the estimated baseline survival
ŜT,0(t;β0) plugged in to estimate the regression parameter β, defined by
U2(β|β0) =
n∑
i=1
mi∑
j=1
wi(tij)
∂e(A¯i(tij);β)
∂β
[
Pi(tij)− ŜT,0(tij;β0) e(A¯i(tij);β)
]
e(A¯i(tij);β)
[
1− ŜT,0(tij;β0) e(A¯i(tij);β)
] , (4.17)
where e(A¯i(tij);β) = exp
{
− ∫ tij
0
β′Ai(s)ds
}
and ŜT,0(tij;β0) is obtained from (4.16) given
t = tij. Solving U2(β|β0) = 0 gives an estimate of β with β0 specified as an initial value.
The iterative algorithm for semi-parametric estimation of regression parameters β and
baseline survival function ST,0(t) in model (4.13) can be summarized by the following steps,
starting with l = 0:
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• Step 1: specify an initial value for β, denoted by β̂l, which can be given by a naive
estimate based on model (4.12) with informative censoring not adjusted for.
• Step 2: given β̂l, solve the estimating equation U1`(θ(β̂l)) = 0 from (4.14) and then
monotonize and smooth the raw estimates, θ̂`, ` = 1, ...,m, to obtain an estimate of
the baseline survival function ŜT,0(t; β̂l).
• Step 3: substitute ŜT,0(t; β̂l) in the estimating function U2(β|β̂l) given in (4.17) to
obtain a new estimate of β, denoted by β̂l+1.
• Step 4: use the new estimate of β as the initial value in Step 1 and repeat Step 2
and Step 3 until the estimates converge, i.e. |β̂l+1 − β̂l| .= 0.
As we obtain the estimate of β, then the baseline survival function ST,0(t) can be estimated
by repeating the Step 2 with β̂ plugged in.
4.2.2 Simulation Study
In this subsection, a simulation will be conducted to study the finite sample performance
of the proposed semi-parametric estimator of β based on an additive hazards model (4.12).
The Bootstrap will be utilized to estimate the standard errors of resulting estimates.
As mentioned before, Martinussen and Vansteelandt (2013) have shown the collapsibil-
ity of additive hazards models, and the model we use to generate failure times will be based
on that. Explicitly, the treatment variable of interest, Ai, is assumed to have a BIN(1, p)
distribution with p = 0.5, and an ancillary variable, Li, is generated from Li|Ai ∼ N(0, 1),
so Li and Ai are assumed to be independent. Failure time Ti is generated from an Expo-
nential distribution with a hazard rate given by λT (t|Li, Ai) = β0 + β1Li + β2Ai, where
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β0 = 1, β1 = 0.2, and β2 = −0.4, so that larger Li is associated with higher risk of failure
and treatment lowers the risk. Following the convention of simulations in this thesis, we
define an administrative end of follow-up time as τ = 5 and discretize time with a grid of
100 per unit, i.e. 0 = a0 < a1 <, ..., < aM = τ with a time increment of 0.01 and M = 500.
As a result, almost all untreated subjects have failed by τ and about 85%−90% of treated
subjects have failed by τ . As shown in Martinussen and Vansteelandt (2013), the model
of Ti conditional on Ai alone is still an additive hazards model with hazard function of the
form
λT (t|Ai) = λT,0(t) + β2Ai, (4.18)
where λT,0(t) = β0 + β1
E(e−β1tLiLi)
E(e−β1tLi ) .
Visit times are generated similarly to Section 4.1.2. That is, for the case where failure
does not discontinue the visit process (CASE I), visit indicators dNk+1’s are generated based
on model (4.10) with Lk replaced by L and with the subscript for subjects suppressed. For
the case where failure occurrence terminates visits (CASE II), dNk+1’s are generated based
on model (4.11) with Lk replaced by L and Y¯
obs
k = x replaced by P¯
obs
k = 1 − x, where
x = 0 or 1, since we defined Y (t) = I(T ≤ t) = 1 − P (t). Corresponding parameters in
model (4.10) and model (4.11) are given by γ0 = −4, γ1 = 0.5, and γ2 = −0.2, and as
a result, the average visit gap time is about 0.41 for the group with A = 0 and is about
0.50 for the group with A = 1 in CASE I, and is about 0.46 when A = 0 and about 0.59
when A = 1 in CASE II. The IIV weights wi(t) are estimated by fitting the semi-Markov
proportional hazards visit gap time model (2.19) with Zi(t
−) = (Li, Ai)′ for CASE I and
Zi(t
−) = (Li, Ai, P¯ obsi (t
−))′ for CASE II, which is implemented by R function phreg. Cut-
points for the piecewise-constant baseline hazard are set as (0.42, 0.69, 0.92) for CASE I
and CASE II, by the principle of comparison with the non-parametric estimate of baseline
hazard produced by coxreg. Remember that in CASE II, when P¯ obsi (t
−) = 0 we fix wi(t)
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as 1.
The naive semi-parametric estimate of β2 is provided by the R function aalen in the
package timereg. If it is known that Ti ∈ (til, tir], we consider Ti = (tir + til)/2, i.e. we
use the mid-point to approximate an interval-censored failure time, so failure times are
completely observed or right-censored. Other than the mid-point approximation, informa-
tive inspection times are not adjusted for in the naive estimation, so naive estimates are
expected to have some bias. They are used as initial values for β2 in the proposed iterative
two-stage semi-parametric estimation and will be compared with the estimates yielded by
our proposed approach. The number of time points where raw estimates of ST,0(t) are
computed, i.e. m, is set to be 26, so in estimating function (4.14) bm = 0.1 so that for
example in CASE I, there are about 69 and 47 actual visits included in [s` − bm, s` + bm]
for A = 0 and A = 1, respectively. In addition, we let hm in the non-parametric kernel
regression (4.16) be 0.1. The antitonic regression for monotonizing the raw estimates of
baseline survival probabilities is implemented by monoreg, kernel smoothing is still imple-
mented by npreg, and the estimating function (4.17) is solved by nleqslv. Kernel function
K(·) in (4.15) is selected to be the EP kernel and K∗(·) in (4.16) is the Gaussian (stan-
dard normal) kernel. Sample size is 300 and 200 simulations are conducted for each case.
Standard errors are estimated for a given sample by a non-parametric bootstrap with 100
replicates. Estimates from the proposed approach, compared with the naive estimates, are
summarized in Table 4.3. A convergence is declared for the IIV weighted semi-parametric
estimator of β2 in model (4.18), when |β̂2,l+1− β̂2,l| < 10−3 where β̂2,l denotes the estimate
of β2 from the lth iteration. Empirical coverage probabilities (ECPs) are computed based
on the 95% empirical confidence intervals constructed by β̂2 ± 1.96 se(β̂2), where se is the
bootstrap estimated standard error. From Table 4.3, it can be seen that for either CASE,
the bias of the IIV weighted estimates is negligible and empirical coverage probabilities are
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close to the nominal level, even though sample size is only 300. On the other hand, the
coverage probabilities of naive estimates are much lower because of large bias.
Table 4.3: Bias, mean of bootstrap estimated standard errors (BSE), empirical standard
error (ESE), mean squared error (MSE) and empirical coverage probability (ECP) of the
proposed estimates and naive estimates for β2 in model (4.18) for two cases: CASE I and
CASE II. True value of β2 is -0.4. Sample size is 300. Number of simulation replicates is
200. Bootstrap sample size is 100.
CASE I
BIAS BSE ESE MSE ECP
naive 0.096 0.087 0.088 0.017 0.79
IIV 0.005 0.123 0.117 0.014 0.94
CASE II
BIAS BSE ESE MSE ECP
naive 0.095 0.087 0.088 0.017 0.79
IIV 0.001 0.122 0.120 0.014 0.94
4.2.3 Discussion on the Extension to the Cox Proportional Haz-
ards Models
For the Cox proportional hazards models, which have a form of
ΛT (t|Ai) = ΛT,0(t) exp(β′Ai), (4.19)
or written as
ST (t|Ai) = ST,0(t)exp(β′Ai). (4.20)
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Huang (1996) proposed a two-step maximum profile likelihood function procedure to esti-
mate (ΛT,0,β) based on model (4.19) for independently case-I interval-censored data, i.e.
current status data. Our proposed iterative two-stage weighted profile GEE approach also
can be applied to the Cox models.
Explicitly, the mean of Pi(tij) in (4.14) and (4.17) should be changed to be ST,0(tij)
exp(β′Ai).
With this form, equation solving might be more difficult. For example, for a fixed β0, the
estimating function (4.14) for baseline survival function θ` = ST,0(s`) can be modified here
as
U∗1`(θ(β0)) =
n∑
i=1
mi∑
j=1
Kb(s` − tij)wi(tij)exp(β′0Ai)
{
Pi(tij)− θexp(β
′
0Ai)
`
}
θ`
[
1− θexp(β′0Ai)`
] , ` = 1, ...,m.
(4.21)
Unlike (4.14), which leads to a closed form estimate of θ`, θ̂` here has to be solved nu-
merically from U∗1`(θ) = 0. A similar change is made to the second estimating function
(4.17) to accommodate a proportional hazards model. Alternatively, piecewise-constant
baseline hazard can be assumed to make the additive hazards model (4.12) or the propor-
tional hazards model (4.19) be “flexibly” parametric, e.g. the piecewise-constant baseline
proportional hazards model (2.5), and then the methodologies introduced in Chapter 2 can
be applied.
So far, we have introduced parametric, non-parametric and semi-parametric estimation
of failure time distributions based on estimating functions weighted by a so-called inverse-
intensity-of-visit (IIV) weight to adjust for the intermittent and informative inspection
times which cause failure times dependently interval-censored. In addition, we also con-
sidered confounded treatments in observational studies in Chapter 3 and introduced an
inverse-probability-of-treatment (IPT) weighting method which is helpful to adjust for
measured confounders. In the next chapter, we will apply these methodologies to the PsA
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Toronto cohort to study treatment with biologics and joint damage as an illustration.
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Chapter 5
APPLICATIONS TO PSA COHORT
In Chapter 2 and Chapter 4, we introduced an inverse-intensity-of-visit (IIV) weighted
estimating function approach to estimate marginal association measure(s) for interval-
censored failure time outcomes. When the visit process is intermittent and informative,
interval censoring may not be independent of failure times. From the simulation studies
shown in the preceding chapters, we have seen that the proposed IIV weighting method
adjusts for outcome-dependent inspection times and eliminates the resulting selection bias.
In this chapter, we will apply this method to the PsA Toronto Cohort Study as an illus-
tration. We saw in Section 1.4.3 that visit times for individuals in this cohort were related
to prior disease status and other factors.
Biologics are presently widely used to reduce signs and symptoms of active arthritis and
to slow the progression of joint destruction in patients with PsA, especially in patients who
have had an inadequate response to one or more DMARDs such as Methotrexate (MTX).
One interesting question is to evaluate the effect of biologics on inhibiting the progression
of joint damage. That is, assess the association between treatment with biologics and time
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to an increase in the number of damaged joints after enrolment. Biologics are recently used
for treating rheumatoid arthritis, and a variety of biological agents have been developed
and licensed during the past few decades. It is noted that patients could be treated
with distinct biological agents at different chronological times. Therefore, our analysis
set is selected by a 1:1 matching of patients in terms of their status of using biologics
by calendar day. Although it is more reasonable to look at one particular drug to assess
a treatment effect, a limited number of one specific drug users makes it hardly feasible.
Thus, we hope that the matching could roughly adjust for the drug variety into account
in the analysis. Explicitly, we first take a patient who began an initial course of biologics
treatment on some calendar day after clinic enrolment and then randomly choose another
patient who had never taken biologics as of the same calendar day. As a result, 414
(207 treated and 207 untreated) patients are included in this analysis set. The calendar
years when the 207 treated patients received biologics and the 207 untreated patients
were randomly selected for matching range from 1981 to 2012 with a median of 2006 (1st
quartile = 2002, 3rd quartile = 2009). A histogram of the frequency of calendar years when
treated and untreated individuals were matched is displayed in Figure 5.1. Most patients
(approximately 85%) were matched between 2000 and 2010. In the present chapter, we
define ti0 as the time when subject i was matched. Let Ai = 1, or 0, be the indicator of
initial biologics status at ti0. Patients’ treatment status may change later, e.g. biologics
may be terminated, paused or switched for inefficacy, adverse effects or other reasons. Here,
we consider two studies: one is to investigate the treatment intention with biologics and
the other is to evaluate the treatment effect of biologics. For the former, since treatment
intention is of interest, patients’ treatment status is allowed to vary after matching. For
the latter, the change of treatment status is considered as a competing risk of the joint
damage event, and estimation of cumulative incidence functions (CIFs) will be the goal.
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We define a failure time outcome, Ti, as the time to an increase in the number of damaged
joints from ti0. Patients are followed up to the last visit prior to the administrative end of
follow-up which is Nov. 2013, and there are no random drop-outs in this case. However,
we consider patients who do not visit for longer than 3 years as lost to follow-up, since the
protocol suggests that patients should be assessed about every six to 12 months. That is,
we artificially censor visit gap times longer than 3 years. In addition, since joint damage
is inspected only at clinic visits and visits are intermittent, failure times Ti are subject to
interval censoring, or right censoring at the last visit. In this study, data is recorded in
days, and the occurrence of failure does not prohibit visits, so this is an example of CASE
I defined in preceding simulations. Since visit gap times are relatively shorter than joint
damage event times Ti, in this chapter, analyses of visit gap times are reported in days,
while analyses of Ti are reported in years. Additionally, the kernel functionK(·) in (4.3) and
(4.15) is selected to be the Epanechnikov (EP) kernel, i.e. K(u) = 3
4
(1−u2)I(|u| ≤ 1), and
the K∗(·) in (4.6) and (4.16) is selected to be the Gaussian kernel, i.e. K∗(u) = 1√
2pi
e−u
2/2
all through this chapter. The convergence tolerance of the regression parameter estimates
in the iterative two-stage semi-parametric estimation procedure is set as < 10−6.
5.1 Association between Joint Damage and Intended
Biologics Treatment
In this study, A represents intended biologics treatment, and we will study its association
with the time T to an increase in the number of damaged joints. Among the 207 treated
patients, 105 have interval-censored failure times and 102 have right-censored failure times.
For the 207 untreated patients, 84 failure times are interval-censored and 123 failure times
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Figure 5.1: Histogram of frequency of the calendar year of matching time, ti0, for the 207
treated patients.
143
are right-censored. On average, treated patients have 9 visits and untreated patients have
7 visits. The gap times between consecutive visits for the treated group have an average of
7.2 months, a median of 6.3 months and a standard error of 3.3 months. For the untreated
group, the average is 7.4 months, the median is 6.3 months, while the standard error is
4.0 months. Although visits are planned to be every 6 – 12 months in this cohort, and
the median of visit gap times is about 6 months in each treatment group, considerable
variability of the frequency and timing of visits is seen. It was mentioned earlier that visit
gap times longer than 3 years are artificially censored so as to avoid extremely large values
of IIV weights. As a result, 38 individuals have visit gap times artificially censored, and
115 visits are deleted in total.
5.1.1 Analysis of Visit Times and Estimation of IIV Weights
To investigate the visit process and to estimate IIV weights, a semi-Markov proportional
hazards model with a piecewise constant baseline, like (2.25), is used to analyse visit gap
times. Models of visit times are fitted in days. The range of calendar dates of visits in
this analysis set is from 1980-01-11 to 2013-03-25. To satisfy the proportional hazards as-
sumption, visit gap times are analysed within subgroups which are defined by the calendar
decade of the previous visit. They are [1980, 2000), [2000, 2010) and [2010, 2013]. For the
lth subgroup, where l = 1, 2, or 3, the model for the intensity of visit gap times has the
form
λN(t|Zi(t−);θl) = λ†N0(B(t);pil) exp(α′lZi(t−)), (5.1)
where λ†N0[B(t);pil] =
∑K
k=1 pil,kIl,k(t), pil = (pil,1, ..., pil,K)
′, Il,k(t) = I{B(t) ∈ (al,k−1, al,k]},
B(t) is the elapsed time or gap time from the previous visit and I is an indicator function
which equals 1 if true and 0 otherwise; pil,k, k = 1, ..., K, are the piecewise constant baseline
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hazards for the lth subgroup, and al,k, k = 1, ..., K, are the corresponding cut-points which
are selected by the comparison with a non-parametric estimate of baseline hazard; and
θl = (pi
′
l,α
′
l)
′. Covariates Zi(t−) may include the interaction of functions of the visit gap
time B(t) and some regressors which have time-varying coefficients, e.g. ESR measures
and the median length of past visit gap times. Proportional hazards assumptions have
been tested by R function cox.zph for a semi-parametric version of model (5.1), which are
accepted for all subgroups. Thus, R function phreg is used for fitting the piecewise constant
hazard semi-Markov model (5.1) with the baseline hazard estimated parametrically. All
regression summaries are given in Tables 5.1-5.3. The attributes of all regressors used in
Tables 5.1-5.3 are listed in Table A.1 in Appendix A.1 at the end of the thesis.
From Table 5.1 for visit times before 2000, we see that there is evidence that visit
intensities are significantly associated with ESR, sex, age, joint damage, at significance
level of α = 0.05. From Tables 5.2 for visit times between 2000 and 2010, factors significant
at α = 0.05 are family history of PsA, NSAIDs, DMARDs, biologics, ESR and the history
of past visits. In Table 5.3, since there are limited visits between 2010 and 2013, there is
not much evidence of significant associations between visit intensities and these risk factors
except for DMARDs and the history of past visits. In addition, we can see that the effects
of ESR and past visit history on the present visit intensities may vary over the period of
gap time B(t). The IIV weights used below are estimated by formula (2.20) defined earlier
with all the covariates that are considered in model fits based on (5.1) which are shown in
Tables 5.1-5.3. The estimated IIV weights ŵi(t) at actual visit times tij’s across subjects
have a minimum of 10.48, a median of 62.50, and a maximum of 8816.
From these analyses we can see that visit times are correlated with time-fixed as well
as time-varying disease-related variables and also associated with past visit history, which
might account for some unknown risk factors of visit intensities.
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Table 5.1: Summary for the 1st subgroup (< 2000) of visit gap times by model (5.1) for
the study of biologics intention. Time is in days. Cut-points selected for this subgroup
are 150, 240, 383, 414, 692. Except for treatment (i.e. ns, dm, bg) time-varying covariates
change only at visits. Variable med.gap denotes the median length of past visit gap times.
coef exp(coef) se(coef) z Pr(> |z|)
ESR -0.0163 0.9838 0.0052 -3.1381 0.0017
sex -0.4012 0.6695 0.2016 -1.9902 0.0466
age -0.0210 0.9793 0.0095 -2.2063 0.0274
PS duration 0.0061 1.0062 0.0082 0.7501 0.4532
PsA duration 0.0011 1.0011 0.0127 0.0887 0.9294
family history of PS 0.0264 1.0267 0.2249 0.1172 0.9067
family history of PsA -0.0197 0.9805 0.4146 -0.0475 0.9621
number of active joints 0.0049 1.0049 0.0094 0.5188 0.6039
number of damaged joints 0.0414 1.0423 0.0130 3.1827 0.0015
NSAIDs 0.3177 1.3739 0.1644 1.9324 0.0533
DMARDs 0.2320 1.2611 0.2288 1.0142 0.3105
biologics 0.0845 1.0882 0.2783 0.3036 0.7615
med.gap 0.0012 1.0012 0.0008 1.4919 0.1357
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Table 5.2: Summary for the 2nd subgroup (2000− 2010) of visit gap times by model (5.1)
for the study of biologics intention. Time is in days. Cut-points selected for this subgroup
are 170, 247, 375, 450, 1030. Variable med.gap denotes the median length of past visit gap
times.
coef exp(coef) se(coef) z Pr(> |z|)
sex 0.0774 1.0805 0.0477 1.6229 0.1046
age 0.0031 1.0031 0.0022 1.4419 0.1493
PS duration 0.0043 1.0043 0.0023 1.8874 0.0591
PsA duration -0.0008 0.9992 0.0029 -0.2864 0.7746
family history of PS -0.0288 0.9716 0.0451 -0.6397 0.5224
family history of PsA -0.2147 0.8068 0.0772 -2.7820 0.0054
number of active joints -0.0027 0.9973 0.0026 -1.0528 0.2924
number of damaged joints 0.0017 1.0017 0.0018 0.8978 0.3693
NSAIDs 0.0902 1.0944 0.0453 1.9919 0.0464
DMARDs 0.1299 1.1388 0.0454 2.8616 0.0042
biologics 0.1377 1.1477 0.0473 2.9130 0.0036
ESR:I(B(t) ≤ 180) 0.0052 1.0052 0.0020 2.5587 0.0105
ESR:I(B(t) > 180) -0.0088 0.9912 0.0020 -4.3467 0.0000
ESR:I(B(t) > 365) -0.0026 0.9974 0.0052 -0.5051 0.6135
med.gap:I(B(t) ≤ 180) -0.0068 0.9932 0.0004 -16.2028 0.0000
med.gap:I(B(t) > 180) -0.0009 0.9991 0.0003 -2.8924 0.0038
med.gap:I(B(t) > 365) 0.0005 1.0005 0.0005 0.9889 0.3227
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Table 5.3: Summary for the 3rd subgroup (≥ 2010) of visit gap times by model (5.1) for
the study of biologics intention. Time is in days. Cut-points selected for this subgroup
are 172, 196, 265, 307, 364. Variable med.gap denotes the median length of past visit gap
times.
coef exp(coef) se(coef) z Pr(> |z|)
ESR -0.0019 0.9981 0.0026 -0.7242 0.4689
sex -0.0204 0.9798 0.0704 -0.2894 0.7723
age 0.0019 1.0019 0.0033 0.5741 0.5659
PS duration 0.0010 1.0010 0.0033 0.3038 0.7613
PsA duration -0.0015 0.9985 0.0043 -0.3440 0.7308
family history of PS -0.0193 0.9809 0.0679 -0.2840 0.7764
family history of PsA -0.0193 0.9809 0.1127 -0.1712 0.8641
number of active joints 0.0008 1.0008 0.0049 0.1606 0.8724
number of damaged joints 0.0007 1.0007 0.0027 0.2376 0.8122
NSAIDs -0.0386 0.9622 0.0650 -0.5936 0.5528
DMARDs 0.1807 1.1980 0.0677 2.6672 0.0076
biologics 0.1109 1.1173 0.0701 1.5826 0.1135
med.gap:I(B(t) ≤ 180) -0.0068 0.9932 0.0008 -8.4731 0.0000
med.gap:I(B(t) > 180) -0.0016 0.9984 0.0005 -2.9983 0.0027
med.gap:I(B(t) > 365) -0.0007 0.9993 0.0016 -0.4552 0.6489
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5.1.2 Estimation of the Failure Time Distribution
In this section, we will apply the IIV weighting approach to non-parametric, parametric,
and semi-parametric estimation of distributions of failure time Ti (time to an increase in
the number of damaged joints) to deal with the intermittent and informative clinic visit
times. Note that all plots and regression parameters of failure time distributions will be
presented with time in years and that there is no censoring upon a change of biologics
status.
First, the non-parametric estimation of survival function or CDF of failure time Ti
which was introduced in Section 4.1.1 will be illustrated for each of the two treatment
groups. The bandwidths bm and hm in (4.1) and (4.6), respectively, are both selected to
be 365 (days). Then, for the treated group, about 138 visits, and for the untreated group,
about 145 visits, are contained in [s`− bm, s` + bm] on average, and contribute to the crude
or raw estimates of ST (s`|A) = Pr(Ti > s`|A) by (4.1), where A = 0 or 1. For each group,
the crude estimates are monotonized by an isotonic regression, and then are smoothed by
a non-parametric kernel regression by (4.6). The final estimate of the survival function of
T , i.e. ST (t|A), A = 0 or A = 1, is shown in Figure 5.2. The grey solid and dashed curves
are the pointwise empirical confidence intervals (ECIs) for the two survival curves, which
are given by ŜT (t|A)± 1.96 se(ŜT (t|A)), where se denotes a bootstrap estimated standard
error. Bootstrap sample size is set to be 100 in this analysis. Turnbull (1976)’s estimator is
utilized as a naive estimation method which does not adjust for the dependent inspection
or visit times for comparison with the proposed weighted approach. In Figure 5.2, it can be
seen that the Turnbull’s estimate of the survival curve, ST (t|A = 0), basically agrees with
the IIV weighted non-parametric estimate. However, Turnbull’s estimator overestimates
the survival probabilities of the treated group (A = 1). Additionally, there is some evidence
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that the weighted estimates of ST (t|A), A = 0 and A = 1, are significantly different, since
the corresponding ECIs hardly overlap. This suggests that patients who were intended to
be treated with biologics are at a higher risk of an increase in the number of damaged joints.
This is explainable because more severely sick patients will be prescribed biologics and these
patients are usually at higher risk of joint damage. Since the initial biologics assignments
are not randomized, later in this section we will apply the IPT weighting method which
was introduced in Section 3.1.2 to adjust for the bias caused by potential confounding
variables. However, the present analysis does not address the efficacy of treatment with
biologics since some patients who did not receive biologics at ti0 later switched to be on it
during follow-up. The analysis here is directed at whether there is an association between
the intended treatment with biologics at ti0 and joint damage.
Next, we will apply the parametric estimation introduced in Section 2.2 to this example.
A piecewise-constant proportional hazards model given treatment A is assumed for failure
times Ti, i.e.
λT (t|Ai) =
S∑
s=1
ρsIs(t) exp (βAi) , i = 1, ..., n, (5.2)
where Is(t) = I{t ∈ (as−1, as]}, s = 1, ..., 4, cut-points are a0 = 0 < a1 = 0.2 < a2 = 1.5 <
a3 = 6 < a4 = +∞, and ρs’s are unknown non-negative constants. The survival function
of Ti is then given by
ST (t|Ai) = exp{−
S∑
s=1
ρsvs(t) exp (βAi)}, i = 1, ..., n, (5.3)
where vs(t) =
∫ t
0
Is(u)du, s = 1, ..., 4. Figure 5.3 displays the non-parametric IIV weighted
estimates of the baseline distribution of failure times, i.e. A = 0. The left plot shows the
baseline cumulative hazard function, ΛT (t|A = 0), and the right plot shows the baseline
CDF, FT (t|A = 0). We can see that a piecewise exponential distribution can be applicable
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Figure 5.2: Non-parametric IIV weighted estimates of ST (t|A) where A = 0, or 1, where
A denotes biologics intention. The number of patients who were followed up to 1, 3, 5, 7
years respectively are 181, 131, 77, 42 for A = 0, and are 183, 140, 102, 63 for A = 1.
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Figure 5.3: Non-parametric IIV weighted estimates of baseline cumulative hazard,
ΛT (t|A = 0), and baseline CDF, FT (t|A = 0), where A denotes biologics intention.
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Figure 5.4: Plot of Turnbull estimates, non-parametric (denoted by non-par), parametric
and semi-parametric (denoted by semi-par) IIV weighted estimates of ST (t|A), where A =
0, or 1, A denotes biologics intention. The number of patients who were followed up to
1, 3, 5, 7 years respectively are 181, 131, 77, 42 for A = 0, and are 183, 140, 102, 63 for
A = 1.
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to this example, and later we will compare the parametric estimated distributions based
on model (5.2) with the non-parametric estimates we have obtained above.
A consistent estimate of β from (5.2) can be obtained by solving the weighted esti-
mating function given in (2.13) where IIV weights are estimated as in the non-parametric
estimation. Given the many parameters in the visit time model (5.1), it is computation-
ally intensive to compute the asymptotic variance by the large sample theory introduced
in Section 2.2.5, so the bootstrap is employed instead to estimate the standard errors of
estimates. As a result, the estimates of ρ1, ρ2, ρ3, ρ4 and β solved by the R function
nleqslv are: 1.033 (0.327), 0.061 (0.056), 0.111 (0.028), 0.079 (0.052), 0.607 (0.212), where
the values in brackets are the bootstrap estimated standard errors. The estimated survival
functions, ST (t|A), are displayed in Figure 5.4, denoted by a blue solid curve and a blue
dashed curve for the treated group (A = 1) and untreated group (A = 0), respectively.
We can see that the IIV weighted parametric estimates agree well with the IIV weighted
non-parametric estimates which are denoted by black solid and dashed curves, though for
A = 0 and when t > 5 years the parametric estimate is apart from the non-parametric
estimate since the fully parametric model (5.2) shapes the estimated curve. The estimat-
ed hazard ratio eβ̂ indicates that patients initially treated with biologics have about 1.83
times the risk of failure of the untreated patients. Also, there is some evidence that two
treatment groups have different risk of joint damage: the 95% empirical confidence interval
for β computed by β̂ ± 1.96 se(β̂) is (0.192, 1.022), which indicates that the difference is
significant at α = 0.05.
Next, we will illustrate the IIV weighted semi-parametric estimation based on an ad-
ditive hazards model which has a form of
λT (t|Ai) = λT,0(t) + γAi, i = 1, .., n, (5.4)
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where λT,0(t) is an unspecified non-negative function of t. The IIV weights are again esti-
mated as in the non-parametric estimation and parametric estimation. Then, the iterative
algorithm introduced in Section 4.2.1 is implemented with the naive estimate of γ given
by R function aalen in the package timereg as an initial value. As a result, the estimate
γ̂ in model (5.4) equals 0.152 with a standard error estimated by bootstrap of 0.043, and
the corresponding 95% empirical confidence interval equals (0.067, 0.237). Therefore, at a
significance level of 0.05, statistical evidence indicates that the two treatment groups have
a different risk of joint damage. Specifically, the intended to be treated patients are found
to be at a higher risk of an increase in the number of damaged joints. The average number
of iterations is about 9, so the algorithm converges well and is not very computationally
intensive in this case. The baseline hazard λT,0(t) can be estimated by solving estimating
function (4.14) and then monotonizing and smoothing the resulting raw estimates. Finally,
the estimated survival curves are also shown in Figure 5.4 by a green solid curve and a
green dotted curve for A = 1 and A = 0, respectively. Additionally, in Figure 5.4, we can
see that for each group, when the IIV weighting method is applied, non-parametric esti-
mates, piecewise exponential parametric estimates, and additive hazards semi-parametric
estimates agree well with each other, which justifies the selection of model (5.2) and model
(5.4) for failure times.
So far, we have demonstrated the IIV weighted estimation for the adjustment of inter-
mittent clinic visits. Nevertheless, it is known that biologics are usually assigned for adult
patients with moderate to severe joint activity. Some biologics such as Adalimumab can
be used alone or are recommended to be used in combination with Methotrexate (MTX)
or other DMARDs. Therefore, joint activity, disease duration, age and other concurrent
treatments could be potential confounders of the association between the initial intention to
treat with biologics and the joint damage event. To eliminate the bias caused by observed
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confounding variables in this observational study, we can employ the inverse-probability-
of-treatment (IPT) weighting method which was introduced in Section 3.1.2 for parametric
estimation. A logistic regression model is fitted for treatment intention, A, at ti0, to esti-
mate the IPT weights (3.6). The model fitting summary is presented in Table 5.4 where
we see that ESR, age, joint activity and NSAIDs are found to be significantly associated
with biologics assignment at α = 0.05. Although subjects for the analyses here were chosen
according to their treatment status (A = 0 or 1), this model, when applied to a randomly
selected person in the study group, will adjust for differences in risk factors across the two
treatment subgroups. For parametric model (5.2), a double weight (3.7) will replace the
IIV weight wi(t|α) in the estimating function (2.13), and the doubly weighted parametric
estimates of survival curves are shown in Figure 5.5 and are denoted by red solid and red
dashed curves. The estimates of ρ1, ρ2, ρ3, ρ4 and β are 0.821 (0.321), 0.102 (0.066), 0.104
(0.048), 0.128 (0.062), and 0.580 (0.260). Similarly, for additive hazards model (5.4), a
double weight (3.7) replaces the IIV weight in the estimating function (4.14) and (4.17)
and the resulting estimates are displayed in Figure 5.6. The estimate of γ in model (5.4)
is 0.155 with a bootstrap estimated standard error of 0.046. The 95% empirical confidence
interval for β in model (5.2) is (0.071, 1.089) and that for γ in model (5.4) is (0.064, 0.246).
Additionally, in Figure 5.5 or Figure 5.6, it is seen that the doubly weighted estimates and
the IIV weighted estimates are very close. That is, the confounders which we considered
in the analysis of Table 5.4 barely bias the estimates, which makes sense in this case, since
patients can change treatment status later but stay in the same group, which was defined
at ti0, for estimation. However, unmeasured confounders may exist, so the analysis results
still could have hidden bias.
We conclude that the patients who were intended to be treated with biologics are at a
relatively higher risk of an increase in the number of damaged joints than those who were
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not intended to be treated. Furthermore, we note again that because some individuals
in the untreated group actually switched to treatment later, we cannot make conclusions
about the efficacy of biologics treatment from this analysis.
Table 5.4: Logistic regression model fitting summary for A at ti0 where A denotes the
intention of biologics.
coef se(coef) z Pr(> |z|)
(Intercept) -1.6699 0.3830 -4.3600 1.30E-05 ***
ESR 0.0159 0.0070 2.2770 0.0228 *
year of enrolment 0.0394 0.0237 1.6580 0.0973 .
year of the visit before ti0 0.0223 0.0314 0.7100 0.478
sex 0.3383 0.2549 1.3270 0.1845
age -0.0483 0.0114 -4.2300 2.34E-05 ***
PS duration -0.0007 0.0124 -0.0580 0.9536
PsA duration 0.0019 0.0195 0.0950 0.9242
family history of PS 0.1907 0.2487 0.7670 0.4431
family history of PsA -0.0333 0.3930 -0.0850 0.9324
number of active joints 0.1261 0.0174 7.2580 3.93E-13 ***
number of damaged joints 0.0212 0.0123 1.7230 0.0849 .
NSAIDs 0.7318 0.2661 2.7500 0.006 **
DMARDs 0.1722 0.2544 0.6770 0.4984
—
Signif. codes: *** 0.001 ** 0.01 * 0.05 . 0.1
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Figure 5.5: Plot of Turnbull, IIV weighted and IIV + IPT doubly weighted parametric
estimates of ST (t|A) based on model (5.3) for the study of biologics intention, where A = 0,
or 1. The number of patients who were followed up to 1, 3, 5, 7 years respectively are 181,
131, 77, 42 for A = 0, and are 183, 140, 102, 63 for A = 1.
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Figure 5.6: Plot of Turnbull, IIV weighted and IIV + IPT doubly weighted semi-parametric
estimates of ST (t|A) based on model (5.4) for the study of biologics intention, where A = 0,
or 1. The number of patients who were followed up to 1, 3, 5, 7 years respectively are 181,
131, 77, 42 for A = 0, and are 183, 140, 102, 63 for A = 1.
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5.2 Association between Joint Damage and Biologics
Treatment: Competing Risks Analysis
In this section, we want to study the efficacy of biologics treatment on time to an increase
in the number of damaged joints. The analysis set includes the 177 patients who initially
started using biologics after 2000 and the 177 untreated patients who were matched with
the treated ones by calendar day. Comparing this analysis set with that used in Section
5.1, we exclude 60 patients who received biologics or were matched prior to 2000, since
biologics, which are widely used recently, were mostly licensed around or after 2000. The
range of visit dates in this analysis set is from 2000-01-17 to 2013-03-25. Among the 177
treated patients, 8.3 clinic visits were attended on average. For the 177 untreated patients,
the average number of visits is 7.4. The estimation of IIV weights is conducted for two
subgroups of visit gap times: [2000, 2010) and [2010, 2013], and the corresponding model
fitting summaries based on model (5.1) are provided in Tables 5.5-5.6. We see that visit
intensities are significantly associated with family history of PsA, treatment with DMARDs
and biologics, ESR, and the history of past visits. The estimated IIV weights ŵi(t) at visit
times tij’s across subjects have a minimum of 11.22, a median of 61.54, and a maximum
of 8373. In this analysis, 14 individuals have long visit gap times artificially censored at 3
years, and 17 visits are deleted in total.
To study the time to joint damage increase under treatment with biologics, i.e. Ai, we
consider the joint damage event and time-to-treatment switch as a pair of competing risks
(CRs). Let Ti1 be the time to joint damage increase under the initial treatment fixed at ti0
and let Ti2 be the time to a treatment switch. Treatment history is recalled retrospectively
at clinic visits and the exact start date and stop date of the usage of a specific drug are
ascertained, so Ti2 can be observed exactly, whereas Ti1 is interval-censored. Since Ti1
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Table 5.5: Model fit summary for the 1st subgroup of visit gap times, i.e. the previous
visit lies in [2000, 2010), based on model (5.1) in the competing risks analysis. Model is
fitted in days. Cut-points selected for this subgroup are 170, 247, 375, 450, 1030. Except
treatment (i.e. ns, dm, bg) other time-varying covariates change only at visits. Variable
med.gap denotes the median length of past visit gap times.
coef exp(coef) se(coef) z Pr(> |z|)
sex 0.0555 1.0570 0.0512 1.0832 0.2787
age 0.0042 1.0042 0.0023 1.8184 0.0690
PS duration 0.0034 1.0034 0.0025 1.3937 0.1634
PsA duration 0.0004 1.0004 0.0034 0.1190 0.9053
family history of PS -0.0149 0.9852 0.0482 -0.3093 0.7571
family history of PsA -0.2433 0.7841 0.0820 -2.9673 0.0030
number of active joints -0.0050 0.9950 0.0028 -1.7866 0.0740
number of damaged joints -0.0008 0.9992 0.0020 -0.3969 0.6914
NSAIDs 0.0440 1.0450 0.0487 0.9053 0.3653
DMARDs 0.1038 1.1094 0.0487 2.1295 0.0332
biologics 0.1769 1.1935 0.0509 3.4721 0.0005
ESR:I(B(t) ≤ 180) 0.0062 1.0063 0.0023 2.7659 0.0057
ESR:I(B(t) > 180) -0.0114 0.9887 0.0024 -4.8263 0.0000
ESR:I(B(t) > 365) -0.0044 0.9956 0.0066 -0.6661 0.5053
med.gap:I(B(t) ≤ 180) -0.0069 0.9932 0.0004 -15.4485 0.0000
med.gap:I(B(t) > 180) -0.0007 0.9993 0.0003 -2.0712 0.0383
med.gap:I(B(t) > 365) 0.0009 1.0009 0.0005 1.7930 0.0730
161
Table 5.6: Model fit summary for the 2nd subgroup of visit gap times, i.e. the previous
visit lies in [2010, 2013], based on model (5.1) in the competing risks analysis. Model is
fitted in days. Cut-points selected for this subgroup are 172, 196, 265, 307, 364. Except
treatment (i.e. ns, dm, bg) other time-varying covariates change only at visits. Variable
med.gap denotes the median length of past visit gap times.
coef exp(coef) se(coef) z Pr(> |z|)
ESR -0.0019 0.9981 0.0026 -0.7393 0.4597
sex -0.0232 0.9771 0.0725 -0.3199 0.7490
age 0.0030 1.0030 0.0033 0.8963 0.3701
PS duration 0.0003 1.0003 0.0034 0.0768 0.9388
PsA duration -0.0012 0.9988 0.0044 -0.2718 0.7858
family history of PS 0.0202 1.0204 0.0697 0.2898 0.7720
family history of PsA -0.0219 0.9784 0.1159 -0.1887 0.8503
number of active joints 0.0002 1.0002 0.0050 0.0356 0.9716
number of damaged joints 0.0006 1.0006 0.0029 0.1918 0.8479
NSAIDs -0.0491 0.9521 0.0673 -0.7304 0.4652
DMARDs 0.1641 1.1784 0.0701 2.3396 0.0193
biologics 0.1173 1.1244 0.0719 1.6308 0.1029
med.gap:I(B(t) ≤ 180) -0.0068 0.9933 0.0008 -8.3028 0.0000
med.gap:I(B(t) > 180) -0.0015 0.9985 0.0005 -2.7119 0.0067
med.gap:I(B(t) > 365) -0.0008 0.9992 0.0017 -0.4944 0.6211
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and Ti2 are not independent given the observed history up to the most recent past visit,
considering treatment switch as the censoring of Ti1 and applying the inverse-probability-
of-censoring weighting (IPCW) is not helpful. Following the convention of CR studies,
we define the observed failure time as Ti = min(Ti1, Ti2, Ci), where we know there is no
random drop-out in this example, so Ci = τi. We let εi be the cause of failure, where
εi = 1 if Ti = Ti1, εi = 2 if Ti = Ti2, and εi = 0 otherwise. First, the additive hazards
model (4.12) is assumed for the subdistribution hazard of cause 1, i.e. λ1(t|Ai), which was
defined by Fine and Gray (1999). One can consider λ1(t|Ai) as the hazard function of the
improper failure time variable Ti1 = I(εi = 1)Ti + I(εi 6= 1)∞. Then, we still have the
survival function model (4.13) which can be written as
S1(t|Ai) = S1,0(t) exp {−γAit} , (5.5)
where S1(t|Ai) = 1 − F1(t|Ai) and F1(t|Ai) = Pr(Ti1 ≤ t|Ai) = Pr(Ti ≤ t, εi = 1|Ai) is
referred to as the cumulative incidence function (CIF) for failure from cause 1 (i.e. joint
damage increase) given biologics status Ai, and S1,0(t) = 1−F1(t|Ai = 0) is unspecified. In
this section, we will investigate the effect of biologics on time to an increase in the number
of damaged joints via the estimation of F1(t|Ai) non-parametrically or semi-parametrically.
The responses in (4.1) for non-parametric estimation are defined as Yi(t) = I(Ti ≤
t, ε = 1), so the corresponding means are θ` = F1(`), for ` = 1, ...,m. For semi-parametric
estimation, the responses in (4.14) and (4.17) are defined as Pi(t) = 1− Yi(t) with means
E{Pi(t)|Ai} = S1(t|Ai) = 1 − F1(t|Ai) that are modelled by (5.5). The bandwidths, bm
and hm, in the non-parametric estimation and the semi-parametric estimation are selected
to be 180 days, so that for either group m equals 12 and there are 100− 120 visits lying in
[s` − bm, s` + bm].
We know that treatment is non-randomized at ti0, so to study the efficacy of biologics
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on a joint damage event, we apply the IPT weights estimated by (3.6) via fitting a logistic
regression like (3.4). The model fitting summary is presented in Table 5.7 where we see
treatment assignment is significantly associated with joint activity, age, ESR, and concur-
rent treatment with NSAIDs at α = 0.05. To adjust for these confounders, we substitute
the IIV weight wi(t) in estimating functions (4.1), (4.14), and (4.17) with the double weight
(3.7) where w∗i is the IPT weight.
Table 5.7: Logistic regression model fitting summary for A at ti0 where A denotes biologics
treatment status in the competing risks analysis.
coef se(coef) z Pr(> |z|)
(Intercept) -1.9146 0.4924 -3.8880 0.0001 ***
ESR 0.0166 0.0077 2.1580 0.0309 *
year of enrolment 0.0340 0.0256 1.3270 0.1844
year of the visit before ti0 0.0651 0.0465 1.4010 0.1613
sex 0.3094 0.2732 1.1330 0.2574
age -0.0478 0.0122 -3.9130 9.13E-05 ***
PS duration 0.0038 0.0130 0.2930 0.7694
PsA duration -0.0083 0.0217 -0.3800 0.7043
family history of PS 0.4130 0.2683 1.5390 0.1237
family history of PsA -0.0448 0.4322 -0.1040 0.9175
number of active joints 0.1256 0.0186 6.7580 1.40E-11 ***
number of damaged joints 0.0254 0.0130 1.9500 0.0512 .
NSAIDs 0.6965 0.2932 2.3760 0.0175 *
DMARDs 0.0254 0.2750 0.0920 0.9264
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Figure 5.7: Plot of unweighted, IIV weighted and IIV + IPT doubly weighted non-
parametric estimates of F1(t|A), where A = 0, or 1, A denotes biologics status in the
competing risks analysis. The number of patients who were followed up to 1, 3, 5, 7 years
respectively are 155, 109, 70, 38 for A = 0, and are, 153, 113, 82, 46 for A = 1.
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Figure 5.8: Doubly weighted non-parametric crude estimate, denoted by a circle, and
isotonic estimate, denoted by a plus, of F1(s`|A), where ` = 1, ...,m and A = 0, or 1.
Variable A denotes biologics status in the competing risks analysis. The number of patients
who were followed up to 1, 3, 5, 7 years respectively are 155, 109, 70, 38 for A = 0, and
are, 153, 113, 82, 46 for A = 1.
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Figure 5.9: Plot of unweighted, IIV weighted and IIV + IPT doubly weighted semi-
parametric estimates of F1(t|A) based on (5.5), where A = 0, or 1, A denotes biologics
status in the competing risks analysis. The number of patients who were followed up to
1, 3, 5, 7 years respectively are 155, 109, 70, 38 for A = 0, and are, 153, 113, 82, 46 for
A = 1.
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Figure 5.7 shows the IIV weighted and the doubly weighted non-parametric estimates
of F1(t|A) for A = 0 and A = 1. Unweighted estimates obtained by setting wi(t) (IIV
weight) and w∗i (IPT weight) as 1 are considered as naive estimates and are also displayed
in Figure 5.7 for comparison. The IIV weighted estimates and naive estimates shown in
Figure 5.7 indicate that treated patients have relatively higher cumulative incidence of an
increase in the number of damaged joints than untreated patients during the early years,
which is not expected and suggests that there may exist bias. Then, after the IPT weight is
further applied, it has been corrected a bit by the measured confounders considered in the
analysis of Table 5.7, and the doubly weighted estimates (red solid and red dashed curves)
in Figure 5.7 indicate that two treatment groups have no difference in terms of cumulative
incidence of joint damage increase. However, there may exist unknown factors which are
associated with joint damage as well as visit times and unmeasured confounders related
to treatment and disease progression that fail to be adjusted for, due to the limitation
of information or data; we will further discuss this later in this chapter and in the next
chapter. In addition to Figure 5.7, raw estimates Y¯`, given in (4.3), and isotonic estimates
for each group when double weights are applied are shown in Figure 5.8.
Figure 5.9 displays unweighted, IIV weighted and doubly weighted semi-parametric
estimates of F1(t|A) versus A, based on the additive hazards model (5.5). We can see that
treated patients and untreated patients have no difference in terms of the incidence of joint
damage increase from the unweighted estimates of F1(t|A). When the IIV weight is applied,
it is found that the two treatment groups have slightly different cumulative incidences,
but when the IPT weight is further applied, it is easily seen that treated patients have
a lower cumulative incidence than untreated patients. The unweighted estimate of γ is
0.001 with a bootstrap estimated standard error (se) of 0.024 and the 95% empirical CI
is (−0.047, 0.049), which indicates there is no evidence that biologics have any effect on
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the risk of joint damage increase at α = 0.05. In this analysis, 500 bootstrap samples are
used to estimate standard errors. The IIV weighted estimate of γ equals -0.008 with a
standard error of 0.035 and the 95% empirical CI is (−0.076, 0.061), so there is once again
no evidence that biologics have an effect on decreasing the risk of joint damage increase.
Then, when the IPT weight is applied, the estimated γ equals -0.034 with a standard error
of 0.037 and a 95% empirical CI of (−0.107, 0.039).
Based on the results here, there is not sufficient evidence that biologics have an effect
on reducing the risk of an increase in the number of damaged joints, though Figure 5.9
based on the additive hazards model (5.5) suggests that treated patients have relatively
lower cumulative incidence of a joint damage increase than untreated patients when the
double weighting method is employed. However, we have to carefully draw conclusions
on these analysis results, because there are several concerns in our data set. Sample size
is small, which gives large standard errors and wide confidence intervals. Also, there are
actually eight specific drugs in the category of biologics and patients may use more than
one drug simultaneously. Here, we consider the class of all biologic drugs as one treatment
since sample size will be even smaller if we focus on one particular drug. Moreover, due to
unmeasured confounders, the bias induced by confounding may not be sufficiently corrected
by the IPT weights. This will be further discussed in the next section. In addition, the
doubly weighted semi-parametric estimates of F1(t|A) shown in Figure 5.9 do not agree
well with the non-parametric estimates shown in Figure 5.7, which may suggest a lack of
fit for the additive hazards model (5.4). By (5.5), we see that the additive hazards model
forces the proportion S1(t|A = 1)/S1(t|A = 0) to grow exponentially over time with a
negative estimate of γ. Model assumption could be relaxed by allowing a time-varying
coefficient γ in model (5.4). This demands further investigation, and it will be considered
as future work.
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5.3 Concluding Remarks on the Analyses
To conclude, intermittent inspection times are common in longitudinal cohort studies,
especially when the protocol is designed to be history-dependent, physician or patient-
driven. Since how often and when patients come to visit the clinic could be associated
with disease status or disease-related variables, naive analysis of the observed data may
lead to misleading conclusions due to the dependent interval censoring. From the above
analyses, we see that the IIV weighted estimates effectively adjust for the informative visit
times and lead to more plausible conclusions.
Like many weighting adjustment methods, the proposed IIV weighted estimating func-
tion approach requires some crucial assumptions. In addition to the condition (B1) about
conditionally independent observation scheme which was introduced in Section 2.2.1 and
the assumption of independent drop-out, we also need the visit time model and the failure
time model to be correctly specified, so careful selection of variables and models is essential.
It is noted that there may exist unknown or unobserved factors and their history between
the outcome process and the visit process in the PsA analyses; that is, the assumption (B1)
could be violated. Thus, the IIV weighting method may not sufficiently adjusts for the
selection bias caused by dependent follow-up. Sensitivity analysis tools, e.g. Scharfstein
et al. (1999), can be helpful to check the impacts of a non-ignorable observation scheme.
In observational studies, direct comparison of two treatment groups could lead to biased
results because of potential confounders, since treatment is not randomized, as we showed
and discussed at the ends of Section 5.1 and Section 5.2. The IPT weighting method can
help with eliminating the bias caused by confounding. However, to draw reliable causal
conclusions the assumption (C1) which assumes that there are no unmeasured confounders
has to be satisfied. In this data set, due to the missing or limited information on poten-
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tial confounding variables between treatment (biologics) and failure times, rigorous causal
conclusions cannot be drawn, but we see that the estimates which are adjusted by the
IPT weights are more plausible and presumably correct some bias induced by confound-
ing. We know that sicker patients are more likely to receive and adhere to biologics which
is known as a second-line treatment. In addition, economic status may be an important
factor because of the high expenses of biologics; we do not have information about this.
Therefore, biomarkers that reveal disease severity, efficacy of other treatments, economic
status, patients’ preferences, and information about side effects could be confounders be-
tween treatment and failure times. Although we have adjusted for potential confounders
such as ESR, joint activity, and joint damage measured at or prior to ti0, other variables
like Health Assessment Questionnaire (HAQ) score, Psoriasis Area Severity Index (PASI),
employment status or education status may be good candidates for confounders but they
have a lot of missingness in our database. Also, we don’t have information available to
check the positivity condition for treatment which was introduced in (C1). Due to the lim-
itation of data, this setting is not ideal for causal inference, because the assumption (C1)
is likely not satisfied. However, the analyses here illustrate the proposed estimation meth-
ods. Moreover, the problems that we discuss are present in the majority of observational
studies, where the assumption of no unmeasured confounders is rarely plausible.
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Chapter 6
CONCLUSION, DISCUSSION AND
FUTURE RESEARCH
In practice, the periodic inspection times of a longitudinal cohort study are often irregular.
For example, in the PsA Toronto Cohort Study, patients visit the PsA clinic at different
times due to circumstances that may relate to their health status, disease status, responses
to therapies, etc. Irregular inspection times may carry information about the outcomes
of interest, e.g. sicker patients visit the clinic more often and are also more likely to
experience disease progression or other disease-related events of interest. In this sense,
when and how often the investigators observe outcomes are dependent on the values of
outcomes or outcome-related variables. In other words, irregular inspection times could be
outcome-dependent and may lead to a biased sample for analysis. As a result, standard
analysis methods such as MLE and GEE methods based on observed data could yield
biased estimates and even misleading conclusions. This was seen in the simulation studies
and the analyses of the PsA cohort study in the preceding chapters. Although multivariate
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regression models which include all the potential common risk factors between the visit
process and the outcome process as covariates may take the outcome-dependent inspection
times into account, the targets of inference are often the marginal or partially conditional
effects of some primary factors on outcomes. The inverse-intensity-of-visit (IIV) weighting
method which is proposed in this thesis adjusts for informative inspection times and results
in the estimates of marginal associations or effects.
When the outcome of interest is a failure time or an event time, intermittent visits and
irregular inspection times could cause failure times to be dependently interval-censored.
Then, standard analysis methods, e.g. MLE based on likelihood (2.1) for interval-censored
data, may lead to biased estimates, because most standard methods and existing software
for failure time data assume that the censoring is independent and non-informative. Sensi-
tivity analysis tools can be used to check the dependence of censoring, e.g. Siannis (2004),
Siannis et al. (2005) and Zhang and Heitjan (2006). It is appealing that our proposed IIV
weighted estimating functions based on a class of (marginal) binary responses defined for
failure times, e.g. Pi(t) = I(Ti > t), can deal with dependent interval censoring and result
in the estimates of marginal or partially conditional effects. Meanwhile, other problems
in survival analysis such as left truncation, informative drop-out times, confounded treat-
ment, and competing risks can be dealt by similar formulations. When failure occurrence
discontinues visits, we proposed to discretize the visit process, create pseudo visits every
time unit after failure occurrence and consider the visit intensities as 1. The discretization
of the visit process is fine in practical studies, since data are recorded in certain time units,
e.g. the PsA data is recorded in days.
The assumptions (B1) in Section 2.2.1 and (B1*) in Section 2.2.4 that a visit time and
the response defined for failure time outcome is independent given the observed history of
covariates, past visits and past responses. This assumption is generally untestable as other
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assumptions for ignorable coarsening. If a visit time is associated with factors which are
not measured, e.g. patients’ preference and personalities, or the history of some variables
between the previous visit and the present one, then the assumption (B1) or (B1*) could be
violated. Random effect models can be considered in that case, but the estimates obtained
from a random effect model usually have a lack of interpretability and the assumption
regarding random effect(s) is usually untestable as well. A combination of the IIV weighted
estimating function approach and random effect models might be considered so that the
known factor or history can be adjusted for by weighting and unknown factors can be
represented by random effects. More discussion on that can be found in Pullenayegum and
Lim (2014).
We have introduced a variety of survival models in simulation studies, e.g. a propor-
tional hazards model, a log-normal AFT model and a semi-parametric additive hazards
model. Some assumptions based on recent articles are proposed to simplify the data gen-
eration and the forms of marginal outcome models, which might not always be plausible
in the real world. For example, we assumed that L¯obs(t−) = L¯(t−) and Lm is independent
of L¯m−1 given A in Section 2.3, following Young and Tchetgen Tchetgen (2014). The key
issue here is that there are few conditional outcome models that lead to marginal models
such as proportional hazards models, so simulations in the literature make very restrictive
assumptions, which do, however, allow assessment of the proposed methods of estimation.
In observational studies, treatments are non-randomized and are often confounded by
known and unknown factors which are common causes of treatment assignments as well as
outcomes. The inverse-probability-of-treatment (IPT) weighting method provides a useful
and convenient way to adjust for measured confounders and mimic a randomized trial so
that causal conclusions can be drawn. Other confounder adjustment methods via propen-
sity scores, such as matching, also could be helpful to eliminate the selection bias induced
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by confounders. However, the important assumption of strongly ignorable treatment as-
signment, i.e. (A1) or (C1), has to be satisfied to ensure no hidden bias is caused by
unmeasured confounders. However, this assumption is generally untestable and too ideal
to be true in practice. For example, in the PsA data, if patients’ unstated preference
about treatments also affects outcome, it could be an unmeasured confounder. Further-
more, in practical studies, even some known factors may fail to be measured properly,
as we discussed in Section 5.3. Good background information may help with the selec-
tion of appropriate potential confounders to reduce selection bias; sound collection and
manipulation of data is also suggested to support reliable causal inference.
In the simulations we have discussed in the preceding chapters, we see that in some
cases coverage probabilities are slightly lower than the nominal level and the empirical
standard errors (ESEs) are a bit greater than the average asymptotic standard errors (AS-
Es), especially when estimating functions are doubly weighted, e.g. in Table 3.2 and Table
3.4. In the PsA case, since some patients have extremely long visit gap times, e.g. longer
than 20 years, which may lead to extremely large values of the IIV weights, wi(t), if the
denominator is an estimated visit intensity of very small value, so we artificially censor visit
gap times longer than 3 years and consider those patients as lost to follow-up. It is known
that large variability in the weights can cause estimators with large variances and the
estimators may even fail to be approximately normally distributed (Robins et al., 2000).
One way to mitigate the variability caused by large weights is to stabilize weights. For
example, the IIV weight wi(t) can be replaced by swi(t) = a(t)/λN(t|Zi(t−)), where a(t)
stabilizes the weights and leaves the estimating functions unbiased (Bu˚zˇkova´ and Lumley,
2007, 2009; Pullenayegum and Feldman, 2013; Pullenayegum and Lim, 2014). Alterna-
tively, we could truncate extremely large weights to reduce the variances of estimates at a
cost of some bias. For example, Bembom and van der Laan (2008) proposed a selection
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of truncation level of the IPT weights on a basis of minimizing the expected MSE of the
estimator. Later, Pullenayegum and Feldman (2013) extended their selection method to
truncate the IIV weights for irregularly observed longitudinal data.
Inverse probability weighting methods usually need the model for outcomes and the
models for weights correctly specified. A class of augmented inverse probability weighted
(AIPW) estimators have been proposed, e.g. Robins et al. (1994); Scharfstein et al. (1999);
Bang and Robins (2005); Seaman and Copas (2009); Pullenayegum and Feldman (2013).
An AIPW estimator is consistent when either the outcome model or the weight model is
correct, so it is also referred to as a doubly robust estimator. If applied to our IIV weighted
estimator, for example, the IIV weighted estimating function (2.23) can be modified as
UDRik =c(µT )
{
dNik
λN (aik|Zi,k−1) [Pik − µT (aik)] +
[
1− dNik
λN (aik|Zi,k−1)
]
[E(Pik|Hobsi,k−1)− µT (aik)]
}
=c(µT )
{
dNik
λN (aik|Zi,k−1) [Pik − E(Pik|H
obs
i,k−1)] + [E(Pik|Hobsi,k−1)− µT (aik)]
}
, (6.1)
where Pik = I(Ti > aik), µT (aik) = E(Pik), and note that Zi,k−1 = h{Hobsi,k−1}. Here,
we consider a discrete visit process as an example and assume that there is no random
drop-out for simplicity. It can be shown that if either the IIV weight model λN(aik|Zi,k−1)
or a “working” outcome model E(Pik|Hobsi,k−1), e.g. (2.33) given in Section 2.3.1, is correctly
specified, then (6.1) is unbiased. Furthermore, the augmented inverse probability weighting
method can be extended to our doubly weighted estimator so that a triply robust estimator
can be obtained, i.e.
UTRik =c(µTa)
{[
dNik
λN (aik|Zi,k−1)
I(Ai = a)
pii(a|Vi) −
dNik
λN (aik|Zi,k−1) −
I(Ai = a)
pii(a|Vi)
]
[P aik − E(P aik|Hobsi,k−1)]
−[E(P aik|Hobsi,k−1)− µTa(aik)]
}
, (6.2)
where P aik = I(T
a
i > aik); µTa(aik) = E(P
a
ik) = Pr(T
a
i > aik); T
a
i is the counterfactual
outcome under treatment a; and we defined the IPT weight w∗i = 1/pii(a|Vi) = 1/Pr(Ai =
a|Vi). Here, we assume E(P aik|dNik,Hobsi,k−1, Ai,Vi) = E(P aik|Hobsi,k−1) for a “working” out-
come model, E(dNik|P aik,Hobsi,k−1, Ai,Vi) = E(dNik|Zi,k−1) for the IIV weight model, and
E(Ai|P aik,Vi,Hobsi,k−1, dNik) = E(Ai|Vi) for the IPT weight model. It can be shown that if
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any one of the IIV weight model, the IPT weight model, and a “working” outcome model
E(P aik|Hobsi,k−1), e.g. (3.12) in Section 3.2, is correct, then (6.2) is an unbiased estimating
function. This is one of my future research directions.
The non- or semi-parametric estimation introduced in Chapter 4 is relatively robust
to the model assumption of the outcome process. Since kernel smoothing is employed,
the selections of bandwidths and kernel functions affect the final estimation results. For
instance, there is a tradeoff between bias and variance when different bandwidths are
chosen. Explicitly, small bandwidths result in smaller bias but larger variances, while
larger bandwidths lead to less variability but more bias. An optimal bandwidth or a data
driven bandwidth might be considered in the future, though a simple selection based on
the number of visits contained by a window, i.e. [t−h, t+h] where h denotes a bandwidth,
works in our simulations and real data analyses.
This thesis research is initially inspired by the intermittent inspection times in the P-
sA cohort study. The impacts of irregular (and potentially informative) inspection times
on the analysis of outcomes have been addressed. The IIV weighting method was pro-
posed and studied by a few authors for irregularly observed longitudinal data. We extend
this method to study time-to-event or failure time data with dependent follow-up. When
inspection times are outcome-dependent, failure times are subject to dependent interval
censoring. Literature on dependently interval-censored failure times is very limited, so
we believe this thesis contributes to this topic significantly. Parametric estimation, non-
and semi-parametric estimation of marginal failure time distributions in the presence of
dependent inspection times has been comprehensively discussed. Monotone smoothing
which can be implemented by existing software is introduced to conduct the IIV weight-
ed non- and semi-parametric estimation procedures. Additionally, causal inference is also
considered and the IPT weight can be easily combined with the IIV weighting method.
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Ideally, regular inspection times make the measured responses be a completely random
sample. Unfortunately, follow-up is often irregular for a variety of reasons in practice. We
suggest that reasons of missed visits or the deviation of planned visit gap times should be
investigated so that appropriate assessment and adjustment of visit times can be achieved.
Then, the introduced IIV weighting method is believed a useful and convenient approach
to eliminate the selection bias due to irregular inspection times.
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Appendix A
A.1 List of Regressors in the Analyses of Clinic Visit
Times and Treatment with Biologics
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Table A.1: Descriptions and center values of the variables regressed in the analyses of
Table 1.1 and Tables 5.1-5.7. Time-varying variables are measured only at visits, except
treatment variables (NSAIDs, DMARDs, biologics) that can change at arbitrary times
and whose full history is known. ESR denotes erythrocyte sedimentation rate (mm/hr);
med.gap denotes median length of past visit gap times (in days).
Variable Value/Level Center Fixed/Time-varying
sex 0: female, 1: male — fixed
year of enrolment continuous 2000 fixed
year of the visit before ti0 continuous 2000 fixed
family history of PS 0: No, 1: Yes — fixed at enrolment
family history of PsA 0: No, 1: Yes — fixed at enrolment
age (in years) continuous 40 time-varying
PS duration (in years) continuous 20 time-varying
PsA duration (in years) continuous 5 time-varying
number of active joints continuous — time-varying
number of damaged joints continuous — time-varying
NSAIDs 0: No, 1: Yes — time-varying
DMARDs 0: No, 1: Yes — time-varying
biologics 0: No, 1: Yes — time-varying
ESR continuous 20 time-varying
med.gap continuous 180 time-varying
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